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Abstract 
Chronic wounds in the elderly often become infected, leading to substantial 
morbidity and mortality. Impaired healing in the elderly is mediated by age-related 
changes in steroid hormones, particularly declining levels of estrogen with 
increasing age. Although the anti-inflammatory activity of estrogen has been 
defined, very little is known about the effects of estrogen deprivation (ageing 
processes) on bacterial clearance. The aim of this study was to determine the effect 
of ageing (estrogen deprivation) on the ability of in vitro human U937-derived 
macrophages and ex vivo human peripheral blood monocyte (HPBM)-derived 
macrophages to eliminate bacteria via phagocytosis. 
Host-pathogen assays were used to measure macrophage-mediated phagocytosis 
of two major wound pathogens, methicillin-resistant Staphylococcus aureus (MRSA) 
and Pseudomonas aeruginosa, under in vitro and ex vivo conditions that model 
estrogen levels in the elderly, young adults and following exogenous estrogen 
supplementation. Epifluorescence, confocal and scanning electron microscopy were 
used to visualise host-pathogen interactions and protein mediators of phagocytosis 
were measured by immunoblotting. Estrogen at concentrations typical of youth or 
supraphysiological levels significantly (P<0.05) increased the phagocytosis and 
effective killing of MRSA and P. aeruginosa in a dose-dependent manner compared 
to estrogen deprivation with significantly enhanced clearance of bacteria by M1 
macrophages compared to M2 or M0 macrophages. Epifluorescence, confocal and 
scanning electron microscopy confirmed estrogen increases co-localisation of 
fluorescent GFP-S. aureus or mCherry-P. aeruginosa within macrophages and 
promotes bacterial internalisation. Activation of estrogen receptor (ER)-alpha (ER-
α) mirrored the stimulatory effect of estrogen on phagocytosis whilst ER-α 
antagonism significantly (n=6; P<0.05) blocked the phagocytic effect of estrogen. In 
contrast, activation of ER-beta (ER-β) had no significant (n=6; P>0.05) effect on 
phagocytosis, confirming estrogen mediates bacterial clearance via specifically 
through ER-α. Immunoblotting analysis demonstrated that enhanced phagocytosis 
by estrogen is associated with altered levels of mediators involved in the actin 
XV 
cytoskeleton of phagocytes including increased levels of FAK, Rac1, Cdc42 and 
RhoG, but reduced levels of RhoA. 
Collectively the findings suggest estrogen may promote the resolution of wound 
bacterial infections during youth but this protection is lost as estrogen levels 
decline with increasing age, resulting in increased propensity and progression of 
wound infections in the elderly. Thus, novel wound dressings that provide local 
estrogen supplementation or selective activation of ER-α and/or specific targeting 
of downstream mediators of the actin cytoskeleton may provide effective 
treatment options for infected wounds in the elderly. 
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1.1 Acute Wound Healing 
Acute wound healing is a complex and dynamic biological process divided into four 
sequential, overlapping phases; haemostasis, inflammation, tissue proliferation and 
remodelling of the tissue scar (Figure 1.1). Immediately after trauma, healing 
initiates with haemostasis (coagulation). This phase is characterised by the 
formation of a fibrin clot within minutes following injury to prevent further blood 
loss and provide a temporary, protective barrier over the wound. The inflammatory 
phase occurs within minutes after injury, with neutrophils being the first 
inflammatory cells recruited from circulation, followed by the recruitment of 
monocytes. The primary objective of inflammation is to localise and eradicate the 
causative irritant or stimuli (e.g. bacteria). Neutrophils peak in numbers at 24 to 36 
hours post wounding whereas monocytes peak at around 5 to 7 days after injury. 
Monocytes undergo a series of changes to differentiate into tissue macrophages. 
Macrophages carry out phagocytosis and release cytokines that encourage the 
recruitment and activation of leukocytes at the injury site. Upon the clearance of 
apoptotic cells, macrophages undergo a phenotypic change from a pro-
inflammatory to a reparative state that encourages the initiation of the 
proliferation phase (Mosser and Edwards, 2010). 
Three to ten days after injury, the proliferation phase starts enabling granulation 
tissue formation, re-epithelialisation and angiogenesis. Proliferation is 
characterised by the creation of a new extracellular matrix (ECM) by fibroblasts, 
angiogenesis by endothelial cells and re-epithelialisation by keratinocytes. The final 
phase is remodelling of a mature tissue scar, which can take several months or, in 
some cases, up to a year post-injury. It is characterised by the remodelling of 
collagen and the vascular maturation of newly formed capillaries, allowing vascular 
density to return to normal within the wound (Guo and DiPietro, 2010). 
For successful healing, wound repair requires progression through all four phases in 
the correct order and timeframe (Singer and Clark, 1999; Guo and DiPietro, 2010). 
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Figure 1.1 Diagrammatic illustration of typical timescale and phases of acute wound 
healing stages. 0 = day of wounding/injury. Figure drawn based on information in Gosain 
and DiPietro (2004) and  Olczyk et al. (2014). 
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1.1.1 Haemostasis 
Immediately after injury, degranulating platelets adhere to damaged blood vessels 
and start a haemostatic reaction, increasing the coagulation cascade to prevent 
extreme blood loss and to provide temporary protection for the wound against 
foreign bodies (Figure 1.2). This is accomplished by vasoconstriction and the 
creation of a platelet plug (Vaughan et al., 2000; Weyrich and Zimmerman, 2004; 
Gilliver et al., 2007). When the platelets come into contact with exposed collagen, 
they become adherent and activated, producing a platelet plug at the wound site.  
This involves a coagulation cascade  in which fibrinogen is transformed to fibrin by 
thrombin, creating a clot of insoluble fibres bound to platelets (Fang et al., 2005). 
The clot forms a provisional matrix rich in fibronectin that acts as a scaffold over 
which cells can migrate during the wound healing process. Platelets in the clot 
release a variety of pro-inflammatory cytokines and growth factors including 
platelet-derived growth factor (PDGF), transforming growth factors β (TGF-β), 
fibroblast growth factor 2 (FGF-2), vascular endothelial growth factor (VEGF) and 
epidermal growth factor (EGF) (Bauer et al., 1985; Guo and DiPietro, 2010). These 
factors induce the recruitment of inflammatory cells from circulation and cells 
involved in the proliferative phase of wound repair including keratinocytes, 
endothelial cells and  fibroblasts (Singer and Clark, 1999; Guo and DiPietro, 2010). 
 
 
5 
 
Figure 1.2. Schematic illustration of haemostasis in acute wound healing. Following an 
injury, platelets adhere to damaged blood vessels and start a haemostatic reaction, 
increasing the coagulation cascade to prevent extreme blood loss. A platelet plug forms 
that provides temporary protection against colonisation of the wound by microorganisms.  
The provisional fibrin matrix also provides a scaffold over which cells can migrate during 
the wound healing process. Figure drawn based on information in Singer and Clark (1999) 
and Guo and DiPietro (2010). 
1.1.2 Inflammatory Phase 
Following injury, the release of cytokines and chemokines by platelets and resident 
immune cells attracts inflammatory cells from circulation to the wound site (Figure 
1.3). Large numbers of circulating neutrophils are recruited to the wound site by 
chemokine and cytokine expression of endothelial surface cellular adhesion 
molecules (CAMs), such as CD11 and CD18 (Ley et al., 2007). Neutrophils are the 
first immune cells to arrive at the wound site within minutes of injury. They peak in 
numbers at 24 to 36 hours post-injury (Mosser and Edwards, 2010). Neutrophils 
start to remove foreign substances and invading microorganisms, such as bacteria, 
via the release of reactive oxygen species (ROS) and lysosomal enzymes, and 
degrade damaged matrix tissues by collagenases and proteinases (Singer and Clark, 
1999). The majority of neutrophils are enclosed in the wound clot and are either 
eliminated with the eschar or by macrophages via phagocytosis (Newman et al., 
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1982). In response to chemoattractants such as TGF-β, macrophage 
chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein (MIP), 
monocytes from the bloodstream subsequently arrive at the wound area and 
differentiate into tissue macrophages, peaking in number around days 5 to day 7 
post-injury (Lorenz and Longaker, 2003; Sen and Roy, 2008). Growth factors mainly 
TGF-β and residues of the remaining extra cellular matrix (ECM) including collagen, 
elastin, fibronectin, and thrombin induce circulating monocytes to adhere to the 
endothelium of blood vessels and migrate into the tissue. Macrophages replace 
neutrophils as the predominant inflammatory cells at the wound site and carry out 
the process of phagocytosis of invading microorganisms, removal of damaged 
tissues and dead neutrophils and the release of growth factors such as PDGF and 
TGF-β (Beanes et al., 2003). Damaged extracellular matrix is degraded by the action 
of macrophage-derived proteolytic enzymes such as metalloproteases. 
Macrophages stimulate re-epithelialisation by releasing insulin-like growth factor-1 
(IGF-1), keratinocyte growth factor (KGF) and EGF (Chen et al., 2004) and 
angiogenesis via the secretion of VEGF (Shaw et al., 1990). During wound clearance, 
macrophages experience a balanced switch from pro-inflammatory (classically 
activated) M1 macrophages to anti-inflammatory (alternately activated) M2 
macrophages (Mosser and Edwards, 2008). 
Adaptive immunity plays a major role in regulating inflammation and improving 
wound healing (Falanga, 2005). The adaptive immune response is late, but specific, 
compared to the innate immune response. It has the capacity to memorise 
invaders/pathogens and induce prompt reactions to later immunological tasks. The 
key cells linked with adaptive immune responses are T cells and B cells (Jameson et 
al., 2002). They are initiated in reaction to antigens or cells presenting antigens. 
When activated, B cells produce specific antibodies that label pathogens for 
destruction, activate the complement system, ingest bacteria, and activate toxins. T 
cells are induced by the major histocompatibility complex (MHC) molecule that 
presents antigens. Antigens presented by MHC class I are detected by CD8+ 
cytotoxic T cells, whereas antigens presented by MHC class II are recognised by 
CD4+ helper T lymphocytes. CD8+ cells are more specialised in targeting cells than 
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CD4+ cells, which are more involved in cytokine production and paracrine signalling 
to adjacent cells. T cells are suggested to play a role in tissue repair (Jameson et al., 
2002). A specific group of T cells known as gamma delta (γδ) T cells, or dendritic 
epidermal T cells, are cells that are able to recognize antigens expressed by 
damaged and/or stressed keratinocytes (Jameson et al., 2002). Research 
demonstrated that (γδ) T cells enhance re-epithelialisation via producing growth 
factors such as Keratinocyte growth factor-7 (KGF-7) and keratinocyte growth 
factor-10 (KGF-10). This has been reported in an animal study where γδT cell 
deficiency led to a delay in wound repair (Jameson et al., 2002). CD4+ and CD8+ 
cells have also been shown to have an impact on the infiltration of neutrophils and 
macrophages to the wound site, which has an evident impact on the regulation of 
the inflammatory phase in wound healing. Furthermore, an induced deficit of CD4+ 
cells is linked with an increase in the levels of interferon gamma (IFN-γ), interleukin-
1 beta (IL-1β), interleukin-6 (IL-6), interleukin-17 (IL-17) and a diminution in 
interleukin-4 (IL-4). However, an induced deficit of CD8+ cells has the opposite 
effect on these inflammatory factors (Chen et al., 2004). A balanced 
innate/adaptive immune reaction is essential for an appropriate inflammatory 
phase and wound healing. 
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Figure 1.3. Representation of the inflammatory phase of acute wound healing. Cytokines 
released by platelets initially attract neutrophils and then monocytes to the wound site. 
Monocytes subsequently differentiate into tissue macrophages. Figure drawn based on 
information in Singer and Clark (1999) and Guo and DiPietro (2010). 
 
1.1.3 Proliferative Phase 
The third phase of the acute wound healing is called the proliferative phase. The 
major events during this phase are ECM formation, re-epithelialisation and 
angiogenesis (Kirsner and Eaglstein, 1993). 
 ECM Formation 
Granulation tissue formation occurs approximately between 3 and 10 days post-
injury. The temporary matrix produced during haemostasis is replaced with a more 
defined granulation tissue, consisting of newly formed blood vessels and various 
cell types including fibroblasts, macrophages and granulocytes within loose 
connective tissue (El Ghalbzouri et al., 2004; El Ghalbzouri and Ponec, 2004). 
Fibroblasts exert several functions during wound healing processes such as wound 
contraction and ECM deposition. Fibroblasts are activated by PDGF and FGF-2, and 
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are encouraged to proliferate by insulin-like growth factor 1 (IGF-1) and TGF-β1 
(Singer and Clark, 1999). TGFβ1, released by macrophages during inflammation and 
induced by mechanical pressure in the ECM, directs fibroblasts to differentiate into 
contractile myofibroblasts (Gabbiani, 1999; Serini and Gabbiani, 1999). Fibroblasts 
attach together and to the extracellular matrix,  producing stress fibres of 
contractile actin bundles that close the wound (Hinz, 2007). Fibroblasts synthesise 
new ECM through the generation of collagen, fibronectin, elastin, 
glycosaminoglycans, proteoglycans and hyaluronic acid (Hinz, 2007). 
 Re-epithelialisation 
Re-epithelialisation is the process of restoring an intact epidermis after cutaneous 
injury, and it involves an orderly series of events including the detachment, 
migration and proliferation of adjacent epidermal keratinocytes across the wound, 
the differentiation of the neo-epithelium into a stratified epidermis, and the 
restoration of an intact epidermal barrier function (Li et al., 2007). Keratinocytes at 
the wound borders proliferate to replace the cells that migrate across the 
temporary wound matrix (Li et al., 2007). The main factors inducing keratinocyte 
migration are EGF, keratinocyte growth factor (KGF), Insulin-like growth factor 1 
(IGF-1) and nerve-growth factor (NGF) (Marikovsky et al., 1993; Tokumaru et al., 
2000). Growth factors that induce re-epithelialisation are released by activated 
platelets during haemostasis and by inflammatory cells, mainly macrophages, 
during inflammation (Li et al., 2007). Keratinocytes upregulate the production of 
proteolytic enzymes including matrix metalloproteinases (MMPs) that contribute to 
create a path between the scab and tissue below. Migration of cells then stops 
causing a rearrangement of the actin cytoskeleton (Jacinto et al., 2001; Mayor and 
Carmona-Fontaine, 2010). 
 Angiogenesis 
Angiogenesis is the revascularisation procedure that re-establishes a blood supply 
to regenerate tissues following wounding. Angiogenesis is induced by growth 
factors including members of the TGF-β family, VEGF, FGF-2 and PDGF, which are 
released during haemostasis, and by inflammatory cells in response to injury  
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(Adams and Alitalo, 2007). Recruited endothelial cells release proteolytic enzymes 
that facilitate their entrance to the wound site, where they multiply and assemble 
into tubular canals, and secrete MMPs, leading to lysis of adjacent tissue. 
Endothelial cells increase in number and reinforce their vessel walls by recruiting 
smooth muscle cells and pericytes, reinstating blood flow to the injured tissue 
(Clark et al., 1982). 
 
Figure 1.4. Schematic illustration of the proliferative phase in wound repair. As the 
inflammatory phase resolves, the overlapping proliferative phase includes the synthesis of 
granulation tissue that is characterised by blood vessel formation and contains recruited 
fibroblasts and macrophages. Keratinocytes at the wound edge migrate over the wound to 
restore the epidermis. Figure drawn based on information in Singer and Clark (1999) and 
Guo and DiPietro (2010). 
1.1.4 Remodelling Phase 
Remodelling is the last phase of wound repair that can endure for many months 
after wounding. It is characterised by a termination of the inflammatory response 
and the continuous remodelling of the ECM. The production/release of cytokines 
stops and inflammatory cells are removed from the wound area by apoptosis 
and/or phagocytosis (Serhan et al., 2008). The new ECM is remodelled over several 
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months to generate a robust dermal structure in which collagen III is gradually 
replaced by collagen I leading to the formation of a mature tissue scar (Singer and 
Clark, 1999). Blood vessels also degenerate during the remodelling phase (Singer 
and Clark, 1999). 
 
Figure 1.5. Schematic representation of the remodelling phase of wound healing. Blood 
vessels degenerate. The provisional extracellular matrix of fibronectin and fibrin is replaced 
with connective tissue, including collagen, and the formation of a mature scar. Figure 
drawn based on information in  Singer and Clark (1999) and Guo and DiPietro (2010). 
1.2 Abnormal Wound Healing 
After an injury, wound healing is vital in re-establishing a new cutaneous barrier 
and preventing infection by invading foreign microorganisms. The speed and quality 
of wound repair are influenced by several factors, with age being a key factor that  
is known to markedly delay healing in the elderly (Ashcroft et al., 2002). 
Pathological circumstances such as, diabetes, contribute directly to the 
development of chronic wounds, with foot ulcers being the most common cause of 
hospitalisation in diabetic patients. The treatments for chronic wounds are often 
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ineffective and place a substantial financial burden on the world’s health 
organisations (Harding et al., 2002; Boulton et al., 2005). 
1.2.1 Age-Related Impaired Healing 
With increasing age, acute wound healing proceeds but becomes delayed. This 
detrimental change in acute wound healing in the elderly is called age-related 
impaired healing and is linked with an increase in skin fragility, reduced immune 
responses and cellular aging (Thomas, 2001). Delayed wound healing in the elderly 
is associated with delayed haemostasis (Ashcroft et al., 1999b), prolonged and 
excessive inflammatory response, delayed re-epithelialisation, impaired 
angiogenesis, and reduced matrix deposition (Ashcroft et al., 1997b; Ashcroft et al., 
2002). Although the inflammatory response becomes more pronounced with 
increasing age, the propensity for wound infections increases in the elderly 
(Ashcroft et al., 2002; Cooper et al., 2015), in part due to the delay in wound repair. 
Moreover, despite the pronounced inflammatory response, evidence suggests that 
increasing age may result in an impaired ability of inflammatory cells to eliminate 
bacteria from the wound site (Emori et al., 1991; Thomas, 2001). It is suggested 
that an excessive presence of macrophages lead to an excessive matrix demolition 
due to the production of great amounts of nitric oxide (NO) and ROS which can 
delay wound healing and cause damage to the wound zone (Sen and Roy, 2008). 
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Figure 1.6. Schematic representation of the effect of age on wound healing. Age-related 
impaired healing is linked with delayed haemostasis, delayed and excessive inflammatory 
response and enhanced pro-inflammatory cytokine production, impaired platelet function 
and delayed re-epithelialisation, in addition to decreased fibroblast proliferation and matrix 
deposition. Figure drawn based on information in Gosain and DiPietro (2004). 
1.2.2 Chronic Wounds 
A chronic wound develops when a wound fails to proceed through an orderly set of 
wound healing phases within an expected timeframe. Chronic wounds can take 
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several months or even years to heal (if they heal at all) properly. Wounds are 
considered chronic if they do not heal within three months (Mustoe, 2005; Adeyi et 
al., 2009). Chronic wounds are mainly linked to an underlying disease that is 
common in the elderly (over 65 years of age). Chronic wounds represent a major 
clinical issue that causes an enormous burden to healthcare services, demanding 
huge medical efforts and a substantial amount of healthcare funds (Harding et al., 
2002; Boulton et al., 2005). Chronic wound treatment costs the UK National Health 
Service (NHS) about £5 billion per annum (Guest et al., 2015). At present, effective 
therapies/treatments for chronic wounds are somewhat limited, making this an 
area of research that needs urgent attention. Chronic wounds are typically trapped 
within the inflammatory phase of wound repair and are characterised by an 
excessive, unabated inflammatory response that leads to tissue breakdown 
(Snyder, 2005; Taylor et al., 2005; Fazli et al., 2009). They are also characterised by 
a loss in the specific balance between the formation and degradation of the 
extracellular matrix (ECM), particularly  collagen and elastin, with a gross shift to 
ECM destruction  (Edwards et al., 2004; Schönfelder et al., 2005).  Chronic wounds 
are characterised by  increased pro-inflammatory cytokine production, decreased 
tissue growth factor secretion, reduced matrix production, delayed but excessive 
inflammation, decreased angiogenesis, delayed re-epithelialisation, bacterial 
infection and defective macrophage function (Hohn et al., 1976; Harding et al., 
2002). There are several underlying pathologies associated with chronic wounds, 
with more than 90 % of chronic wounds being venous, diabetic or pressure ulcers 
(Boulton et al., 2005). Moreover, it has been reported that diabetic foot ulcers and 
venous leg ulcers have an increased number of B cells and an inferior CD4+/CD8+ 
ratio in comparison with acute wounds, mainly due to a lower number of CD4+ cells 
(Moore et al., 1997). 
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Figure 1.7. Patients with a chronic wound. A typical example of; (A) diabetic foot ulcer, (B) 
diabetic foot ulcer developing gangrene (Jeffcoate and Harding, 2003), (C) venous leg ulcer 
and (D) pressure foot sore (Grey et al., 2006). 
  Venous Ulcers 
Venous ulcers (Figure 1.7c) are most frequently observed in the elderly and 
represent approximately 70 % of chronic wounds of the lower leg (Baker et al., 
1991). Venous ulcers mainly develop in the gaiter area of the leg and signify a 
clinical manifestation of sustained venous hypertension, typically characterised by 
excessive vascularisation and unhealthy granulation tissue formation. At an 
advanced stage, venous ulcers can  impair the function of the calf muscle (Cockett, 
1955; Grey et al., 2006). 
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Research has suggested the delay in healing and development of venous ulcers is 
connected with an inappropriately excessive inflammatory response (White and 
Ryjewski, 2005). It is thought that leukocytes recruited during the inflammatory 
phase are trapped in the microcirculation of the wounded leg (Moyses et al., 1987) 
and release inflammatory mediators that lead to further recruitment and 
accumulation of leukocytes. Inflammatory cells release proteolytic enzymes that 
break down  the dermal structure, leading to the development of an ulcer (Wysocki 
and Grinnell, 1990; Grinnell et al., 1992). 
 Diabetic Ulcers 
It has been reported that 15 % of diabetic patients in the UK are at risk of 
developing a chronic diabetic foot ulcer (Guo and DiPietro, 2010), and around 85 % 
of diabetic ulcer patients will require an amputation of their lower leg due to the 
development of gangrene (Figure 1.7b) (Apelqvist and Larsson, 2000; Boulton, 
2004; Clinton and Carter, 2015). Diabetes is characterised by an alteration of blood 
sugar levels  which can cause nerve damage leading to autonomic neuropathy and 
vasculopathy (microcirculation dysfunction) (Boulton, 2004). This can generate local 
hypertension and hypoxia, resulting in an ulcer due to tissue necrosis. A diabetic 
ulcer (Figure 1.7a) typically develops on feet and ankle regions that are repetitively 
exposed to mechanical pressures. Diabetic ulcers occur frequently in patients who 
develop diabetic neuropathy, because they are incapable of sensing and relieving 
cutaneous pressure and pain (Boulton et al., 1983; Boulton, 2004). Like many 
chronic wounds, diabetic wounds exhibit impaired macrophage and neutrophil 
function, in turn increasing the risk of infection and prolonging healing time. 
  Pressure Ulcers 
A pressure ulcer, also called a pressure sore (Figure 1.7d), is local damage of the 
skin and/or underlying tissues, resulting from pressure, or pressure combined with 
shear (Black et al., 2007). Pressure ulcers are mostly hospital-acquired chronic 
wounds, occurring predominantly in the elderly and particularly in patients who 
remain stationary for a long period of time, such as paralysed or disabled patients 
(Allman et al., 1995). Pressure ulcers are usually small ulcers caused by the 
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interruption of blood flow to the tissue by persistent pressure. The absence of 
oxygen at the pressure site results in necrosis of the tissue and the development of 
a pressure sore (Black et al., 2007). 
1.3 Wounds and Bacteria 
1.3.1 Wound Infection 
It is believed that low levels of bacteria in a wound have a beneficial impact on 
acute wound healing by stimulating the inflammatory response and improving 
granulation tissue formation (Robson, 1997).  However, chronic wounds, that take 
months or years to heal, typically have microbes surviving and proliferating within 
the wound site. Research has indicated that all chronic wounds are subject to 
colonisation with a varied range of bacteria (Bowler and Davies, 1999).  When the 
bacteria outweigh the host’s immune system, the result is infection (Friedman and 
Su, 1984). It has been reported that the environment of chronic wounds is 
potentially favourable to bacterial infections, particularly when the wound tissue is 
ischaemic and dry (Rubinstein et al., 1983; Whiston et al., 1994). 
1.3.2 Bacterial Species in Chronic Wounds 
Numerous studies have demonstrated that the main bacterial species found in 
chronic wounds are S. aureus, P. aeruginosa, S. epidermidis, Streptococcus spp, 
Enterococcus spp. and coliform bacteria (Hansson et al., 1995; Bowler, 1999; 
Gjødsbøl et al., 2006; Kirketerp-Møller et al., 2008; Rybtke et al., 2015). Research 
has identified bacterial species present in infected surgical wounds of 676 patients. 
The most dominant pathogen was S. aureus (28.2 %), followed by P. aeruginosa 
(25.2 %), E. coli (7.8 %), S. epidermidis (7.1 %) and Enterococcus faecalis (5.6 %) 
(Giacometti et al., 2000). The most frequent bacteria cultured from chronic wounds 
are illustrated in Table 1.1. 
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Table 1.1. Bacteria frequently associated with chronic wounds.  
Information in table adapted from (Robson, 1997; Bowler and Davies, 1999). 
Gram-positive Gram-negative 
Aerobe Anaerobe Aerobe Anaerobe 
Staphylococcus Peptostreptococcus Pseudomonas Bacteriodes 
Streptococcus Clostridium Escherichia Prevotella 
Enterococcus   Klebsiella Fusobacterium 
It has been reported that chronic wounds are notably susceptible to S. aureus 
infections (Bowler and Davies, 1999; Beasley and Hirst, 2004). Along with anaerobic 
bacteria, S. aureus is known to be the most predominant bacteria found in chronic 
wounds, followed by P. aeruginosa, Peptostreptococcus spp. and Bacteriodes spp. 
(Louie et al., 1976; Lookingbill et al., 1978; Stephens et al., 2003; Davies et al., 
2004). 
Staphylococcus spp. and Pseudomonas spp. are the aerobic species most frequently 
detected in all wound types, with a great predominance in chronic wounds (Davies 
et al., 2004). 
  Staphylococcus aureus 
S. aureus is a facultative anaerobic Gram-positive cocci, typically 1 µm in diameter. 
It is commonly found on the skin, nose and in the respiratory tract (Stryjewski and 
Corey, 2014; Chambers, 2001). In normal healthy and immunocompetent people, S. 
aureus colonisation of the skin, intestinal tract, or nasopharynx is not pathogenic. 
However, it is considered the classic opportunist since it is frequently associated 
with wound infections and abscesses (Chambers, 2001; Missiakas and Schneewind, 
2016). 
Subpopulations of S. aureus comprise antibiotic resistant strains, such as 
methicillin-resistant S. aureus (MRSA). Penicillin was the antibiotic of choice to treat 
infections with S. aureus. After the acquisition of a resistance to penicillin, 
methicillin was introduced in 1959 as a treatment for penicillin-resistant S. aureus 
(Jevons, 1961; Jessen et al., 1969). However, reports from the UK indicated the first 
case of MRSA just two years later (in 1961) and, during the period between the 
1960s and the 1990s, hospital-acquired MRSA cases became increasingly common, 
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leading to a serious worldwide health problem (Enright et al., 2002). MRSA is now 
recognised as a nosocomial pathogen (hospital acquired-MRSA) throughout the 
world (Diekema et al., 2001). However, cases of MRSA in healthy, community-
resident individuals have been recorded towards the end of the 1990s, with such 
infections referred to as community-acquired MRSA (Naimi et al., 2001). MRSA has 
the ability to live and survive undetected in a host without provoking any symptoms 
(Stryjewski and Corey, 2014). Nevertheless, the pathogen can cause endocarditis, 
sepsis, and meningitis if it is introduced into the bloodstream, or if the host is 
incapable of developing a normal immune response (i.e. immunocompromised). 
Vancomycin was the only antibiotic used as a treatment for MRSA. However, 
resistance to this antibiotic has also been reported in recent years (Hiramatsu et al., 
1997; Cardona and Wilson, 2015). 
MRSA is frequently linked with chronic wounds. Giacometti et al. (2000) reported 
that 54.4 % of S. aureus isolated from surgical wounds were discovered to be 
methicillin-resistant. The treatment of chronic wounds infected with MRSA 
represents a big challenge for the modern healthcare organisations (Beasley and 
Hirst, 2004). When chronic wounds are heavily infected with MRSA, or other 
hospital-acquired pathogens, treatment may necessitate aggressive medication 
with last line of defence antibacterial therapies (Beasley and Hirst, 2004). 
  Pseudomonas aeruginosa 
P. aeruginosa is a Gram-negative bacillus, typically 3 µm × 0.5 µm in diameter. It is 
an opportunistic pathogen and a causative agent of a wide range of diseases in both 
immunocompromised and otherwise healthy patients (Passador et al., 1993; Ryan 
and Ray, 2004). It is a typical-multidrug-resistant (MDR) organism known for its 
ubiquity, its fundamentally advanced antibiotic resistance mechanisms, and its link 
with serious diseases, particularly nosocomial infections such as sepsis (Cross et al., 
1983). It is also considered to be a serious danger to patients with impaired host 
defences, such as patients with burn wounds and cystic fibrosis (CF) (Hachem et al., 
2007). 
20 
P. aeruginosa has the ability to produce a biofilm in several environments (O'Toole 
and Kolter, 1998; Costerton et al., 1999; Yoon et al., 2002). Biofilms are surface-
attached bacterial communities in which microbial aggregates are enclosed in a 
self-formed, extracellular polymeric matrix (Whitchurch et al., 2002; Matsukawa 
and Greenberg, 2004; Fazli et al., 2009). Biofilms have a specific complex 
architecture and structure with biochemical characteristics that lead to increased 
bacterial resistance against host immune mechanisms and antibiotics (O'Toole and 
Kolter, 1998; Costerton et al., 1999; Mah et al., 2003). Thus, it is usually difficult to 
treat such biofilms effectively with antibiotics since the biofilm structure appears to 
protect the bacteria from diverse environmental factors (Stover et al., 2000). 
Biofilms of P. aeruginosa can be the cause of many chronic opportunistic infections 
in immunocompromised and elderly patients. It is the main cause of mortality and 
morbidity in CF patients, since it adapts, persists and produces biofilms in anaerobic 
CF environments, as opposed to the aerobic biofilms typically formed under 
laboratory conditions (Oliver et al., 2000; Singh et al., 2000). 
P. aeruginosa are resistant to a wide range of antibiotics and has the ability to 
acquire additional resistance after failed treatments. Resistance of P. aeruginosa to 
many common first-line antibiotics, such as carbapenems, polymyxins, and more 
lately tigecycline, has been demonstrated (Strateva and Yordanov, 2009). However, 
such antibiotics are still in use in cases where resistance has not yet been 
determined. The antibiotic fluoroquinolone is one of the few antibiotics that are 
efficient against P. aeruginosa. In some hospitals, treatment with this drug is 
severely controlled to avoid the progress of resistant strains (Köhler et al., 1997; 
Pesci et al., 1999). Although S. aureus has been established as a main participant in 
chronic wounds, recent evidence has demonstrated that P. aeruginosa infects the 
deeper layers of the chronic wounds (Fazli et al., 2011; Rybtke et al., 2015). 
1.3.3 Chronic Wounds and Biofilms 
The growth of microorganisms in chronic wounds has been shown to take the form 
of irregularly shaped micro-colonies that can comprise hundreds of bacteria 
(Bjarnsholt et al., 2008; Rybtke et al., 2015).  
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It is becoming increasingly apparent that biofilms play an important role in the 
production and maintenance of the chronic wound environment (Davis et al., 2008; 
James et al., 2008a; Kirketerp-Møller et al., 2008; Fazli et al., 2009). Nevertheless, 
the role of biofilms in chronic wounds is still not entirely understood, but it is 
supposed that their presence could be one of many causes of non-healing wounds 
(Bjarnsholt et al., 2005; Jensen et al., 2007; Fazli et al., 2009). Chronic impaired 
wounds are frequently colonised with biofilms of multiple bacterial species 
including S. aureus and P. aeruginosa (Clinton and Carter, 2015). Treatment of 
biofilm-infected wounds is extremely difficult due to the polymicrobial nature of 
these biofilms, and their high resistance to traditional antibiotic combinations 
(Clinton and Carter, 2015). Compared to normal wounds, chronic wounds are highly 
susceptible to colonisation with biofilms (James et al., 2008b). This makes wound 
infection one of the main factors that delay wound healing in chronic wounds 
(James et al., 2008b). 
Antimicrobial genes of biofilms, composed of one or multiple bacterial species, can 
interact with each other leading to an increased virulence of the overall biofilm 
(James et al., 2008b). Moreover, the metabolism of these multi-species biofilms can 
contribute to the development of antibacterial resistance, leading to auto-
regeneration of the biofilm after treatment with antibiotics (Fauvart et al., 2011). 
When established, biofilms become difficult to eradicate leading to a higher 
persistence of chronic wounds (James et al., 2008b). 
1.3.4 Bacterial Invasion of Host Tissues 
Invading bacteria adhere to host cells, generally epithelial cells, and start colonising 
host tissues. Bacteria develop complex strategies to successfully invade and survive 
inside the host (Cossart and Sansonetti, 2004). The key mechanisms by which 
bacteria invade the host include adhesion to host cells, release of toxins causing 
tissue damage, and development of resistance against host antimicrobial defences, 
thus assuring effective growth and survival (Finlay and Falkow, 1989; Galan, 1994; 
Ofek and Doyle, 2012). Such resistance mechanisms are particularly important in 
establishing a persistent, chronic infection. 
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Bacteria bind to host cells using filamentous proteins named adhesins, such as pili 
and fimbriae. Lipopolysaccharide (LPS), M proteins, capsule, glycocalyx and 
lipoteichoic acids all act directly or indirectly as adhesins  (Ofek and Doyle, 2012). It 
is known that the membrane surface of host cells and bacteria are negatively 
charged, leading them to repel each other (Gottenbos et al., 2001). However, when 
bacteria use adhesins, their hydrophobicity changes, which is a key feature that 
allows them to adhere to host cells (Peschel, 2002). Bacteria release a range of 
molecules, such as enzymes and endotoxins, which cause host tissue damage. 
Endotoxins are produced by both Gram-positive and Gram-negative bacteria and 
act mainly to disturb host cell functions. Endotoxins, produced by Gram-negative 
bacteria including, P. aeruginosa, are normally expressed on their cell wall and are 
typically released in huge quantities after bacterial lysis (Shenep and Mogan, 1984). 
LPS is a component of the Gram-negative bacterial membrane and is the most 
common endotoxin (Ulevitch and Tobias, 1999). The over-reaction to LPS can cause 
severe inflammatory diseases such as sepsis (Peyssonnaux et al., 2007) 
  Host-Pathogen Interactions 
Research has largely described the immune system response to free-living (not in a 
biofilm arrangement) pathogenic infection. It is essential to understand the 
immune system’s response to bacteria and apply that understanding to acute and 
chronic wound infections (Wolcott et al., 2008; Mahla et al., 2013). 
The host has highly developed approaches to recognise and identify bacteria and 
other microorganisms. Innate immunity (Figure 1.8) is initiated by pathogen-
associated molecular patterns (PAMPs), which are molecules expressed on the cell 
membrane of bacteria and microorganisms. PAMPs are recognised by pattern 
recognition receptors (PRRs) expressed on the membrane of immune cells 
(Hoffmann et al., 1999; Janeway and Medzhitov, 2002; Broz and Monack, 2013; 
Fukata and Arditi, 2013). PAMPs, such as LPS, bind to PRRs including Toll-like 
receptors (TLRs), and initiate a signalling cascade normally, via activation of nuclear 
transcription factor kappa beta (NF-κB) (Aliprantis et al., 1999; Kopp and 
Medzhitov, 1999). This event initiates the immune system to release a variety of 
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pro-inflammatory cytokines, such as granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-
stimulating factor (M-CSF), interferon-gamma (IFN-γ), tumour necrosis factor alpha 
(TNF-α), interleukin-1 (IL-1), interleukin-8 (IL-8) and interleukin-6 (IL-6) (Wolcott et 
al., 2008). These cytokines, particularly IL-8, are responsible for regulating the 
recruitment and the activation of neutrophils, and upregulating antibacterial 
activity in macrophages and dendritic cells. As the innate immune response 
progresses, pathogenic invaders are labelled with complement, allowing 
neutrophils and macrophages to identify, bind, engulf and finally digest them 
(Shepherd, 1986). Neutrophils are then digested by tissue macrophages to avoid 
host tissue destruction that could result from excessive secretion of neutrophil-
derived proteases.  
The PRRs are distributed into four functional families: Toll-like receptors (TLRs), 
nucleotide-binding oligomerisation domain-like receptors (NLRs), C-type lectin 
receptors (CLRs), and RIG-1 like receptors (RLRs) (Kopp and Medzhitov, 1999). 
Several TLRs respond to constituents of Gram-positive and Gram-negative bacteria 
and stimulate the immune inflammatory reaction (Hoffmann et al., 1999). 
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Figure 1.8. Innate immunity in host-pathogen interaction. When TLRs are activated, the 
innate immune response is initiated through the release of chemokines and cytokines. The 
acquired immune response is initiated by cytokines of Th1 and Th2, resulting in the 
production of antibodies. Figure drawn based on information in Basset et al. (2003). 
 
The activated complement system (Figure 1.9) consists of three main pathways: 
classical pathway, alternative pathway and lectin pathway. Complement is a key 
player of the innate immune system, providing a quick, robust response against 
foreign invaders, but it also has a very significant impact on the acquired immune 
system involving T and B cells to remove invaders (Dunkelberger and Song, 2010). 
Thirty proteins are involved in the complement pathways (Sarma and Ward, 2011). 
One of their main roles is to lyse microorganisms and to encourage the production 
of inflammatory mediators that attract phagocytes  and initiate the inflammatory 
response (Sarma and Ward, 2011). The main complement components involved in 
host cell recruitment at the infection site are C3a, C4a and C5a. Even though the 
complement system comprises several proteins, they all finally converge in the 
production of C3, which is the most abundant complement protein in the blood. C3 
is converted into various active forms including C3a, C3b, C5a and the membrane 
attack complex (C5b-9) (Sarma and Ward, 2011). 
The alternative pathway is an antibody independent pathway and represents a key 
element of innate immunity. It is initiated by molecules such as carbohydrates and 
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endotoxins found on foreign invaders (Qu et al., 2009). The classical pathway 
depends on the production of antibodies, and is a key element of the adaptive 
specific immune system (Sarma and Ward, 2011). The lectin pathway is activated by 
the binding of either mannose binding lectin (MBL) or ficolin to carbohydrates 
present on the membrane of invaders, including bacteria, viruses and parasites 
(Sarma and Ward, 2011). 
During bacterial infection, C3 is cleaved to opsonin (C3b), which binds to the 
pathogen to enable the immune phagocytic cells to remove the foreign invader 
(Walport, 2001; Sarma and Ward, 2011). Key cells of the innate immunity are 
epithelial, mast and dendritic cells in addition to phagocytic cells such as 
neutrophils, monocytes and macrophages. 
 
Figure 1.9. Representation of the complement system in host-pathogen interactions. 
Proteins of the complement system all converge at C3, which is then cleaved into C3b. C3b 
binds to the pathogen, resulting in its recognition and removal by immune cells, mainly via 
phagocytosis. Figure drawn based on information in Dumitru et al. (2000). 
  The Phagocytosis Process 
Phagocytosis is a complex process whereby a phagocyte eliminates or engulfs large 
cargo 0.5> µm by an actin-dependent mechanism (Mukherjee et al., 1997; Aderem 
and Underhill, 1999). The term “professional phagocytes” was first introduced by  
Rabinovitch (1995). It includes a specialised subset of host cells such as monocytes, 
macrophages, neutrophils and dendritic cells (Ginhoux and Guilliams, 2016). 
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Phagocytosis serves as a system to clear away the cellular and non-cellular 
materials from the extracellular space. It also removes microorganisms, such as 
bacteria, via opsonisation (antibody or complement) binding or pathogen-specific 
receptors (Arandjelovic and Ravichandran, 2015). 
Phagocytes are attracted to an infection site via chemotaxis in response to 
chemokines, cytokines such as IL-8, and bacterial elements such as LPS (Aliprantis et 
al., 1999). The process of phagocytosis begins with recognition of foreign invaders 
by a phagocytic cell. Microorganisms, such as bacteria, associate with the surface of 
the phagocyte resulting in actin polymerisation (Freeman and Grinstein, 2016; 
Garcia-Gomez et al., 2016), arrangement of the actin cytoskeleton followed by 
engulfment, phagosome and phagolysosome formation. Bacterial destruction is 
mediated by lysosomal enzymes and ROS (Pauwels et al., 2017). 
Many receptors contribute to phagocytosis with many particles being detected by 
several receptors such as antibody receptors (e.g. Fc receptor) and/or complement 
receptors (CR), in addition to the dual function of some receptors in  internalisation 
and adhesion (Freeman and Grinstein, 2014; Freeman and Grinstein, 2016). It is 
important that immune cells can distinguish harmful invaders from self (Randow et 
al., 2013), which is achieved through recognition of pathogen-associated 
particulates by phagocytic receptors (Santoni et al., 2015; Silva-Gomes et al., 2016). 
These particulates are recognised by pattern recognition receptors (PRRs) on the 
membrane of phagocytes (Broz and Monack, 2013; Fukata and Arditi, 2013). 
Pathogen-associated molecular patterns (PAMPs) that are recognised by PRRs 
include lipopolysaccharides (LPS) from Gram-negative bacteria, lipoteichoic acid 
(LTA) from Gram-positive bacteria, mannans from yeast and formulated bacterial 
peptides (Bæk et al., 2016; Galinari et al., 2017; Lam et al., 2017; Pauwels et al., 
2017). 
When the innate system is functioning appropriately, the eradication of bacteria 
and pathogens occurs quickly but when the system is compromised by host 
comorbidities, bacteria can become difficult to eradicate. After eliminating an 
invading pathogen, the immune system memorises the pathogen and develops 
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long-term defences against it, known as adaptive immunity (acquired immune 
response) (discussed in 1.1.2) (Wolcott et al., 2008).  
  Monocytes/Macrophages 
Monocytes are cells that circulate in the blood, spleen, and bone marrow, and 
represent around 10% of the entire population of human leukocytes (Geissmann et 
al., 2010). They are the biggest white blood cells, and have distinctive 
morphological structures, such as irregular cell shape, a folded or kidney-shaped 
nucleus, and cytoplasmic vesicles. Monocytes remain circulating in the bloodstream 
for about 1 to 3 days before moving into tissues, where they differentiate into 
macrophages or dendritic cells. If they are not recruited into tissues by a stimulus, 
they die and are removed by other immune cells. Monocytes are created in the 
bone marrow from hematopoietic stem cells (HSCs) and mature over successive 
differentiation phases: the common myeloid progenitor (CMP) (Akashi et al., 2000), 
the granulocyte-macrophage progenitor (GMP) (Akashi et al., 2000), the 
macrophage and dendritic cell precursors (MDP) (Fogg et al., 2006), and the 
committed monocyte progenitor (cMoP) (Hettinger et al., 2013; Italiani and 
Boraschi, 2014). Monocytes are considered to be the main reservoir of myeloid 
precursors for the regeneration of tissue macrophages and dendritic cells. 
However, some subpopulations of macrophages and dendritic cells (for instance 
skin Langerhans cells (LC), lymphoid organ dendritic cells and brain microglia) are 
generated originally from the MDP instead of monocytes (Liu et al., 2009; Boltjes 
and Van Wijk, 2014), and in some circumstances, they can be directly generated 
from the bone marrow (Ajami et al., 2007).  
Human peripheral blood monocytes are a heterogeneous population of cells 
(Passlick et al., 1989; Italiani and Boraschi, 2014). Recent studies have indicated 
that human monocytes are divided into three functional subsets (Italiani and 
Boraschi, 2014). The characterisation of these subsets is under investigation since it 
remains largely unclear, as do the exact functions they play in inflammation in vivo, 
in comparison with activated macrophages (see below).  
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Macrophages are heterogeneous phagocytic cells that reside in lymphoid and non-
lymphoid tissues of all adult humans and animals. When they are inactive (under 
normal healthy conditions), they represent up to 15 % of the entire number of 
immune cells. However, this percentage becomes higher in reaction to 
inflammatory stimuli. Depending on their tissue location, macrophages have 
various designations such as alveolar macrophages (lung), osteoclasts (bone), 
Küpffer cells (liver), histiocytes (connective tissue), and skin Langerhans cells (skin) 
(Gautier et al., 2012). Macrophages exert the same functions in all tissues. They are 
crucial in the immune response to pathogens (by producing and directing the 
inflammatory response), in tissue development, in monitoring tissue changes, and 
in the maintenance of steady-state tissue homeostasis (by elimination of apoptotic 
cells, by remodelling and repairing tissues, and by the production of growth 
factors). Macrophages are equipped with a broad range of pathogen-recognition 
receptors that make them efficient at phagocytosis, and they induce the production 
of inflammatory cytokines (Lin et al., 2008). 
Macrophages are characterised by the ability to engulf and digest cellular debris, 
microbes, cancer cells, and any other substance that does not express on its surface 
the normal, healthy-cell specific proteins, via a process known as phagocytosis 
(Duque and Descoteaux, 2015). In addition to phagocytosis, macrophages play a 
crucial role in both innate (non-specific) and adaptive (specific) immunity as they 
have the capacity to present antigens to other immune cells, such as T cells, to 
release cytokine (pro-inflammatory/anti-inflammatory mediators) and to move in 
response to chemokines in a process called chemotaxis (Duque and Descoteaux, 
2015). Macrophages are also crucial for the secretion of growth factors and 
cytokines. Growth factors and cytokines cause the attraction and division of cells 
involved in tissue repair (Werner and Grose, 2003), leading to angiogenesis, re-
epithelialisation of wounds, and the formation of new extracellular matrix 
(Greenhalgh, 1998; Stashak et al., 2004). 
Evidence has shown that there are numerous, activated forms of macrophages 
(Mosser and Edwards, 2010). There are two subtypes of macrophages, designated 
as M1 and M2. M1 macrophages encourage inflammation through the secretion of 
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pro-inflammatory cytokines whereas M2 macrophages reduce inflammation and 
encourage tissue repair (Mills, 2012). Lipopolysaccharide (LPS) and interferon-
gamma (IFN-γ) are typically present in infected wounds and lead to the generation 
of M1 macrophages. In contrast, M2 macrophages that stimulate tissue formation 
(e.g. during wound healing), are promoted by factors such as  by interleukin-4 (IL-4) 
(Biswas and Mantovani, 2010; Sica and Mantovani, 2012). 
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Table 1-2. Main functions of tissue resident macrophages.  
Apart from tissue-specific roles, tissue macrophages exert a series of common roles including removal of cellular debris, immune surveillance, wound 
repair, defence against microorganisms including bacteria, and the origination and resolution of inflammation. Figure adapted from Italiani and Boraschi 
(2014). 
Tissue Macrophages Tissue location Functions 
Heart macrophages Heart Surveillance. 
Osteoclasts Bone Bone modelling and remodelling, support to haematopoiesis  (Pollard, 2009; Blin-Wakkach et al., 2014). 
Microglia Brain Brain progress, immune surveillance, synaptic remodelling (Paolicelli et al., 2011; London et al., 2013). 
Alveolar macrophages Lung Clearance of surfactant and inhaled pathogens (Maus et al., 2002). 
Intestinal 
macrophages 
Gut 
Tolerance to microbiota, defence against pathogens, intestinal haemostasis (Zigmond and Jung, 2013). 
Bone marrow 
macrophages 
Bone marrow 
Reservoir of monocytes, waste removal (Davies et al., 2013). 
Langerhans cells Skin Immune surveillance. 
Küpffer cells 
Liver Toxin elimination, lipid metabolism, erythrocyte, microbes’ clearance, and cell debris clearance from blood (Kle 
(Klein et al., 2007; Ganz, 2012). 
Adipose tissue 
associated 
macrophages 
Adipose tissue 
Metabolism, adipogenesis, adaptive thermogenesis (Nguyen et al., 2011). 
Marginal zone, red 
pulp macrophages 
Spleen 
Erythrocyte clearance, iron recycling, uptake of microorganisms from blood (Den Haan and Kraal, 2012). 
Inflammatory 
macrophages 
All tissues 
Protection against pathogens and harmful stimuli (Labonte et al., 2014). 
Healing macrophages All tissues Angiogenesis, branched morphology (Mantovani et al., 2013). 
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U937 monocytes are an eternal human cell line commonly used to generate  
macrophage-like cells for in vitro studies. U937 cells exhibit characteristics of 
immature monocytes and, after conversion into macrophages, these cells display 
similar features and characteristics to human tissue macrophages (Minafra et al., 
2011).  Phorbol 12‐Myristate 13‐Acetate (PMA), also known as TPA, is a phorbol 
ester used to transform monocytes into macrophage-like cells in vitro. PMA‐treated 
U937 cells express high levels of CD11b, CD11c and protein kinase-C (PKC) 
(Sintiprungrat et al., 2010). When treated with PMA, U937 monocytes upregulate 
their cell adhesion molecules, such us beta‐2 integrins (CD11a, CD11c, CD18 and 
CD11b) allowing the cells to attach to cell culture flask surfaces. PMA triggers 
calcium and phospholipid‐dependent isoforms of PKC and encourages cyclic AMP 
metabolism, initiating maturation into a macrophage-like morphology (Luscinskas 
et al., 1994). 
1.4 Estrogen 
Estrogens are a group of sex steroid hormones which were first discovered by Edgar 
Allen and Edward Doisy in 1923 (MacCorquodale et al., 1936). In humans, three 
main forms of estrogen are described; estradiol, estrone and estriol with 17-β-
estradiol being the most potent and biologically active form. Estrogen is involved in 
several physiological roles such as the regulation of ovulation and fertility, 
development of female secondary sexual characteristics, synthesis of lipoproteins, 
regulation of insulin sensitivity, maintenance of bone mass, and conservation of cell 
growth and cognitive function (Cagnacci et al., 1992). Estrogen is also important in 
males as it is involved in spermatogenesis (Gladen et al., 1996; Miura et al., 1999; 
O’donnell et al., 2001), maintaining the density of bone (Stĕpán et al., 1989; Daniell, 
1997) and cardiovascular health (Group, 1973; Eriksson et al., 1989). Evidence has 
suggested that estrogen deficit is a key regulator of delayed wound healing in the 
elderly (Ashcroft et al., 1997b; Ashcroft and Ashworth, 2003). Estrogen has 
protective anti-inflammatory proprieties in several tissues, such as the brain 
(Straub, 2007). Despite the anti-inflammatory effect of estrogen on the skin, 
mediated via macrophage migration inhibitory factor (MIF) (Hardman et al., 2005), 
estrogen has been reported to stimulate wound repair independently from its anti-
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inflammatory effects in both genders. Systemic and peripheral levels of estrogen 
decline with increasing age in both males and females (with this diminution highly 
noticeable in post-menopausal females) (Ashcroft et al., 1997b). HRT-treated post-
menopausal females heal acute wounds faster than their age-matched control 
counterparts, who take no estrogen supplementation (Ashcroft et al., 1997b). 
Another study indicated that topical estrogen supplementation enhanced wound 
healing in elderly male and female patients, connected with a reduced 
inflammatory response  (Ashcroft et al., 1997b; Ashcroft et al., 1999b). Accordingly, 
these findings collectively indicate that estrogen has notably beneficial effects on 
wound healing. 
1.4.1 Estrogen Biosynthesis 
Estrogens are produced from cholesterol (Figure 1.10). Cholesterol is converted by 
several enzymes to androgens, such as testosterone and androstenedione, which 
are then converted to estrogens through the action of the P450 enzyme aromatase, 
in the endoplasmic reticulum of estrogen-producing cells (Payne and Hales, 2004). 
In adipose tissues, androstendione is converted to estrone whilst in ovarian 
granulosa cells testosterone is converted into estradiol. Aromatase is found in many 
peripheral tissues such as bone (Nawata et al., 1995), adipose tissue (Simpson, 
2000), brain  (Azcoitia et al., 2001) and vascular smooth muscle (Ling et al., 2004). 
In females at the age of reproduction, systemic estrogen is produced mainly by the 
ovary. It is fundamentally biosynthesised in the granulose cells of the ovarian 
follicles and the corpora lutea. In males, the gonad produces the largest quantity of 
systemic estrogen. However, a substantial amount of estrogen is also produced 
locally in peripheral tissues, acting in an autocrine and paracrine manner (Labrie et 
al., 1998). A substantial amount of inactive steroid precursors including 
dehydroepiandrosterone (DHEA), its sulphate (DHEA-S), and androstenedione (4-
dione) are produced by the adrenals and converted into active steroid hormones in 
peripheral tissues (Labrie et al., 1998). Several peripheral human tissues, such as 
adipose tissue, bone and skin can produce active estrogens and androgens locally 
from conversion of adrenal-derived precursors (Nelson and Bulun, 2001). The 
reduction in the formation of DHEA-S by the adrenals during aging results in a 
33 
dramatic fall in the formation of androgens and estrogens in peripheral target 
tissues, a situation which could be associated with age-related diseases (Labrie et 
al., 1998). 
Estrogen is synthesised locally in both young and old females and becomes 
progressively more important after postmenopause, when systemic levels are lost. 
After the menopause, estrogen biosynthesis changes from a systemic source 
produced by the ovaries, to a local source, synthesised in peripheral tissues (Picard 
et al., 2000). However, the rapid decline in the local production of estrogens with 
increasing age means peripheral estrogen is still insufficient to compensate for the 
loss in systemic estrogen levels. 
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Figure 1.10. Estrogen biosynthesis from cholesterol and androgen precursors. CYP = 
Cytochrome P450, HSD = Hydroxysteroid dehydrogenase and AKR = Aldo-keto reductase 
enable hormone synthesis. Figure adapted from Blair (2010). 
1.4.2 Estrogen Receptors 
Estrogen has multiple functions, such as the regulation of haemostasis, 
inflammation, cell growth and differentiation. Over the past decades, the existence 
of two nuclear and membrane-bound estrogen receptor (ER) proteins have been 
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identified: ER-alpha (ER-α) and ER-beta (ER-β). ER-α was first discovered in 1958 
(Jensen and Jacobson, 1960), whereas ER-β was first identified in rat prostate and 
ovary in 1996 (Mosselman et al., 1996). The biological effects of estrogens are 
mediated by the binding of estrogen to ER homodimers or heterodimers (Matthews 
and Gustafsson, 2003), and subsequent activation or repression of gene 
transcription and  signalling pathways, including ligand-dependent/independent 
pathways (Paige et al., 1999), estrogen response element (ERE)-independent 
pathways and non-genomic pathways. The ligand-dependent pathway is the central 
pathway. Interestingly, estrogen signalling can directly target specific ER genes and 
upregulate the expression of mRNA (Gruber et al., 2002; Ascenzi et al., 2006). 
Recent research also suggests estrogen could have a direct influence on 
inflammatory cells, such as monocytes and macrophages, and other cells in the 
human skin such as keratinocytes, due to the nuclear and membrane-bound 
localisation of ER proteins. (Weusten et al., 1986; Stimson, 1988; Cocchiara et al., 
1990). The response of these particular inflammatory cells depends on the local 
levels of estrogen and the maturity (stage of differentiation) of the cells (Ashcroft 
and Ashworth, 2003). 
1.4.3 Effect of Estrogen on Skin 
It is commonly accepted that the age-related reduction in estrogen levels is linked 
with skin degeneration. Estrogen deficiency results in detrimental effects on skin’s 
appearance (dry fragile skin, sagging, wrinkling) with decreased thickness and 
collagen(Ashcroft et al., 1999b; Shah and Maibach, 2001). Estrogen has been shown 
to have an opposite effect, improving collagen quality, improving skin thickness and 
augmenting vascularisation. The link between menopause and wound healing has 
been investigated where it was reported that systemic estrogen supplementation 
results in an intensification of collagen deposition in post-menopausal women 
(Savvas et al., 1993; Ashcroft et al., 1997b), whereas topical estrogen increases 
collagen I and III deposition in the skin of postmenopausal women, conserving skin 
thickness (Savvas et al., 1993; Sauerbronn et al., 2000). Another study on post-
menopausal women reported that there was a reduction in collagen type I and 
mainly type III in the skin of post-menopausal women compared to pre-menopausal 
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women, and a decrease in type III/type I ratio within the dermis. This alteration is 
predominantly associated with estrogen deficiency (Affinito et al., 1999; Horng et 
al., 2017). It has also been reported that estrogen replacement therapy can 
improve skin elasticity by 5% per year (Brincat et al., 1987). When locally applied on 
the skin of post-menopausal women, estradiol significantly increased the 
production of hydroxyproline and collagen fibres (Albright et al., 1941; Affinito et 
al., 1999; Sator et al., 2001; Horng et al., 2017). 
Additionally, topical estrogen improves the fibres elasticity in the dermis (Albright 
et al., 1941; Sator et al., 2001). Estrogen also augments the deposition of 
glycosaminoglycans in the ECM, enhances skin turgor and water retention, 
stimulates keratinocytes and inhibits matrix metalloproteinase (MMP) synthesis 
(Brincat, 2000). 
1.4.4 Estrogen and Wound Healing 
Recent research has demonstrated the key role of sex-steroid hormones in 
inflammation and wound healing process (Guo and DiPietro, 2010; Gilliver et al., 
2007). This is particularly observed in age-related impaired wound healing research 
where there is an important impact of these hormones on the inflammatory 
response in vivo. 
The impact of estrogen on wound healing was first studied in animals in 1947 
(Sjövall, 1947; Horng et al., 2017) and then in humans in 1953 (Sjöstedt, 1953; 
Horng et al., 2017). Afterwards, there has been an accumulating body of evidence 
supporting that estrogen has a key impact on wound healing (Brincat et al., 1987; 
Varila et al., 1995) (Affinito et al., 1999; Sauerbronn et al., 2000; Mills et al., 2005; 
Hardman and Ashcroft, 2008; Brufani et al., 2009; W.-L. Lee et al., 2013; Midgley et 
al., 2016; Mukai et al., 2016; Chenu et al., 2017; Leblanc et al., 2017; Horng et al., 
2017; Pepe et al., 2017; Wilkinson and Hardman, 2017). It has been indicated that 
estrogen deficiency contributes to cutaneous aging and delayed and/or impaired 
wound healing (Mukai et al., 2016; Wilkinson and Hardman, 2017). It has also been 
reported that estrogen replacement therapy could improve the skin elasticity by 5% 
in one year (Brincat et al., 1987). When locally applied on the skin of 
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postmenopausal women, estradiol significantly increases the production of 
hydroxyproline and collagen fibres (Affinito et al., 1999; Horng et al., 2017). Similar 
effects on the skin and collagen fibres were observed with systemic oral estrogen 
replacement therapy (Sauerbronn et al., 2000). 
Variance in  the human immune system between male and female subjects have 
been identified in some epidemiological and medical studies (McGowan et al., 
1975; Bone, 1992), with evidence indicating women have an improved immune 
system compared to men (Gulshan et al., 1990; Wichmann et al., 1996). This 
enhanced immune system in women is attributed to the hormonal regulation of the 
immune system. Other experiments have indicated that estrogen has an immune-
improving impact during stress and by contributing resistance to several pathogenic 
infections (Yamamoto, 1999). Ashcroft et al. (1997b) have reported that both 
systemic and topical estrogen treatments enhance wound healing in elderly men 
and women. Estrogen has been shown to accelerate re-epithelialisation, encourage 
angiogenesis, promote matrix deposition and wound contraction, dampen the 
inflammatory response and the inhibit expression of pro-inflammatory cytokines 
and proteolytic mediators (Ashcroft and Ashworth, 2003). 
  Effect of Estrogen on the Inflammatory Phase of Wound healing 
It is commonly known that age-related impaired healing is associated with an 
excessive and prolonged inflammatory response, linked with increased 
inflammatory cell migration and adhesion, and increased pro-inflammatory 
cytokines such as TNFα (Ashcroft and Ashworth, 2003). Recent research has 
indicated that chronic wounds are associated with elevated levels of elastase and 
MMPs, which are released by neutrophils/macrophages and linked with extreme 
tissue destruction (Gosain and DiPietro, 2004). Estrogen controls and dampens the 
early inflammatory response during acute wound healing by inhibiting neutrophil 
infiltration to the wound by reducing the expression of neutrophil adhesion 
molecules (Ashcroft et al., 1999b).  Estrogen causes a decrease in tissue-damaging 
proteases levels, such as elastase, and an increase in the content of collagen and 
fibronectin in the dermis (Ashcroft et al., 1999b). Furthermore,  estrogen increases 
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the oxidative metabolism of neutrophils, suggesting estrogen deprivation should 
lead to diminished phagocytic capability of neutrophils, an increased risk of 
infection and a postponement in healing (Ashcroft and Ashworth, 2003). Estrogen is 
also believed to have a direct influence on monocytes and macrophages, due to 
their possession of nuclear and membrane-bound ER (Weusten et al., 1986; 
Suenaga et al., 1996; Suenaga et al., 1998). Macrophage migration inhibitory factor 
(MIF) is a pro-inflammatory cytokine released by monocytes, macrophages, 
neutrophils, endothelial cells and keratinocytes. This cytokine is known to be a 
major regulator of the effects of estrogen on wound healing (Gilliver et al., 2010). 
Ashcroft et al. (2003) reported that mice with estrogen deficiency have higher MIF 
levels, resulting in an  elevated inflammatory response and delayed wound healing, 
whereas MIF null-mice displayed enhanced wound healing, with lower 
inflammation and greater matrix formation. Estrogen causes a down-regulation of 
MIF expression leading to a decline in inflammation, enhanced matrix deposition, 
increased re-epithelialisation and an overall accelerated wound repair (Ashcroft and 
Ashworth, 2003; Ashcroft et al., 2003). 
  Effect of Estrogen on the Proliferative Phase of Wound Healing 
Estrogen improves the proliferative phase of wound healing by enhancing re-
epithelisation, wound contraction, granulation tissue construction and 
angiogenesis. Estrogen enhances the mitogenesis of keratinocytes and increases 
the speed of re-epithelialisation and wound contraction in post-menopausal 
women (Ashcroft et al., 1997b). The rate of wound re-epithelialisation of post-
menopausal women treated with HRT for more than 3 months was similar to levels 
of re-epithelialisation in pre-menopausal females, whereas a non-HRT post-
menopausal group showed diminished re-epithelialisation. One feature of this 
improved re-epithelialisation following estrogen supplementation is due to 
increased proliferation of epidermal keratinocytes (Raja et al., 2007). Estrogen 
promotes PDGF expression by monocytes and macrophages (Mendelsohn and 
Karas, 1999), leading to mitogenesis and chemotaxis of fibroblasts and a 
subsequent increase in wound contraction and ECM deposition (Seppä et al., 1982). 
Estrogen also enhances fibrosis by increasing wound TGF-β1 levels (Ashcroft et al., 
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1997b; Ashcroft et al., 1999b), resulting in enhanced formation of ECM, particularly 
collagen deposition (Ashcroft and Ashworth, 2003). Estrogen promotes 
angiogenesis, leading to increased granulation tissue (Iyer et al., 2012) through a 
direct stimulation of endothelial cells (Rubanyi et al., 2002). Estrogen increases 
endothelial cell attachment to laminin, collagen I and IV, laminin, and fibronectin. In 
addition, estrogen enhances the creation of capillary-like structures by endothelial 
cells, when positioned on a reconstructed basement membrane (Morales et al., 
1995). 
  Effect of Estrogen on the Remodelling Phase of Acute Wound Healing 
Estrogen improves wound remodelling by controlling the degradation of collagen 
through wound proteases. Topical estrogen supplementation increases the 
deposition of collagen in during the remodelling phase of wound repair in elderly 
patients (Ashcroft et al., 1997b; Ashcroft et al., 1999b). Estrogen also acts by 
stimulating the expression of TGF-β1 to improve collagen deposition in the dermis 
(Ashcroft et al., 1997b; Ashcroft et al., 1999b). Matrix collagen deposition at 7 and 
84 days post-wounding was decreased in post-menopausal women lacking HRT 
treatment. In contrast, post-menopausal females who took HRT for more than 3 
months had similar levels of matrix collagen deposition and wound remodelling as 
younger pre-menopausal females (Ashcroft et al., 1997b; Ashcroft et al., 1999b). 
1.4.5 Estrogen and Chronic Wounds 
Since systemic estrogens decline with age, it has been suggested that estrogen 
deprivation in the elderly could possibly be linked with pathological wound healing. 
Margolis et al. (2002) performed a case-cohort study to investigate the protective 
effects estrogen on chronic wounds. Patients aged oved 65 years receiving HRT 
treatment were shown to be 30-40% less likely to develop a venous leg ulcer than 
age-matched patients lacking HRT supplementation (Margolis et al., 2002). Chronic 
wounds are characterised by an excessive and chronic prolonged inflammation. 
High levels of  inflammatory mediators, including TNFα, TGFβ,  IL-1, IL-6, IGF-1 and 
MMPs, present in chronic wound exudate (Ashcroft et al., 1997b; Ashcroft et al., 
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1999b) are downregulated via the action of estrogen (Straub, 2007; Wira et al., 
2015). 
1.5 Aim and Objectives 
Despite its anti-inflammatory activity in wound healing, the effect of estrogen on 
bacterial clearance from acute or chronic wounds remains largely unknown. 
Moreover, it is not known whether estrogen deprivation in the elderly exacerbates 
chronic wound infections. However, there is a vital need to develop novel 
therapeutic strategies to treat bacterial wound infections in the elderly and one 
exciting approach is to enhance innate host responses so the immune system is 
better able to eradicate potential pathogens. Thus, the aim of this study was to 
determine the effects of estrogen on the phagocytic function of macrophages using 
in vitro and ex vivo host-pathogen models of the inflammatory phase of age-related 
impaired healing. 
Specific objectives of this study were to: 
 Generate an in vitro model of HPBM and U937 monocyte differentiation into 
M0-like, M1-like and M2-like macrophages. 
 
 Determine the effect of estrogen on the phagocytosis of Gram-positive 
(MRSA) and Gram-negative (P. aeruginosa) wound pathogens by U937- and 
HPBM-derived macrophages. 
 
 Compare the effect of age-related changes in estrogen levels on the 
phagocytic activity of M0-like, M1-like and M2-like macrophages against 
Gram-positive and Gram-negative bacteria. 
 
 Explore the role of ER-α and ER-β in mediating the effects of estrogen on the 
phagocytosis of bacteria by pro-inflammatory M1-like macrophages. 
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 Investigate the effect of estrogen on downstream mediators of phagocytosis 
including regulating protein levels of FAK, Rac1, RhoA, Cdc42 and RhoG in 
pro-inflammatory M1-like macrophages. 
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2.1 Materials 
Alexa Fluor 647-conjugated anti-human MMR/CD206 (BioLegend, UK) 
Bicinchoninic acid assay reagent (Sigma-Aldrich, UK) 
Bovine serum albumin (Fisher Scientific, UK) 
Brain heart infusion agar (Oxoid, UK) 
Brain heart infusion broth (Oxoid, UK) 
Chloramphenicol (Sigma-Aldrich, UK) 
Diarylpropionitrile (Sigma-Aldrich, UK) 
Dimethylsulphoxide (Sigma-Aldrich, UK) 
Dulbecco's phosphate-buffered saline (Sigma-Aldrich, UK) 
Estrogen (Sigma-Aldrich, UK) 
Ethanol (Fisher Scientific, UK) 
Ethylenediaminetetraacetic acid (Fisher Scientific, UK) 
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (Fisher Scientific, 
UK) 
EZ-ECL chemiluminescence detection kit (Biological Industries IBH Ltd, USA) 
Fluorescein isothiocyanate (FITC)-conjugated anti-human CD11c antibody (Clone 
Bu15; BioLegend, UK) 
Fluorescein isothiocyanate (FITC)-conjugated anti-human CD197 (CCR7) antibody 
(BioLegend, UK) 
Foetal bovine serum (Lonza, UK) 
Fulvestrant (Sigma-Aldrich, UK) 
Gentamicin (Sigma-Aldrich, UK) 
Glutaraldehyde (Sigma-Aldrich, UK) 
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Green fluorescent protein (GFP)-S. aureus strain SH1000 (Kind gift from Paul 
Williams, Professor of Molecular Microbiology, Centre for Biomolecular Sciences, 
Faculty of Medicine & Health Sciences, University of Nottingham, UK) 
Human blood cell culture medium (Cell Applications Inc, San Diego, USA) 
Human peripheral blood CD14+ monocytes (Cell Applications Inc, San Diego, USA) 
Hydrogen chloride (Thermo Fisher Scientific, UK) 
Interferon gamma (Sigma-Aldrich, UK) 
Interleukin-4 (Sigma-Aldrich, UK) 
Interleukin-13 (Sigma-Aldrich, UK) 
Lipopolysaccharide from the membrane of Escherichia coli (Sigma-Aldrich, UK) 
MCherry- P. aeruginosa strain PAO1 (Kind gift from Paul Williams, Professor of 
Molecular Microbiology, Centre for Biomolecular Sciences, Faculty of Medicine & 
Health Sciences, University of Nottingham, UK)  
Methanol (Thermo Fisher Scientific, UK) 
Methicillin Resistant Staphylococcus aureus strain 11 (Hospital isolates, 
Manchester, UK) 
Mouse primary antibody to Cdc42 (Abcam, UK) 
Mouse primary antibody to Cyclophilin (Abcam, UK) 
Mouse primary antibody to Fak (Abcam, UK) 
Mouse primary antibody to Rac1 (Abcam, UK) 
Mouse primary antibody to RhoA (Abcam, UK) 
Mouse primary antibody to β-actin (Abcam, UK) 
Mouse primary antibody to β-tubulin (Abcam, UK) 
Nitrocellulose membrane (GE Healthcare Life Sciences, UK) 
Nutrient agar (Oxoid, UK) 
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Nutrient broth (Oxoid, UK) 
Paraformaldehyde (Sigma-Aldrich, UK) 
Penicillin – streptomycin (Lonza, UK) 
Peroxidase-HRP anti-mouse IgG (produced in A9044 rabbit) (Sigma-Aldrich, UK) 
Peroxidase-HRP anti-rabbit IgG (produced in goat) (Sigma-Aldrich, UK) 
pH meter (Hanna Instruments, UK) 
Phalloidin–tetramethylrhodamine B isothiocyanate conjugate from Amanita 
phalloides (Fluka, Germany) 
Phorbol 12-myristate 13-acetate (Applichem, Germany) 
Propylpyrazoletriol (Sigma-Aldrich, UK) 
Protease inhibitor cocktails (Sigma-Aldrich, UK) 
Pseudomonas aeruginosa strain PAO1 (Hospital isolates, Manchester, UK) 
Pyrazole triol (Sigma-Aldrich, UK) 
Rabbit primary antibody to RhoG (Abcam, UK) 
Roswell Park Memorial Institute Medium (RPMI) (Lonza, UK) 
Saline tablets (Sigma-Aldrich, UK) 
Skimmed milk powder (Premier Foods Group, UK) 
Sodium chloride (Thermo Fisher Scientific, UK) 
Sodium deoxycholate, phenylmethylsulfonyl fluoride (Thermo Fisher Scientific, UK) 
Sodium dodecyl sulfate (Sigma-Aldrich, UK) 
Sodium hydroxide (Fisher Scientific, UK) 
Tamoxifen (Sigma-Aldrich, UK) 
Tetracycline (Sigma-Aldrich, UK) 
Theophylline, 8-[(benzylthio)methyl]-(7CI,8CI) (Sigma-Aldrich, UK) 
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Trypan blue (Lonza, UK) 
Trypsin EDTA (Lonza, Belgium) 
Tris base (Fisher Scientific, UK) 
Tris hydrochloride (Fisher Scientific, UK) 
Tris (hydroxymethyl) aminomethane (THAM) hydrochloride (Fisher Scientific, UK) 
Triton X-100 (Lonza, Belgium) 
Tween-20 (Fisher Scientific, UK) 
U937 Human monocytic cell line (Health Protection Agency Culture Collections, UK) 
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2.2 Methods 
2.2.1 Preparation of RPMI-1640 Complete Medium 
Foetal bovine serum (FBS) was heat-inactivated in a water bath maintained at 56 °C 
for 30 minutes. Roswell Park Memorial Institute (RPMI)-1640 (L-Glutamine, 25 mM 
HEPES) supplemented with 10% FBS and 100 I.U./mL penicillin-streptomycin was 
prepared under aseptic conditions and referred to as RPMI-1640 complete medium 
throughout the study. 
2.2.2 Estrogen Treatment Preparation 
Estrogen (17β-estradiol) was prepared to final concentrations of 1 x 10-7 M, 1 x 10-8 
M, 1 x 10-9 M and zero M in antibiotic-free RPMI-1640 complete medium or human 
blood cell culture medium (HBCCM). Concentrations of estrogen were chosen 
according the previously published models of ageing to represent physiological 
levels of estrogen (1 x 10-8 M) typical of young human adults, supraphysiological 
levels of estrogen (1 x 10-7 M) to model estrogen supplemention, estrogen 
deprivation (1 x 10-9 M) to represent declining levels found in elderly humans and 
an absolute absence of estrogen (zero M) (Ashcroft and Ashworth, 2003; Hardman 
et al., 2005; Sproston et al., 2018). 
2.2.3 Cell Culture 
U937 monocytes were cultured under aseptic conditions at 37 °C and 5% CO2 using 
RPMI-1640 complete medium. CD14+ human peripheral blood monocytes (HPBM) 
were cultured in HBCCM under aseptic conditions at 37 °C and 5% CO2. The U937 
and HPBM cell suspensions were centrifuged at 500 g for 7 minutes before the 
medium was aspirated. U937 monocytes and HPBM were maintained at 0.5 x 106 
cells/mL and 1 x 106 cells/mL respectively by resuspension in fresh medium every 
other day. Sterile filtered 0.4% trypan blue dye was used to check cell viability 
according to published methodologies (Mir et al., 1991) using a 1:1 ratio of cell 
suspension to trypan blue and counting the number of non-viable cells that took up 
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the blue dye using a TC10 automated cell counter (Bio-Rad, USA). The viability of 
the cells was above 80% for all experiments. 
2.2.4 Differentiation of Monocytes into M0 Macrophages 
HPBM and U937 monocytes at a concentration of 1 x 106 viable cells/mL were 
differentiated into macrophage-like cells by incubating with 50 ng/mL phorbol 12-
myristate 13-acetate (PMA) in RPMI complete medium for 24 hours at 37 °C and 5% 
CO2. Cells were washed twice with complete medium and then incubated for a 
further 48 hours in PMA‐free complete medium to obtain resting macrophages 
known as M0 macrophages (Daigneault et al., 2010; Rios de la Rosa et al., 2017). 
2.2.5 Generation of M1 and M2 Macrophages 
U937 monocytes and HPBM were cultured as described in 2.2.3. Cells were 
differentiated into resting M0 macrophages as described in 2.2.4. The medium was 
aspirated and the cells washed twice with complete medium. M1 and M2 
macrophages were generated using the method adapted from Rios de la Rosa et al. 
(2017). For M1 differentiation/polarisation, M0 macrophages were incubated with 
100 ng/mL lipopolysaccharide (LPS) and 20 ng/mL interferon gamma (IFN‐γ) in 
PMA‐free complete medium for 24 hours at 37 °C and 5% CO2. The adherent cells 
were washed twice with LPS/IFN‐γ-free complete medium and then incubated with 
complete cell culture medium for 4 days at 37 °C and 5% CO2, with medium changes 
every 48 hours to obtain classically activated resting M1 macrophages. For M2 
differentiation/polarization, M0 macrophages were incubated for 24 hours with 20 
ng/mL interleukin-4 (IL-4) and 20 ng/mL interleukin-13 (IL-13) in complete medium. 
The adherent cells were washed twice with IL-4/IL-13-free complete medium prior 
to incubation in complete medium for 4 days, with medium changes every 48 hours 
to obtain alternatively activated resting M2 macrophages. 
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2.2.6 Flow Cytometry 
  Confirming the Differentiation of Monocytes into M0 Macrophages 
Differentiation of U937 and HPBM monocytes into M0 macrophages was confirmed 
by flow cytometry via analysis of CD11c+ surface marker expression. Monocytes and 
M0 macrophages were seeded in 1 mL of RPMI/HBCCM complete medium at a 
density of 1 × 106 cells/mL in 12-well plates according to methods described in 2.2.3 
and 2.2.4 respectively.  Adherent macrophages were detached from six replicate 
wells by removing the supernatant and adding 250 µL trypsin EDTA for 3 minutes at 
37 °C and 5% CO2. The trypsin EDTA was neutralised by adding 250 µL RPMI/HBCCM 
complete cell culture medium before being washed (centrifugation of well 
constituents at 500 g for 7 minutes and resuspension of the cell pellet) in 1 mL 
complete medium. The monocytes (6 replicate wells) and detached macrophages (6 
replicate wells) were then centrifuged at 500 g for 7 minutes and supernatants 
discarded prior to fixing pelleted cells with 200 µL 4% paraformaldehyde in 
Dulbecco's phosphate-buffered saline (DPBS) for 10 minutes at room temperature 
(RT). Cells were washed twice in 200 µL DPBS. Half the fixed macrophage samples 
(n = 3) and half the fixed monocyte samples (n=3) were stained for 30 minutes at RT 
with FITC-conjugated anti-human CD11c antibody diluted 1:40 with 10% FBS in 
DPBS. The remaining fixed monocyte (n = 3) and fixed macrophage (n = 3) samples 
were prepared as unstained negative controls by incubating at RT for 30 minutes 
with 10% FBS in DPBS lacking antibody. Unbound antibody was removed from 
samples by two sequential wash steps in DPBS, before resuspension in 500 µL DPBS. 
CD11c surface marker expression was assessed on 10,000 events (live, individual 
cells) with a BD Accuri C6F1 cytometer (BD Biosciences, USA). Data were analysed 
with BD Accuri C6 Software after gating events in the forward scattered channel 
(FSC)/side scattered channel (SSC) and fluorescence parameter 1 (FL1-A) windows. 
The average percentage CD11c+ cells (%) and median fluorescence intensity (MFI) 
were determined relative to unstained negative control U937/HPBM monocytes. 
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  Polarisation of M0 Macrophages into M1/M2 Macrophages 
Polarisation of U937 and HPBM M0 macrophages into M1/M2 macrophages was 
confirmed by flow cytometry via analysis of CD197+ and CD206+ surface marker 
expression respectively. M0 macrophages were seeded in 1 mL of RPMI/HBCCM 
complete medium at a density of 1 × 106 cells/mL in 12 well plates according to 
methods described in 2.2.4. M0 macrophages were polarised into M1 (n = 6 
replicate wells) and M2 (n = 6 replicate wells) macrophages as described in 2.2.5. 
Adherent M0/M1/M2 macrophages (n = 6 replicate wells) were detached using 
trypsin, fixed with 4% paraformaldehyde and washed twice with DPBS as described 
in 2.2.6.1. Supernatants were discarded and half the M0/M1/M2 samples (n = 3 
replicate wells) were stained for 30 minutes at RT with FITC-conjugated anti-human 
CD197 (CCR7) antibody diluted 1:50 with 10% FBS in DPBS, washed twice with 500 
µL DPBS before being incubated with Alexa Fluor 647-conjugated anti-human 
MMR/CD206 antibody (1:50 with 10% FBS in DPBS) for 30 minutes at RT. The 
remaining M0/M1/M2 samples (n = 3 replicate wells) were incubated at RT for 1 
hour with 10% FBS in DPBS lacking any antibodies (unstained negative controls). 
Two sequential wash steps were performed in DPBS prior to resuspension in 500 µL 
DPBS as described in 2.2.6.1. Samples were analysed as described in 2.2.6.1 after 
gating events in the FSC, SSC, FL1-A and fluorescence parameter 2 (FL2-A) windows.  
The average percentage CD197+/CD206+ cells (%) and median fluorescence intensity 
(MFI) were determined relative to the unstained M0 macrophages. 
2.2.7 Bacterial Culture Preparation 
Methicillin-resistant Staphylococcus aureus (MRSA) strain 11, Pseudomonas 
aeruginosa strain PAO1, green fluorescent protein (GFP) labelled-S. aureus strain 
SH1000WT and mCherry-P. aeruginosa strain PAO1 were used in this project. When 
required, cultures of MRS11 and PAO1 were inoculated onto nutrient agar (NA) 
plates and incubated at 37 °C for 24 hours. Cultures of GFP-S. aureus were 
inoculated onto brain heart infusion (BHI) agar plates supplemented with 10 µg/mL 
chloramphenicol and incubated at 37 °C for 24 hours. Cultures of mCherry- P. 
aeruginosa strain PA01 were inoculated onto NA plates supplemented with 1.25 
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µg/mL tetracycline and incubated at 37 °C for 24 hours. The bacterial inoculated 
agar plates were stored at 4 °C and replaced every four weeks. 
When required for experimental assays, MRSA 11 and P. aeruginosa PAO1 were 
cultured in nutrient broth (NB) overnight at 37 °C on an orbital shaker (New 
Brunswick Scientific, USA). Ten-fold serial dilutions of each broth were prepared in 
saline and 100 µL aliquots were inoculated onto duplicate NA plates with 
subsequent incubation at 37 °C overnight, whilst the broths were refrigerated 
overnight at 4 °C to inhibit further bacterial growth. The colony-forming units (CFU) 
counted on the NA plates were used to calculate the density of bacteria (CFU/mL) 
in each NB, taking into account the dilution factor. The neat broths were 
centrifuged at 3500 rpm for 10 minutes and the bacterial cell pellets washed twice 
with saline prior to re-suspension at 2 x 106, 2 x 105, and 2 x 104 CFU/mL in saline. 
GFP-S. aureus strain SH1000WT was cultured in BHI broth supplemented with 10 
µg/mL chloramphenicol and incubated at 37 °C overnight on an orbital shaker. Ten-
fold serial dilutions of the broth were prepared in saline and 100 µL aliquots of each 
dilution were inoculated onto duplicate BHI agar plates supplemented with 10 
µg/mL chloramphenicol with subsequent incubation at 37 °C overnight. The neat 
broth was refrigerated overnight at 4 °C to inhibit further bacterial growth. The CFU 
counted on the agar plates were used to calculate the density of bacteria (CFU/mL) 
in the neat broth, taking into account the dilution factor. The bacterial broth was 
centrifuged at 3500 rpm for 10 minutes and the cell pellet washed twice with saline 
prior to re-suspending the bacteria at 2 x 105 CFU/mL in saline. 
Red mCherry-P. aeruginosa strain PAO1 was cultured in NB supplemented with 1.25 
µg/mL tetracycline and incubated at 37 °C overnight on an orbital shaker. Ten-fold 
serial dilutions of the broth were prepared in saline and 100 µL aliquots of each 
dilution were inoculated onto duplicate NA plates supplemented with 1.25 µg/mL 
tetracycline with consequent incubation at 37 °C overnight. The neat broth was 
refrigerated overnight at 4 °C to inhibit further bacterial growth. The CFU counted 
on the agar plates were used to calculate the density of bacteria (CFU/mL) in the 
neat broth, taking into account the dilution factor. The bacterial broth was 
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centrifuged at 3500 rpm for 10 minutes and the cell pellet washed twice with saline 
prior to re-suspending the bacteria at 2 x 105 CFU/mL in saline. 
2.2.8 In vitro and Ex vivo Host-Pathogen Interaction Assays 
  Interaction of M0 Macrophages with MRSA and PAO1 
M0 resting macrophages generated from HPBM and U937 monocytes were 
prepared in 24-well plates as described in 2.2.4. The medium was aspirated and 
replicate wells (n = 6) were treated with different concentrations (1 x 10-7 M, 1 x 10-
8 M, 1 x 10-9 M and zero M) of estrogen in corresponding antibiotic-free medium 
(HBCCM or RPMI-1640 for macrophages derived from HPBM and U937 respectively) 
for 24 hours at 37 °C and 5% CO2. In addition, replicate (n = 6) blank control wells 
consisting of antibiotic-free HBCCM or RPMI-1640 medium, but lacking 
macrophages, were prepared and incubated for 24 hours at 37 °C and 5% CO2. 
Replicate negative control wells (n = 6) were prepared by treating macrophage-
containing wells with 1 x 10-7 M bovine serum albumin (BSA) in corresponding 
antibiotic-free medium and incubating for 24 hours at 37 °C and 5% CO2. The 
supernatant was removed from all wells prior to treating with 1 µg/mL LPS and 100 
ng/mL IFN-γ in corresponding antibiotic-free medium for 2 hours at 37 °C and 5% 
CO2. 
The supernatant was removed from all wells before inoculating the macrophages 
with 1 x 104 CFU of bacteria in a total volume of 100 µL antibiotic-free medium 
containing 1 µg/mL LPS and 100 ng/mL IFN-γ (1:1). Plates were incubated for 3 
hours at 37 °C and 5% CO2 to enable host-pathogen interactions (phagocytosis) to 
occur. 
Following the 3 hours host-pathogen interaction period, the supernatant of each 
well was collected. M0 macrophages were released from each well by adding 450 
µL trypsin EDTA and incubating for 3 minutes at 37 °C and 5% CO2. The trypsin EDTA 
was neutralised by adding 450 µL antibiotic-free medium to each well. The 
constituents of each well (900 µL) were collected and added to the previously 
collected supernatant (100 µL) and thoroughly mixed. Aliquots (100 µL) of each 
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sample were then inoculated onto NA plates in duplicate and incubated at 37 °C 
overnight. The number of CFU formed on the agar plates were counted to calculate 
the bacterial recovery in each sample following the period of host-pathogen 
interaction. 
  Interaction of M1/M2 Macrophages with MRSA and PAO1 
Classically activated resting M1 macrophages and alternatively activated resting M2 
macrophages were generated from HPBM and U937 macrophages as described in 
2.2.5. The medium was aspirated and 3-hour host-pathogen interaction assays were 
conducted as described in 2.2.8.1. 
2.2.9 Interaction of M0 Macrophages with GFP- S. aureus 
M0 U937 macrophages were prepared in 50 mL cell culture flasks as described in 
2.2.4. The medium was discarded and the cells washed with complete RPMI 
medium. Flasks were treated with different concentrations (1 x 10-7 M, 1 x 10-8 M, 1 
x 10-9 M and zero M) of estrogen in antibiotic-free RPMI medium for 24 hours at 37 
°C and 5% CO2. A negative control flask was prepared by treating with 1 x 10-7 M 
BSA and incubating at 37 °C and 5% CO2 for 24 hours. The supernatants in all flasks 
were discarded before treating all flasks with 1 µg/mL LPS and 100 ng/mL IFN-γ (all 
in antibiotic-free RPMI medium) for 2 hours at 37 °C and 5% CO2. 
The supernatants were discarded and each flask was then inoculated with 1 x 105 
CFU of GFP-S. aureus in a total volume of 10 mL antibiotic-free RPMI medium 
containing 1 µg/mL LPS and 100 ng/mL IFN-γ. All flasks were incubated for a 3-hour 
period of host-pathogen interaction at 37 °C and 5% CO2 prior to collecting the 
supernatant of each flask. Adherent M0 macrophages were released from each 
flask by adding 5 mL trypsin EDTA and incubating for 3 minutes at 37 °C and 5% CO2 
with gentle detachment using a sterile cell scraper. A volume of 5 mL antibiotic-free 
RPMI medium was added to each flask to neutralise the EDTA and the contents of 
each flask (10 mL) was combined with the previously collected supernatant (10 mL) 
and thoroughly mixed. Each sample (20 mL) was centrifuged at 500 g for 7 minutes 
and the cell pellet re-suspended in 5 mL antibiotic-free RPMI medium. 
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A countess II FL cell counter (Life technologies, USA) was used to detect the GFP 
signals and capture images (n = 10) of bacterial internalisation within macrophages 
from each flask. The phagocyte density, number of internalised bacteria, total 
number of macrophages and total bacterial counts were determined from images in 
order to calculate the total number of phagocytes/mL and the ratio of bacterial 
internalisation/recovery. 
2.2.10 Gentamicin Protection Assay  
U937 monocytes (1 x 106 cell/well) were seeded in a 24-well plate and 
differentiated into resting M0 macrophages as previously described in 2.2.6.1. Cells 
were treated with estrogen (1 x 10-7 M, 1 x 10-8 M, 1 x 10-9 M and zero M) or 1 x 10-7 
M BSA and stimulated with LPS (1 µg/mL) and IFN-γ (100 ng/mL) before being 
incubated with 1 x 104 CFU of MRSA 11 and P. aeruginosa PAO1 for 3 hours as 
described in 2.2.8.1. Protection gentamicin assay was performed according to 
methods detailed by Hockenberry et al. (2016). After a three-hour incubation 
period, the supernatant (100 µL) was collected and the wells were treated with 
0.1% Triton X-100 (100 µL) in DPBS for 5 minutes at 37 °C and 5% CO2 to release the 
membrane-adherent bacteria. The supernatant was collected and the cells were 
washed 10 times with DPBS before being incubated with 50 µg/mL gentamicin in 
antibiotic-free RPMI medium for 1 hour to eradicate extracellular and membrane-
bound gentamicin-sensitive bacteria. The supernatant was discarded and the cells 
were washed 10 times with DPBS. The supernatant was discarded and cells were 
detached after incubation with 400 µL Trypsin EDTA at 37 °C and 5% CO2 for 3 
minutes. A volume of 400 µL antibiotic-free RPMI medium was added to each well 
to neutralise the trypsin EDTA. The constituents of each well (800 µL) were then 
collected and added to the previously collected supernatants (200 µL) and 
thoroughly mixed. CFU/mL were counted after plating 100 µL aliquots on duplicate 
NA plates and incubating at 37 °C overnight. 
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2.2.11 Visualising Host-Pathogen Interactions  
 Fluorescence Microscopy 
Silicon wafers (Montco Technologies, USA) were cut at a diameter of 1 cm2 and 
sterilised with 70% ethanol for 30 minutes before being rinsed with dH2O and 
washed with DPBS for 10 minutes. U937 monocytes (0.5 x 106 cell/well) were 
seeded and differentiated into adherent M0 macrophages on sterile silicon wafers 
inside a 12- well plate. Cells were treated with/without estrogen (1 x 10-7 M) or 1 x 
10-7 M BSA, stimulated with LPS (1 µg/mL) and IFN-γ (100 ng/mL), and incubated 
with GFP S. aureus or mCherry P. aeruginosa (both at 1 x 105 CFU) using methods 
described in 2.2.8.1. The supernatant from each well was removed and the cells 
were fixed with 4% paraformaldehyde in DPBS for 10 minutes at RT. The 
supernatants were discarded and the cells washed three times with DPBS before 
being incubated with Triton X-100 in DPBS (0.1%) for 5 minutes at RT. The cells 
were washed three times with DPBS and treated with a blocking buffer (3% BSA in 
DPBS) for 1h at RT. The supernatants were aspirated and the cells were 
immediately treated with phalloidin–tetramethylrhodamine B isothiocyanate 
conjugate from Amanita phalloides (1:200 in blocking buffer) and incubated in the 
dark at RT overnight. The supernatant was removed and the cells were washed 
three times with DPBS. The silicon wafers with attached cells were removed using 
sterile tweezers and attached to a microscope slide using double-sided tape. 
Samples were observed at 100X on a Nikon E600 epifluorescence microscope 
(Nikon, Japan) and at 63X under a Leica TSC SPE1000 confocal microscope (Leica 
Microsystems, UK). Z-stack analysis was performed on samples to localise the 
bacterial internalisation by macrophages. 
 Scanning Electron Microscopy  
Sterile silicon wafers of 1 cm2 diameter were washed with DPBS for 10 minutes 
before being placed in 12-well plates. Adherent U937 M0 macrophages were 
generated on the silicon wafers. Cells were treated with/without estrogen (1 x 10-7 
M) or 1 x 10-7 M BSA, stimulated with LPS (1 µg/mL) and IFN-γ (100 ng/mL), and 
incubated with 1 x 105 CFU of MRSA 11 or PAO1 for 1 hour at 37 °C and 5% CO2 
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using methods described in 2.2.8.1. Following the 3-hour period of host-pathogen 
interaction, the silicon wafers from each well were collected and fixed with 2.5% 
glutaraldehyde in DPBS. Samples were incubated at 4 °C overnight. The silicon 
wafers were washed twice in DPBS, then soaked in 20% methanol/ethanol for 30 
minutes, 40% methanol/ethanol for 30 minutes, 60% methanol/ethanol for 30 
minutes, 80% methanol/ethanol for 30 minutes, and finally in 100% 
methanol/ethanol for 30 minutes twice before being dried overnight in a vacuum-
assisted desiccator (Sigma-Aldrich, UK). A Supra 40VP scanning electron microscope 
(Zeiss, Germany) was used to capture scanning electron microscopy (SEM) images 
using SmartSEM software (Carl Zeiss Ltd, Germany) to compare the internalisation 
of MRSA strain 11 or P. aeruginosa strain PAO1 by M0 macrophages with/without 
presence of estrogen. 
2.2.12 Estrogen Receptor Stimulation/Blockade 
HPBM and U937 monocytes were differentiated into M1 macrophages as described 
in 2.2.5. Replicate wells (n = 6) were treated with 1 x 10-7 M BSA, 1 x 10-7 M 
estrogen, zero M estrogen, 1 x 10-6 M tamoxifen, 1 x 10-6 M propyl pyrazole triol 
(PPT), and 1 x 10-6 M diarylpropionitrile (DPN) (all prepared in complete RPMI 
medium) and incubated at 37 °C and 5% CO2 for 24 hours. Treatments were 
aspirated and the cells washed with DPBS. A volume of 500 µL of complete RPMI 
medium was added to each well and incubated for 24 hours at 37 °C and 5% CO2. 
Further replicate wells (n = 6) containing M1 macrophages were treated with 1 x 10-
6 M fulvestrant and 1 x 10-6 M theophylline, 8-[(benzylthio)methyl] (TPBM) in 
complete RPMI medium for 24 hours. Treatments were aspirated and the cells 
washed with DPBS. Cells were treated with 1 x 10-7 M estrogen and incubated at 37 
°C and 5% CO2 for 24 hours. 
Host-pathogen interaction assays were then performed for 3 hours in all wells as 
described in 2.2.8 and bacterial (MRSA11 and PAO1) recovery determined. 
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2.2.13 Investigating Mediators of Host-Pathogen Interactions by Immunoblotting 
 Preparation of Buffers 
TBS-Tween buffer, adjusted to pH 7.4 
 10 mM Tris-base 
 140 mM Sodium chloride (NaCl) 
 0.1% Tween-20 
 Distilled water (dH2O) 
Blocking buffer, adjusted to pH 7.4 
 1% BSA in TBS-Tween 
RIPA buffer 
 140 mM Sodium chloride (NaCl) 
 25 mM Tris-hydrochloride (Tris-HCl) 
 1 mM Ethylenediaminetetraacetic acid (EDTA) 
 0.5 mM Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic 
acid (EGTA) 
 0.5% Sodium deoxycholate, phenylmethylsulfonyl fluoride (PMSF) 
 1% Triton X-100 
 0.1% Sodium dodecyl sulfate (SDS) 
 0.1% Protease inhibitors cocktail 
 Ultrapure water 
 Protein Extraction and Quantification 
U937 monocytes were differentiated into M1 macrophages in three T25 flasks (1 x 
107 cells/flask) using methods described in 2.2.5. The medium in all flasks was 
discarded and adherent M1 macrophages were treated with 10 mL of 1 x 10-7 M 
BSA (negative control), zero M estrogen or 1 x 10-7 M estrogen in RPMI complete 
medium in a single flask and incubated at 37 °C and 5% CO2 for 24 hours. The 
treatments were aspirated and cells washed with DPBS before incubation with 3 mL 
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trypsin EDTA for 3 minutes at 37 °C and 5% CO2 to initiate cell detachment. A 
volume of 3 mL complete RPMI medium was added to the flasks to neutralise the 
trypsin EDTA. Cells were transferred into 50 mL centrifuge tubes and centrifuged at 
500 g for 7 minutes. Supernatants were discarded and 200 µL of ice-cold radio 
immunoprecipitation assay (RIPA) buffer containing protease inhibitor cocktail 
(1:1000) was added the cell pellets in order to lyse the cells. Samples were 
transferred to −80 °C for 30 minutes. Cells were defrosted at 37 °C and sonicated 10 
times for 10 seconds, mixing well between each period of sonication. Samples were 
then centrifuged for 5 minutes at 12000 g and the lysates were collected on ice. 
The total protein content of each sample was quantified using the bicinchoninic 
acid (BCA) protein quantification assay according to the manufacturer’s 
instructions. Briefly, a 1 mg/mL stock solution of BSA in dH2O was used to provide a 
set of protein standards (0.8, 0.6, 0.4 and 0.2 mg/mL). A volume of 25 µL of each 
BSA standard was added to a 96-well plate with dH2O (zero mg/mL BSA) used as a 
blank. A working BCA solution, consisting of reagents A and B (1:50) was prepared 
as described in the BCA kit. A volume of 200 µL of this solution was added to all the 
BSA standards and incubated at 37 °C for 30 minutes before measuring the 
absorbance at 562 nm. A standard curve of absorbance against protein 
concentration was generated from the protein standards and used to determine 
the concentration of total protein in cell lysates via interpolation. Protein samples 
were normalised to 20 mg/mL prior to storage at -80 °C for later use. 
 Immunoblotting 
A volume of 5 μL of each of the protein samples (n = 6) was blotted onto 
nitrocellulose membranes. BSA at a concentration of 1 mg/mL (n = 6) was used as a 
negative control. The membranes were allowed to dry before being treated with 
the blocking buffer and then incubated at RT on a rocking shaker (Cole-Parmer, UK) 
for one hour with rocking at 50 rpm. The buffer was discarded and the membranes 
were treated with primary antibodies specific for the proteins Rac1, Fak, RhoG, 
RhoA, Cdc42 and β-tubulin (Table 2.1) overnight at 4 °C with rocking at 30 rpm. The 
primary antibodies were recovered (stored at 4 °C for further use) and the 
membranes washed five times for 5 minutes each with TBS-Tween buffer. The 
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membranes were treated with the horseradish peroxidase (HRP) anti-mouse IgG 
(produced in the A9044 rabbit) or HRP anti-rabbit IgG (produced in goat) secondary 
antibodies as appropriate, made in blocking buffer (1:1000), and incubated at RT for 
1 hour with rocking at 50 rpm. When the primary antibody was raised in mouse, a 
rabbit anti-mouse secondary antibody was used. When the primary antibody was 
raised in rabbit, a goat ant-rabbit secondary was used (Table 2.1). The secondary 
antibodies were removed and membranes were washed five times for 5 minutes  
with TBS-Tween buffer. A working EZ-ECL chemiluminescence detection solution, 
consisting of reagents A and B (1:1) was prepared in the dark according to the 
manufacturer’s instructions provided in the EZ-ECL kit. The membranes were 
covered with EZ-ECL working solution and incubated in the dark for 2 minutes at RT. 
Excess solution was aspirated and the membranes were visualised with a Chemidoc 
Touch Transilluminator (Bio-Rad, USA) using the Image LabTM Touch Software at 1-
minute exposure times. Dot blots were measured and analysed using ImageJ 
Software (Version 1.48). 
Table 2-1. Primary and secondary antibodies used for immunoblotting. 
Primary 
antibody 
Working 
concentration 
Host primary 
species 
Secondary 
antibody 
Host secondary 
species 
β-tubulin  1:5000 Mouse 
HRP anti-
mouse IgG Rabbit 
Rac1 2 μg/mL Mouse 
HRP anti-
mouse IgG Rabbit 
Fak 0.5 μg/mL Mouse 
HRP anti-
mouse IgG Rabbit 
RhoG  1:500 Rabbit 
HRP anti-
rabbit IgG Goat 
RhoA 2 μg/mL Mouse 
HRP anti-
mouse IgG Rabbit 
Cdc42  1:500 Mouse 
HRP anti-
mouse IgG Rabbit 
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3.1 Introduction  
3.1.1 Estrogen Promotes Wound Healing 
Active estrogens are secreted by the gonads into the bloodstream, with smaller 
amounts of active hormones produced by the adrenals. However, a substantial 
amount of inactive steroid precursors, including DHEA, its sulphate DHEA-S and 
androstenedione (4-dione) are produced by the adrenals and converted locally into 
active estrogens (such as 17β-estradiol) in peripheral tissues such as adipose tissue, 
bone and skin (Labrie et al., 1998; Nelson and Bulun, 2001). The reduction in the 
formation of DHEA-S by the adrenals during ageing results in a dramatic fall in the 
formation of active estrogens in peripheral target tissues, a situation which is 
strongly associated with age-related processes such as age-related impaired healing 
(Labrie et al., 1995). 
Estrogen declines significantly in postmenopausal women, due to a rapid decline in 
ovarian secretion of estrogens and a loss of both adrenal-derived estrogen and its 
precursors with increasing age. In men, estrogen declines rapidly with increasing 
age, largely due to a loss of adrenal-derived estrogen and its precursors. It is 
believed that the decline in estrogen in both sexes with increasing age results in 
detrimental effects on skin appearance (dry skin, sagging, wrinkling) and wound 
healing (Hardman et al., 2007). However, the detrimental effect of hormone-driven 
ageing (estrogen deprivation) on the development and progression of wound 
infections remains largely unknown. 
Ageing is known to be a key risk factor for impaired wound healing, with the 
declining production of estrogen in the elderly being the main key regulator of age-
related delayed wound healing (Hardman and Ashcroft, 2008). The reduction in 
estrogen that occurs with increasing age has a pronounced effect on cutaneous 
healing in both genders. Ashcroft et al. (1997a) and Ashcroft et al. (1999a) reported 
that estrogen deficiency causes a significant delay in wound healing, with topical 
and systemic estrogen replacement reversing this delay. Moreover, estrogen 
supplementation promoted age-related wound healing in both elderly males and 
females (Ashcroft et al., 1999a; Guo and DiPietro, 2010). 
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Estrogen has been shown to accelerate re-epithelialisation, promote angiogenesis, 
enhance matrix deposition and wound contraction, dampen the inflammatory 
response (Ashcroft and Ashworth., 2003). In particular, the key role of estrogen in 
regulating inflammation has been extensively reviewed (Guo and DiPietro, 2010; 
Gilliver et al., 2007), with estrogen supplementation decreasing the inflammatory 
response in elderly subjects of both genders (Ashcroft et al., 1997b; Ashcroft et al., 
1999a). Delayed wound healing in the elderly is associated with a delayed but 
prolonged and excessive inflammatory response, with dysregulated expression of 
pro-inflammatory cytokines and proteolytic mediators. However, despite the 
pronounced inflammatory response, evidence suggests increasing age may result in 
an impaired ability of inflammatory cells to eliminate bacteria from the wounds 
(Emori et al., 1991; Thomas, 2001). Indeed, the propensity for wound infections 
increases in the elderly, in part due to the delay in wound repair (Cooper et al., 
2015). 
Impaired wounds often become colonised with a variety of microbial species, such 
as S. aureus, P. aeruginosa, Proteus species and anaerobic bacteria (Gjødsbøl et al., 
2006; Kirketerp-Møller et al., 2008; Rybtke et al., 2015). When innate immunity 
functions appropriately, the eradication of wound bacteria is generally successful 
without intervention. However, if the host immune system becomes compromised 
by comorbidities, particularly in the elderly, clearance of wound bacteria can fail in 
the absence of effective treatments. In particular, if wounds become heavily 
infected with MRSA, P. aeruginosa or other hospital-acquired pathogens, treatment 
might necessitate aggressive medication with last line of defence antibacterial 
therapies (Beasley and Hirst, 2004). Indeed, the treatment of wounds infected with 
MRSA or P. aeruginosa represent a big challenge for the modern healthcare 
organisations (Beasley and Hirst, 2004). 
This study used in vitro and ex vivo assays to investigate the effects and potential 
mechanisms by which estrogen can affect the clearance of MRSA and/or P. 
aeruginosa. Previous work suggests the sex steroid hormones, particularly estrogen 
and testosterone, play a role in regulating host responses to infection. Findings 
indicate testosterone acts as an immunosupressor, whereas estrogen activates the 
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immune system (Cutolo et al., 2004). These effects are linked with sexual 
dimorphism found in bacterial infections, where males (human and animal) are 
more vulnerable to bacterial infections than females (Klein and Roberts, 2010). In 
addition, changes in estrogen levels during menstrual cycles and pregnancy can 
influence  bacterial infections (García-Gómez et al., 2012). Administration of sex 
steroid hormones, such as estrogen, in models of ovariectomized mice can control 
the progression of bacterial infections, acting as a supplement to antibiotic 
therapies. In line with this, some bacteria have developed potential mechanisms to 
degrade sex steroid hormones or reduce their effectiveness(García-Gómez et al., 
2012). 
3.1.2 Macrophages and Wound Healing 
Macrophages are amongst the main inflammatory cell types present in age-related 
impaired wounds where inflammation is typically pronounced and prolonged. The 
phenotype of macrophages changes during the phases of wound healing (Mosser 
and Edwards, 2010). Following injury, pro-inflammatory macrophages, known as 
“M1” macrophages, arrive at the wound site in order to remove foreign invaders 
such us bacteria, debris and dead cells. During acute wound healing, as the tissue 
starts to heal, M1 macrophages undergo a process of conversion into macrophages 
that promote anti-inflammatory effects, referred to as “M2” macrophages, to 
resolve inflammation (Koh and DiPietro, 2011). Macrophages also have key roles in 
vascularisation, arranging themselves nearby restored blood vessels in order to 
support their fusion and stability (Ogle et al., 2016). Macrophages release matrix 
metalloproteinases (MMPs) to breakdown the provisional extracellular matrix prior 
to undergoing apoptosis in order to bring about the deposition of mature matrix in 
the dermis as the wound progresses through the proliferative phase of wound 
repair (Vannella and Wynn, 2017). However, in  non-healing wounds, macrophages 
persist in a pro-inflammatory state and the transition to an anti-inflammatory 
phenotype is blocked (Hesketh et al., 2017). 
Macrophages in the skin are either derived from a resident tissue-macrophage 
population established before birth or from circulating bone marrow-derived 
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monocytes that are recruited to the site of injury and differentiate into 
macrophages (Malissen et al., 2014; Vannella and Wynn, 2017). When the wound 
site is infiltrated by microorganisms such as bacteria, monocyte-derived 
macrophages are systemically recruited within 24 hours post-injury in order to carry 
out phagocytosis (Minutti et al., 2017). 
Tissue-resident macrophages serve as early indicators of an injury or foreign 
invading pathogens (Malissen et al., 2014) by recognizing PAMPs such as LPS via 
binding to TLRs. Responses to PAMPs include initial recruitment of neutrophils to 
the wound area within minutes of the injury to eliminate foreign invaders (Malissen 
et al., 2014). Monocytes are subsequently recruited to the wound area to intensify 
the inflammatory response and become the predominant inflammatory cell type at 
around 3-7 days post-injury (Davies et al., 2013). Dermal tissue-resident 
macrophages can be identified by numerous surface markers, such as CD64, CD11c, 
CD14, CD16, CD68, CD71 and CCR5 (Malissen et al., 2014). Close to the resolution of 
injury, dermal tissue macrophages self-renew, and eliminate apoptotic cells as the 
tissue returns to homeostasis (Davies et al., 2013). 
Dendritic cells in the skin can also be derived from monocytes (e.g. Langerhans 
cells). Langerhans cells and macrophages share many similarities such as expressing 
similar surface markers (e.g. F4/80, CD14, and IL-10), which makes it difficult to 
distinguish between these two types of cell (Malissen et al., 2014). Many 
researchers consider Langerhans cells as a type of tissue-resident macrophage, as 
they also have a very similar gene expression profile (Davies et al., 2013; Doebel et 
al., 2017; Minutti et al., 2017). Interestingly, it has been reported that there is a link 
between healing diabetic foot ulcers and augmented numbers of Langerhans cells 
(Stojadinovic et al., 2013). However, the exact function of Langerhans cells in 
wound repair (particularly impaired wound healing) has not been clarified yet 
(Stojadinovic et al., 2013). 
3.1.3 Effect of Estrogen on Macrophages 
Estrogen is believed to be a key player in regulating immune responses against 
bacterial infections (Cutolo et al., 2004). Known for its anti-inflammatory 
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proprieties, estrogen is reported to resolve excessive inflammation by directly 
effecting inflammatory responses of monocytes and macrophages (Ashcroft et al., 
2003; Guo and DiPietro, 2010). Previous research reported that ovariectomized 
mice expressed high numbers of macrophages in injured tissues compared to 
normal healthy mice during the wound healing process (Ashcroft et al., 2003). 
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine, 
produced by many cell types (Calandra and Roger, 2003). MIF induces the 
production of other cytokines and growth factors by inflammatory cells such as 
TNF-α, IL-1 and IL-6 (Ashcroft et al., 2003; Hardman et al., 2005). MIF is a key pro-
inflammatory mediator inhibited by estrogen during wound healing (Ashcroft et al., 
2003; Hardman et al., 2005). MIF is  upregulated in human and murine impaired 
wounds in vivo (Ashcroft et al., 2003; Hardman et al., 2005; Emmerson et al., 2009), 
whereas MIF is decreased in wounds following exposure to estrogen (Ashcroft et 
al., 2003). Recent research indicated that estrogen inhibits MIF production by tissue 
macrophages (Ashcroft et al., 2003; Hardman et al., 2005). 
TNF-α is a key pro-inflammatory cytokine released by activated macrophages and is 
associated with chronic wounds in the elderly (Emmerson et al., 2009). After a 
pathogenic infection, bacterial clearance is reliant on effective regulation of TNF-α, 
and abnormal expression of the cytokine may cause substantial morbidity and 
mortality (Billiau and Vandekerckhove, 1991). Uncontrolled TNF-α production is 
also associated with the progression of several autoimmune diseases, such as 
rheumatoid arthritis, which are more dominant in females than males (Zandman-
Goddard et al., 2007). TNF-α wound levels are reduced in healthy premenopausal 
females and young males in comparison with postmenopausal females and elderly 
males (Vural et al., 2006). Research suggests that estradiol suppresses the 
production of TNF-α in murine macrophages (Deshpande et al., 1997; Srivastava et 
al., 1999). 
Long-time exposure of ex vivo macrophages to estrogen augments the expression 
of iNOS and the production of numerous cytokines, particularly IL-1β, IL-12 and IL-6 
following TLR4 activation by LPS. Other studies have reported anti-inflammatory 
effects of estrogens on macrophages in vitro (Deshpande et al., 1997; Ghisletti et 
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al., 2005). For example, a 2-hour estrogen treatment of macrophages (RAW 264.7 
cell line) in vitro caused a substantial reduction in the expression of the 
inflammatory mediators IL-1α, IL-6, and TNF-α by splenic macrophages following 
TLR4 activation (Deshpande et al., 1997; Ghisletti et al., 2005). 
In summary, estrogen accelerates wound healing and is associated with a reduced 
inflammatory response. Estrogen inhibits the recruitment of monocytes to the 
wound and reduces the production of macrophage-derived pro-inflammatory 
mediators. However, the precise role estrogen plays in macrophage-mediated 
bacterial clearance has not been elucidated to date. Thus, this study used in vitro 
and ex vivo models of host-pathogen interaction to investigate estrogen-mediated 
phagocytosis of bacteria by human U937- and HPBM-derived macrophages. 
Macrophage-mediated phagocytosis of two major wound pathogens, MRSA and P. 
aeruginosa, were assessed under in vitro and ex vivo conditions that model 
estrogen levels in the elderly (estrogen deprivation), physiological concentrations in 
young adults and following exogenous estrogen supplementation. U937 and HPBM-
derived macrophages are routinely used as flexible models of macrophages to study 
numerous aspects of the inflammatory response; including chemotaxis, 
phagocytosis, apoptosis and cytokine production (Hall, 2017). 
3.2 Aim and Objectives 
3.2.1 Aim 
To investigate the effects of age-related changes in estrogen levels on the 
phagocytic function of M0 macrophages using in vitro and ex vivo models of host-
pathogen interactions. 
3.2.2 Objectives 
 To compare the phagocytic function of M0 U937- and HPBM-derived 
macrophages under in vitro and ex vivo conditions of physiological 
(typical of youth) and supraphysiological levels of estrogen, estrogen 
deprivation and the absolute absence of estrogen. 
67 
 To determine the effect of estrogen on the phagocytosis of Gram 
positive (MRSA) and Gram negative (P. aeruginosa) wound pathogens by 
U937- and HPBM-derived M0 macrophages. 
 To visualise estrogen-mediated internalisation of Gram positive (MRSA) 
and Gram negative (P. aeruginosa) bacteria by U937- and HPBM-derived 
M0 macrophages. 
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3.3 Methods 
3.3.1 Generation of U937- and HPBM-Derived M0 Macrophages 
The differentiation of U937 and HPBM monocytes into macrophages was confirmed 
by flow cytometry as described in Section 2.2.6.1. U937 and HPBM monocytes were 
cultured as described in Sections 2.2.3. Cells were treated with/without 50 ng/mL 
PMA as described in Section 2.2.4 to induce differentiation of monocytes into 
macrophages. Cells were then stained with FITC-conjugated anti-CD11c antibody as 
described in 2.2.6.1. The expression of CD11c (relative MFI and % fluorescence) on 
untreated control monocytes was then compared with PMA-treated M0 
macrophages by flow cytometry as described in Section 2.2.6.1. 
3.3.2 Effect of Estrogen on Bacterial Growth 
Before conducting host-pathogen assays to test the effect of estrogen on the 
macrophage-mediated phagocytosis of MRSA and PAO1, it was important to 
investigate its direct effect  on the growth of both pathogens. 
MRSA 11 and PAO1 were cultured in NB overnight as described in Section 2.2.7. 
Neat broths were centrifuged at 3500 rpm for 10 minutes and the bacterial cell 
pellets washed twice with saline before re-suspension at 1 x 104 CFU/mL (see 
Section 2.2.7) in 1 mL saline alone (zero M estrogen) or 1mL saline containing either 
1 x 10-8 M estrogen or 1 x 10-7 M BSA (negative control). Bacterial suspensions were 
then incubated at 37 °C on an orbital shaker for 3 hours. Aliquots (50 µL) of each 
sample were then inoculated onto NA plates in duplicate and incubated at 37 °C 
overnight. The number of CFU formed on NA plates were counted in order to 
calculate the growth of bacteria in each sample. 
3.3.3 Effect of Estrogen on the Clearance of MRSA/PAO1 by M0 Macrophages  
  Phenol Red-Free Medium Controls 
In order to determine whether the phenol red component of cell culture medium 
had an effect on estrogen-mediated phagocytosis of MRSA/PAO1 by M0 
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macrophages, in vitro host-pathogen assays were conducted using RPMI medium 
containing/lacking phenol red. U937 monocytes were cultured in phenol red-free 
RPMI medium or RPMI complete medium using methods described in Section 2.2.3. 
M0 macrophages generated in Section 3.3.1 were then treated with physiological 
estrogen (1 x 10-8 M), prepared in either phenol-free RPMI medium or RPMI 
complete medium, for 24 hours and then incubated with MRSA or PAO1 for 3 h. 
Recovered bacterial colonies were then determined as described in Section 2.2.8.1. 
  Multiplicity of Infection (MOI) 
The effect of estrogen on phagocytosis over a range of starting bacterial 
inoculations was assessed for both MRSA or PAO1. U937 M0 macrophages 
generated in Section 3.3.1 were treated with 1 x 10-8 M estrogen for 24 hours prior 
to incubation for 3 hours with different concentrations (1 x 103 CFU, 1 x 104 CFU, 1 x 
105 CFU and 1 x 106 CFU) of MRSA or PAO1 to give initial bacteria: macrophage 
ratios of 0.001, 0.01, 0.1 and 1.  Recovered bacterial colonies were then determined 
as described in Section 2.2.8.1. 
  In vitro and Ex Vivo Host-Pathogen Interaction Assays 
U937 and HPBM M0 macrophages generated in Section 3.3.1 were treated in wells 
with different concentrations (1 x 10-7 M, 1 x 10-8 M, 1 x 10-9 M and zero M) of 
estrogen for 24 hours as described in Sections 2.2.2 and 2.2.8.1. Cells were 
incubated with MRSA or PAO1 (1 x 104 CFU) for 3 hours and bacterial recovery was 
determined as described in Section 2.2.8.1. 
3.3.4 Interaction of Estrogen-Treated U937 M0 Macrophages with GFP- S.aureus 
U937 M0 macrophages generated in Section 3.3.1 were incubated in flasks with 
different concentrations (1 x 10-7 M, 1 x 10-8 M, 1 x 10-9 M and zero M) of estrogen 
for 24 hours as described in Sections 2.2.2 and 2.2.8.1. Cells were then incubated 
with GFP- S. aureus (1 x 105 CFU/mL) for 3 hours prior to detection of GFP signal as 
described in Section 2.2.9. 
70 
3.3.5 Gentamicin Protection Assay 
In order to confirm that internalisation of  MRSA and PAO1 by U937 and HPBM M0 
macrophages was leading to bacterial killing rather than simply bacterial 
sequestration, a gentamicin protection assay was conducted to determine bacterial 
survival within macrophages using methodologies described in Sections  2.2.10 and 
3.3.1. 
The gentamicin protection assay is commonly used in host-pathogen research due 
to the incapability of gentamicin to penetrate the membrane of eukaryotic cells 
(Elsinghorst, 1994). The gentamycin protection assay was performed to investigate 
the effect of estrogen on the killing of intracellular MRSA and PAO1 as gentamicin 
was previously described to eradicate extracellular bacteria, but not intracellular 
bacteria due to its poor ability to permeate the macrophage membrane (Hamad et 
al., 2010; Hockenberry et al., 2016). Moreover, incubating cells with gentamicin kills 
bacteria that fail to penetrate cells, and any bacterial recovery obtained following 
lysis of the macrophages must be due to bacterial survival within the macrophages. 
The gentamicin protection assay is a very sensitive technique that can allow the 
detection of even single colonies of bacteria in cells (Elsinghorst, 1994). 
3.3.6 Visualising Host-Pathogen Interactions 
Internalisation of GFP S. aureus or mCherry- P. aeruginosa by U937 and HPBM M0 
macrophages, with/without estrogen treatment, was confirmed by fluorescence 
microscopy as described in Section 2.2.11.1. Host-pathogen interactions between 
U937 or HPBM M0 macrophages and MRSA/PAO1, with/without estrogen 
treatment, were visualised by SEM as described in Section 2.2.11.2. 
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3.4 Results 
3.4.1 Differentiation of Monocytes into M0 Macrophages 
According to previous research, monocytes (including U937 monocytes) can 
differentiate into macrophage-like cells via stimulation with PMA through PKC 
activation (Gidlund et al., 1981; Koeffler, 1983; Kiley and Parker, 1995). 
Figure 3.1 illustrates alterations in the morphology of U937 cells after treatment 
with PMA at 50 ng/mL for 24 hours. Round floating monocytes were transformed 
into adherent cells characterised by increased adhesion, formation of clumps and 
ruffled cell membranes. 
 
Figure 3.1. Morphological changes of U937 monocytic cells after treatment with 50 ng/mL 
PMA for 24 hours. Round floating monocytes (A) were differentiated into adherent cells (B) 
that formed clumps and had ruffled cell membranes. Images were taken using an Axiovert 
40C inverted phase contrast microscope. Inserts show enlargements of highlighted cells. 
The conversion of U937 and HPBM monocytes into a distinct population of 
macrophages was confirmed via detection of the FITC-conjugated anti-human 
CD11c surface marker (Rios de la Rosa et al., 2017) by flow cytometry (Section 
2.2.6.1). U937 PMA-differentiated cells were almost exclusively (99.6%) CD11c+ 
(Figure 3.2) whereas untreated control U937 monocytes predominantly lacked the 
CD11c surface marker (0.2% CD11c+). The CD11c MFI was significantly (P<0.001) 
higher in PMA-treated U937 cells compared to untreated control U937 monocytes, 
confirming PMA transformed U937 monocytes into adherent U937 M0 
macrophages. 
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There was high expression of CD11c by PMA-differentiated HPBM cells (76% 
CD11c+), whereas the CD11c macrophage surface marker was almost absent (0.3% 
CD11c+) in untreated control HPBM (Figure 3.3). The MFI of CD11c  was significantly 
(P<0.05) greater in PMA-treated HPBM cells compared to untreated control HPBM, 
confirming the transformation of HPBM into adherent M0 macrophages had 
occurred following PMA treatment.  
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Figure 3.2. Flow cytometry confirming U937 monocytes differentiation into Mo macrophages. The conversion of U937 monocytic cells into macrophages 
was established via detection of the CD11c surface marker by flow cytometry. Phorbol 12-myristate 13-acetate (PMA)-differentiated cells almost exclusively 
expressed the CD11c macrophage marker, whereas monocytes predominantly lacked the CD11c surface marker (A). Two distinct populations of U937 cells 
were detected (B) with significantly (P<0.01) higher median fluorescence intensity (MFI) from U937 PMA-treated cells compared to undifferentiated U937 
monocytes (C). Data are presented as average of n = 3 experiments. * Indicates significant difference (One-way ANOVA) in MFI (P<0.01). Error bars 
represent the standard error of the mean (StEM). 
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Figure 3.3Flow cytometry confirming HPBM differentiation into M0 macrophages. The differentiation of HPBM into macrophages was assessed via 
detection of the CD11c surface marker by flow cytometry. Phorbol 12-myristate 13-acetate (PMA)-differentiated cells highly expressed CD11c whereas 
monocytes predominantly lacked the CD11c surface marker (A). Two distinct cell populations were detected (B) with significantly (P<0.05) higher median 
fluorescence intensity (MFI) observed on HPBM PMA-treated cells compared to untreated monocytes (C). Data are presented as average of n = 3 
experiments. * Indicates significant difference (One-way ANOVA) in MFI (P<0.05). Error bars represent the standard error of the mean (StEM). 
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3.4.2 Effect of Estrogen on the Growth of MRSA and PAO1 
The effect of estrogen (1 x 10-7 M) on the growth of MRSA and PAO1 colonies after 
3 hours incubation was investigated compared to a BSA (1 x 10-7 M) negative 
control and a untreated saline control. Estrogen had no significant effect on the 
MRSA or PA01 growth (P>0.05) (Figure 3.4A and Figure 3.4B) compared to the 
controls. These results indicated that estrogen had no direct effect on the growth of 
MRSA or PAO1 compared to the controls. 
 
Figure 3.4. Effect of estrogen on MRSA and PAO1 growth. Estrogen (1 x 10-7 M) had no 
significant (P>0.05) effect on the growth of MRSA (A) or PA01 (B) compared to the 1 x 10-7 
M bovine serum albumin (BSA) negative control (NC) or the untreated saline control.  Data 
are presented as average of n = 24 experiments. 
3.4.3 The Effect of Phenol Red on Bacterial Clearance 
The effect of phenol red on the clearance of MRSA and PAO1 by U937 M0 
macrophages with/without estrogen treatment was investigated. The findings 
confirmed that phenol red in the RPMI cell culture medium had no significant effect 
on the MRSA (A) and PAO1 (B) recovery compared to RPMI medium lacking phenol 
red (P>0.05), regardless of the presence of estrogen (Figure 3.5). Physiological (1 x 
10-8 M) estrogen levels significantly decreased MRSA and PA01 recovery compared 
to the negative control (P<0.05), both in the presence or absence of phenol red. 
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Figure 3.5. Effect of phenol red on bacterial clearance by M0 macrophages. Phenol red in 
cell culture medium had no significant effect on the recovery of MRSA (A) or PA01 (B) 
compared to the absence of phenol red (P>0.05), regardless of the presence/absence of 
estrogen (1 x 10-8 M). Physiological (1 x 10-8 M) estrogen levels significantly (*: P<0.05) 
decreased the MRSA (A) and PAO1 (B) recovery compared to the negative control (NC), 
with or without phenol red. Data are an average of n = 10 experimental repeats with error 
bars representing the standard error of the mean (StEM). 
3.4.4 Multiplicity of Infection (MOI) 
The effect of physiological estrogen (1 x 10-8 M) on the uptake of MRSA by M0 
macrophages, in vitro, was investigated. Cells were incubated with a range of initial 
MRSA inoculations (1 x 103 CFU, 1 x 104 CFU, 1 x 105 CFU and 1 x 106 CFU) (Figure 
3.6). The absence of estrogen had no significant effect (P>0.05) on the MRSA 
recovery compared to negative control. Physiological estrogen significantly 
decreased (P<0.05) the MRSA recovery, in comparison with the BSA control with all 
MOIs. The bacterial recovery of MRSA significantly increased (P<0.05) following 
estrogen (1 x 10-8 M) supplementation as the MOI [bacteria : macrophage ratio] 
increased from 0.001 to 1. However, the MRSA recovery followed a similar pattern 
throughout, regardless of the MOI ratio, with estrogen consistently increasing 
(P<0.05) MRSA clearance at all MOIs. 
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Figure 3.6. Effect of physiological estrogen on the recovery of MRSA by M0 macrophages 
in vitro. Cells were incubated with MRSA at MOIs of 0.001 (A), 0.01 (B), 0.1 (C) and 1 (D). 
Following treatment of macrophages with physiological estrogen (1 x 10-8 M), MRSA 
recovery significantly decreased (P<0.05), at all MOIs, in comparison with the absence (zero 
M) of estrogen and the negative control (NC). Data represent mean recovery (CFU/mL) ± 
standard error of the mean (StEM), n = 10. *: P<0.05, indicate significant differences in the 
MRSA/PAO1 recovery compared to the NC. 
Figure 3.7 illustrates the effect of physiological estrogen (1 x 10-8 M) on the 
internalisation of PAO1 by macrophages. After incubating the macrophages with a 
varied range of initial PA01 colonies (1 x 103 CFU, 1 x 104 CFU, 1 x 105 CFU and 1 x 
106 CFU), the absence of estrogen had no significant effect (P>0.05) on the recovery 
of in comparison with the BSA control. Interestingly, physiological estrogen 
significantly decreased (P<0.05) the PAO1 recovery, in comparison with the NC 
control at all MOIs. The PAO1 recovery significantly increased (P<0.05) following 
estrogen (1 x 10-8 M) supplementation as the MOI [bacteria : macrophage ratio] 
increased from 0.001 to 1. However, the PAO1 recovery followed a comparable 
pattern throughout, regardless of the MOI ratio, with estrogen consistently 
increasing (P<0.05) PAO1 clearance at all MOIs. 
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Figure 3.7. Physiological estrogen decreases the recovery of PAO1 by M0 macrophages in 
vitro. U937-derived M0 macrophages were incubated with PAO1 at MOIs of 0.001 (A), 0.01 
(B), 0.1 (C) and 1 (D). Physiological estrogen (1 x 10-8 M) significantly decreased (P<0.05) the 
PAO1 recovery at all MOIs, in comparison with the absence (zero M) of estrogen and the 
negative control (NC). Data represent mean recovery (CFU/mL) ± standard error of the 
mean (StEM), n = 10. *: P<0.05, indicate significant differences in the MRSA/PAO1 recovery 
compared to the NC. 
3.4.5 Effect of Estrogen on MRSA and PAO1 Clearance 
  Effect of Estrogen on MRSA and PAO1 Clearance by U937 Macrophages 
The effect of estrogen on the clearance of MRSA and PAO1 by U937 M0 
macrophages was investigated. The absolute absence of estrogen (zero M) showed 
no significant (P>0.05) change in the number of recovered MRSA or PA01 colonies 
(Figure 3.8A and Figure 3.8B) compared to the BSA negative control (NC). 
Estrogen significantly (P<0.01) reduced the recovery of MRSA colonies compared to 
the negative control in a dose-dependent manner. The MRSA recovery (Figure 3.8A) 
was significantly (P<0.01) reduced from 1886 CFU/mL in the NC to 1759 CFU/mL, 
1295 CFU/mL and 936 CFU/mL with estrogen at a concentrations of 1 x 10-9 M, 1 x 
10-8 M and 1 x 10-7 M respectively. The MRSA recovery decreased significantly 
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(P<0.01) between increasing estrogen concentrations, with physiological estrogen 
concentrations (1 x 10-8 M) significantly reducing MRSA recovery compared to 
estrogen deprivation, and supraphysiological estrogen concentrations (1 x 10-7 M) 
significantly reducing MRSA recovery compared to physiological estrogen levels. 
Physiological estrogen (1 x 10-8 M) and supraphysiological estrogen (1 x 10-7 M) 
significantly (P<0.05) reduced the PAO1 recovery (Figure 3.8.B) from 2410 CFU/mL 
in the NC to 2105 CFU and 1960 CFU respectively. The PAO1 recovery also 
decreased significantly (P<0.05) between physiological and supraphysiological 
estrogen levels. 
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Figure 3.8. Estrogen enhances the uptake of MRSA11 (A) and PAO1 (B) by U937 M0 
macrophages. Following treatment of U937 M0 macrophages with estrogen (1 x 10-7 M, 1 x 
10-8 M) MRSA (A) and PAO1 (B) recovery significantly decreased in a concentration-
dependant manner in comparison to the absence (zero M) of estrogen and the negative 
control (NC). Data represent mean recovery (CFU/mL) ± standard error of the mean (StEM), 
n = 48. *: P<0.05, **: P<0.01 indicate significant differences in the MRSA/PAO1 recovery 
compared to the NC. 
  Effect of Estrogen on MRSA and PAO1 Clearance by Ex Vivo M0 
Macrophages 
Host-pathogen assays were repeated with human peripheral blood monocytes 
(HPBM) in order to determine whether estrogen has similar effects on the MRSA 
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and PAO1 recovery with macrophages derived from primary human monocytes. In 
the absence of estrogen (zero M estrogen) there was no significant difference 
(P>0.05) in the clearance of MRSA or PA01 compared to the negative control 
(Figure 3.9.A and Figure 3.9.B). In contrast, estrogen treatment significantly 
reduced (P<0.05) MRSA recovery compared to the negative control in a dose-
dependent manner. Physiological (1x10-8 M) and particularly supraphysiological 
(1x10-7 M) levels of estrogen were highly effective at increasing MRSA clearance, 
significantly decreasing (P<0.01) MRSA recovery (1775 CFU/mL, 1246 CFU/mL 
respectively) compared to the negative control (2692 CFU/mL). Estrogen had similar 
effects on the clearance of PAO1 when treated with physiological (1x10-8 M) or 
supraphysiological (1x10-7 M) levels, significantly (P<0.05) reducing PA01 recovery 
(2252 CFU/mL and 1817 CFU/mL respectively) compared to the negative control 
(2631 CFU/mL). 
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Figure 3.9. Estrogen enhances the uptake of MRSA11 (A) and PAO1 (B) by HPBM M0 
macrophages. Following treatment of HPBM M0 macrophages wth estrogen (1 x 10-7 M, 1 x 
10-8 M) the recovery of MRSA/PAO1 was significantly reduced in comparison to the 
negative control (NC). Error bars represent the mean ± standard error of the mean (SEM), n 
= 6. *: P<0.05, **: P<0.01 indicate significant differences in the MRSA/PAO1 recovery 
compared to the NC. 
3.4.6 GFP S. aureus Host-Pathogen Assay 
  Effect of Estrogen on The Recovery of GFP- S. aureus 
The effect of estrogen on the recovery of fluorescent GFP-labelled S. aureus 
colonies was investigated. U937-derived M0 Macrophages were incubated with 
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GFP-S. aureus for 3 hours. The bacterial colonies were tracked via detection of GFP 
signals inside and outside the macrophages using a countess II fluorescent cell 
counter. Images (n = 10) of bacterial internalisation within macrophages were 
captured. The phagocyte density, number of internalised bacteria, total number of 
macrophages and total bacterial counts were determined from images in order to 
calculate the bacterial recovery, total number of phagocytes/mL and the ratio of 
bacterial internalisation. 
Consistent with previous results, physiological and supraphysiological levels of 
estrogen significantly reduced the S. aureus recovery (P<0.05) in a concentration-
dependant manner in comparison with the absence of estrogen and BSA controls 
(Figure 3.10). 
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Figure 3.10. Estrogen increases the uptake of GFP-S. aureus by U937 M0 macrophages. 
Following treatment of U937 M0 macrophages with physiological and suppraphysiological 
estrogen (1 x 10-9 M, 1 x 10-7 M), the S. aureus recovery was significantly reduced in a 
concentration-dependant manner in comparison to the absence (zero M) of estrogen and 
the BSA control (NC). Data represent mean recovery (CFU/mL ± standard error of the mean 
(StEM), n = 10. **: P<0.01 indicate significant differences in the GFP-S. aureus recovery 
compared to the NC. 
  Effect of Estrogen on Phagocyte Density 
The effect of estrogen on the number of active phagocytes after the 3-hour period 
of host-pathogen interaction was investigated (Figure 3.11). Stimulation of cells 
with 1 x 10-8 M or 1 x 10-9 M estrogen did not have any significant effect (P=0.16 
and P=0.99 respectively) on phagocyte density (3.0 x 105 phagocytes/mL and 2.8 x 
105 phagocytes/mL respectively) compared to the negative control (2.3 x105 
phagocytes/mL) (Figure 3.11). However, supraphysiological (1 x 10-7 M) levels of 
estrogen significantly increased (P < 0.01) the number of active phagocytes (3.7 x 
105 phagocytes/ mL) in comparison to the negative control (NC). 
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Figure 3.11. Estrogen Promotes an Increase in the Number of Active Phagocytes. 
Supraphysiological (1 x 10-7 M) levels of estrogen significantly (*: P<0.05, **: P<0.01) 
increased the detection of GFP signals inside macrophages compared to the negative 
control (NC). Data indicate mean number of active phagocytes per mL (n = 8) ± standard 
error of the mean (StEM). 
  Effect of Estrogen on the Proportion of Total GFP S. aureus Internalised by 
U937-Derived Macrophages 
Figure 3.12 illustrates the proportion of total GFP- S. aureus internalised by U937-
derived macrophages following treatment with 17β-estradiol. When the cells were 
treated with zero M and 1 x 10-9 M estrogen, there was no significant (P=0.89) 
effect on the proportion of GFP- S. aureus internalised (0.58) in comparison to the 
negative control (NC). However, when U937-derived macrophages were treated 
with physiological (1 x 10 -8 M) or supraphysiological (1 x 10 -7 M) levels of estrogen, 
there was a significant increase (P< 0.05) in the proportion of internalised bacteria 
(0.66 and 0.78 respectively) compared to the NC. 
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Figure 3.12. Effect of estrogen on the ratio of GFP- S. aureus internalisation. Data are 
presented as average of n = 8 experiments. * P<0.05, **: P<0.01 Indicate significant 
differences (One-way ANOVA) in bacterial recovery (P<0.05). Error bars represent the 
StEM. 
3.4.7 Effect of Estrogen on Bacterial (MRSA and P. aeruginosa) Killing by U937-
Derived Macrophages. 
In order to determine the effect of estrogen on bacterial killing by U937-derived 
macrophages, a gentamicin protection assay was performed. The gentamycin 
protection assay is commonly used to confirm the killing of internalised bacteria by 
phagocytes, or recover viable bacteria from inside phagocytes when pathogens are 
able to evade host cell responses and grow within phagocytes (Elsinghorst, 1994). 
The assay utilised gentamycin to eliminate non-internalised (extracellular) bacteria 
after a 3-hour period of host-pathogen interaction, followed by the lysis of washed 
macrophages to recover internalised bacteria. Gentamycin is unable to pass across 
the host cell membrane so only bacteria that have been successfully internalised 
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(phagocytosed) by immune cells but remain viable within phagocytes at the end of 
the host-pathogen interaction are recovered by the assay (Elsinghorst, 1994., 
Waldbeser et al., 1994; Hess et al., 2004; Oelschlaeger, 2010). 
Similar to previous assays, physiological (1 x 10 -8 M) and supraphysiological (1 x 10 -
7 M) levels of estrogen significantly (P<0.05) decreased the recovery of viable 
internalised MRSA and PAO1 by U937 M0 macrophages in a dose-dependent 
manner (Figure 3.13) compared to the BSA (NC) and untreated controls. The data 
confirmed estrogen was not simply promoting internalisation of bacteria, but was 
also increasing the killing of phagocytosed MRSA and PAO1 by U937-derived 
macrophages. The absence of estrogen or estrogen deprivation (1 x 10 -9 M) did not 
significantly (P>0.05) effect the killing of internalised MRSA and PAO1 by U937-
derived macrophages compared to the NC. 
Physiological (1 x 10-8 M) and supraphysiological estrogen (1 x 10-7 M) significantly 
(P<0.05) reduced the MRSA recovery (Figure 3.12.A) from 976 CFU/mL in the NC to 
787 CFU and 692 CFU respectively. The PAO1 recovery also decreased significantly 
(P<0.05) from 1019 CFU/mL in the BSA control to 822 CFU/mL and 692 CFU/mL 
following treatment with physiological (typical of youth) and supraphysiological 
levels of estrogen respectively. 
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Figure 3.13. Estrogen promotes the killing of MRSA (A) and PAO1 (B) by U937-Derived 
Macrophages. Physiological (1 x 10 -8 M) and supraphysiological (1 x 10 -7 M) levels of 
estrogen significantly (*: P<0.05, **: P<0.01) promoted the killing of internalised MRSA (A) 
and PAO1 (B) by M0 macrophages compared to the negative control (NC). Data indicate 
mean (n = 6) viable internalised bacteria (CFU/mL) ± standard error of the mean (StEM). 
3.4.8 Visualisation of Bacterial Internalisation 
  Epifluorescence Microscopy 
In order to visualise and compare the phagocytosis of pathogens, with and without 
estrogen treatment, U937-derived macrophages were incubated with GFP S. aureus 
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or mCherry P. aeruginosa prior to staining for phalloidin–tetramethylrhodamine B 
isothiocyanate conjugate from Amanita phalloides (Figure 3.14.A), or labelling with 
CD18 mouse monoclonal antibody and stained for goat anti-mouse IgG (H+L) 
superclonal secondary antibody, alexa fluor® 488 conjugate (Figure 3.14.B). Images 
were captured using a 100X objective on a Nikon E600 epifluorescence microscope 
(Section 2.2.11.1). 
The absence of estrogen (A2 and B2) had no effect on the bacterial internalisation 
compared to the BSA negative controls (A1 and B1). However, it is clear that 
estrogen treated macrophages internalised more of the S. aureus and P. aeruginosa 
colonies (A3 and B3) than untreated cells. 
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Figure 3.14. Effect of estrogen on the internalisation of GFP labelled-S, aureus (A) and mCherry-P. aeruginosa by U937 macrophages. U937-derived 
macrophages were treated with/without supraphysiological (1 x 10-7 M) estrogen supplementation for 24 hours prior to incubation with GFP labelled-S, 
aureus SH1000 (A) or mCherry labeled-PAO1 (B) for 3 hours. U937-derived macrophages were stained for phalloidin–tetramethylrhodamine B 
isothiocyanate conjugate from Amanita phalloides (A) or mouse anti-human CD18 monoclonal antibody followed by a goat anti-mouse IgG (H+L) 
superclonal secondary antibody, alexa fluor® 488 conjugate (B). The internalisation of S. aureus and P. aeruginosa by U937-derived macrophages (white 
arrows) was promoted by treatment with estrogen (A3 and B3) compared to negative control (NC) (A1 and B1) or macrophages lacking estrogen exposure 
(A2 and B2). 
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  Z-Stack Analysis by Confocal Microscopy 
To confirm the internalisation of bacteria by estrogen-treated U937 macrophages, 
Z-stacks were performed on phalloidin-stained phagocytes to visualise a series of 
layers through the interior of phagocytes and identify  intracellular GFP-S. aureus 
colonies using a 63X objective on a Leica TSC SPE1000 confocal microscope.  Z-
stacks (example layer shown in (Figure 3.15) spanning the mid-intracellular region 
of estrogen-treated U937 macrophages (stained red) contained GFP-S. aureus 
colonies that fluoresced green, confirming the intracellular localisation of GFP-S. 
aureus inside (red) macrophages (Panel C). The size of Z-steps was set at 0.04 µm in 
this experiment. 
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Figure 3.15. Z-Stack Demonstrating GFP-S. aureus Localisation inU937-Derived M0 macrophages Following Estrogen Supplementation. Bright green 
fluorescence was observed from GFP labeled S. aureus SH1000 (A). U937-derived M0 macrophages stained with phalloidin–tetramethylrhodamine B 
isothiocyanate conjugate from Amanita phalloides fluoresced red (B). The merged image confirmed several GFP-S. aureus colonies were located in the mid-
intracellualr region of estrogen-treated U937 M0 macrophages after 3 hours of host-pathogen interaction (C). 
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  Scanning Electron Microscopy 
In order to visualise and compare detailed features of the interactions between 
MRSA or PAO1 and macrophages, samples were visualised using a Supra 40VP 
scanning electron microscope as described in 2.2.11.2 (Figure 3.16). The moment of 
the MRSA and PAO1 uptake shows in the images (Panels B and C) as the estrogen 
treated macrophage sends out pseudopodia to engulf the invading bacteria. 
Surprisingly, the morphological response of macrophages toward PAO1 (Panewl B) 
was distinct to and somewhat more pronounced than  the response to MRSA (Panel 
C) in terms of the formation of membrane extensions, warranting further 
investigation. In concordance with these findings, PAO1 recovery was consistently 
higher than MRSA recovery in all host-pathogen experiments, supporting the notion 
of bacteria-specific interactions. 
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Figure 3.16. The Interaction of U937-derived M0 Macrophages with Gram Positive (MRSA11) and Gram Negative (PAO1) Bacteria Following Estrogen 
Supplementation. SEM images illustrating morphological changes in membrane extensions in estrogen-treated, U937-derived M0 macrophages after a 1h 
period of host-pathogen interaction with MRSA11 and PAO1. Control U937-derived M0 macrophages (Aa, Ab), MRSA11 (Ac) and PAO1 (Ad) were visualised 
before conducting the host-pathogen assay. Following the 1-hour period of host-pathogen interaction, estrogen-treated U937 M0 macrophages sent out 
morphologically distinct pseudopodial extensions to engage PAO1 (B) and MRSA (C) bacteria (yellow arrows). 
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3.5 Discussion 
Wound infection is commonly quoted as a significant cause of delayed wound 
healing in the elderly and chronic wounds (Yotis, 1967). Chronic wounds are 
frequently colonised with a diverse range of Gram-positive and Gram-negative 
bacteria particularly S. aureus and P. aeruginosa (Dowd et al., 2008). Studies of age-
related impaired wound healing suggest that sex steroid hormones, particularly 
estrogen, may have a significant impact on the inflammatory response in vivo. 
Treatments with topical and systemic estrogen have been indicated to enhance the 
rate of acute wound healing in both elderly men, and particularly post-menopausal 
women, by reducing the inflammatory response (Gilliver et al., 2007). Although 
estrogen has been shown to promote human acute wound healing in the elderly 
(Ashcroft et al., 1999a), the effect of this hormone on bacterial clearance and 
wound infections has received little attention to date. 
First, it was very important to develop and generate a successful in vitro model of 
monocyte-derived macrophages. PMA induced the differentiation of both U937 and 
human peripheral blood monocytes (HPBM) into M0 macrophages (Figure 3.2 and 
figure 3.3). This was confirmed via a high expression of the CD11c surface marker 
by macrophages, with monocytes lacking the marker. U937 and HPBM are known 
precursors of tissue macrophages and dentritic cells in vitro (Sintiprungrat et al., 
2010). PMA was described to induce the conversion of monocytes into 
macrophage-like cells in vitro (Martinez et al., 2008; Rios de la Rosa et al., 2017). 
Our results are supported by several reports as recent research reported that PMA‐
treated monocytes express high levels of CD11b, CD11c and protein kinase-C (PKC) 
(Sintiprungrat et al., 2010). When treated with PMA, monocytes were shown to 
upregulate cell adhesion molecules including the beta‐2integrins (CD11a, CD11c, 
CD18 and CD11b) allowing the cells to attach to cell culture flask surfaces in vitro. 
PMA triggers calcium and phospholipid‐dependent isoforms of PKC and encourages 
cyclic AMP metabolism, initiating maturation into a macrophage-like morphology 
(Luscinskas et al., 1994). 
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A 3-hour incubation of both MRSA and P. aeruginosa with estrogen had no 
significant effect on their rate of growth. Therefore, any direct effect of estrogen on 
MRSA and PAO1 could be excluded during the host-pathogen assays in this study, 
with any changes in the number of bacteria instead arising solely due to the effect 
of estrogen on the interaction of macrophages with bacteria. These results are 
supported with many previous studies showing steroids, particularly estrogen and 
progesterone, have no effect on bacterial growth (Lev, 1959). However, some non-
endogenous steroids have been reported to decrease the growth of many Gram-
positive bacteria (Casas-Campillo et al., 1961; Yotis, 1967), but the exposure to 
these steroids periods was for substantially longer periods than 3 hours.  
The effect of phenol red on the host-pathogen interaction assays was investigated. 
Phenol red in the RPMI cell culture medium had no significant effect on  MRSA and 
PAO1 recovery compared to RPMI medium lacking phenol red, regardless of the 
presence or absence of estrogen.  Phenol red was shown to have very weak 
estrogenic effects on MCF-7 human breast cancer cells, with an affinity that was 
0.001% that of 17β-estradiol (Berthois et al., 1986). Other studies reported that 
phenol red had no effect on estrogen-sensitive T47D breast cancer cells, primary 
immature rat pituitary cells or immature rat uterine cells (Welshons et al., 1988). 
Thus, published findings are in concordance with the data in this study, 
demonstrating phenol red in the cell culture medium has negligible influence on 
host-pathogen interactions. 
Multiplicity of infection (MOI) assays were then performed to investigate the effect 
of physiological estrogen (1 x 10-8 M) on phagocytosis over a range of starting 
bacterial inoculations (1 x 103 CFU, 1 x 104 CFU, 1 x 105 CFU and 1 x 106 CFU) for 
both MRSA or PAO1. The SERM tamoxifen, an estrogen-like molecule was found to 
enhance the bactericidal activity of neutrophils against P. aeruginosa in vitro and 
MRSA in vivo where (Corriden et al., 2015) conducted in vitro host-pathogen assays 
at MOIs of 0.1. Findings in this study agree with published reports. The bacterial 
recovery of MRSA and PA01 following estrogen (1 x 10-8 M) supplementation 
significantly increased as the MOI [bacteria: macrophage ratio] increased from 
0.001 to 1. However, the bacterial recovery followed a similar pattern throughout, 
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regardless of the MOI ratio, with estrogen consistently increasing (P<0.05) bacterial 
clearance at all MOIs. 
The effect of estrogen on the phagocytosis of the two major wound pathogens 
MRSA and P. aeruginosa by macrophages was investigated in this study. The results 
of the initial in vitro host-pathogen interaction assays (3.4.5.1) demonstrated novel 
data showing estrogen significantly (P<0.05) enhances the internalisation of both 
MRSA and P. aeruginosa in a dose-dependent manner following exposure to 
activated U937-derived M0 macrophages in vitro. 
Li et al. (2000) extracted microglial cells from brain tissues of patients with 
Alzheimer disease. Similar to experimental procedures in this chapter, the 
macrophages were treated with 1 x 10-7 M estrogen for 24 hours and 48 hours prior 
to incubation with amyloid β‐peptide (Aβ) for 24 hours. Estrogen was found to 
enhance the uptake of Aβ by brain macrophages (microglia) in a time‐ and dose-
dependent manner. In order to confirm that estrogen enhances the phagocytic 
activity of microglia via a general engulfment mechanism, not specific to Aβ only, Li 
et al. (2000) re-conducted the same experiments replacing Aβ with Escherichia coli. 
Intriguingly, estrogen significantly increased the internalisation of E.coli in a 
concentration-dependent manner in comparison with the vehicle  controls. These 
findings highlight the beneficial effects of estrogen on the phagocytic ability of 
microglia in the brain. However, other types of macrophages were not  assessed 
and only E.coli was investigated so it remains unclear whether the effects of 
estrogen could be observed with varied bacterial species and strains, especially 
antibiotic-resistant strains. 
Crompton et al. (2016) investigated  the effect of estrogen on  cutaneous murine 
wound healing following exposure to LPS derived from Klebsiella pneumoniae. 
Exposure of immune cells to LPS caused a  substantial delay in wound healing. They 
then co-treated LPS-treated wounds with 17β-estradiol, and interestingly, the delay 
in wound repair was reversed, with accelerated healing noted in mice  following 
estrogen treatment (Crompton et al., 2016). The results of this report were 
interesting but Crompton et al. (2016) only used locally applied K. pneumonia-
derived LPS in their model of infection. In order to generate realistic models of 
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infected wounds  it is important to develop assays that infect wounds with live 
bacterial strains, not just bacterial-derived factors such as LPS. It is also important 
to consider both Gram-positive and Gram-negative models of infection.  Moreover, 
K. pneumoniae is not a major wound pathogen compared to S. aureus and P. 
aeruginosa, which are the most frequently  isolated bacterial species from infected 
wounds (Giacometti et al., 2000; Gjødsbøl et al., 2006; Kirketerp-Møller et al., 2008; 
Rybtke et al., 2015). 
In vitro studies using cell lines provide only limited evidence to predict effective 
effects in humans. Thus, this study also confirmed findings in ex vivo primary 
human peripheral blood monocytes (HPBM) to establish a body of evidence using 
both a Gram-positive and a Gram-negative bacterium. Similar to results obtained 
with U937-derived macrophages in vitro, physiological and supraphysiological 
estrogen significantly increased (P<0.05) the internalisation of both MRSA and 
PAO1 in comparison to the negative control. 
Li et al. (2000) investigated the effect of estrogen on the uptake of fluorescent- 
E.coli by microglial cells using a fluorescence microplate reader, and showed 
estrogen enhanced the internalisation of E.coli in a concentration- and time-
dependant manner. In line with this, and using similar experimental settings, data 
from the M0 macrophages-GFP S. aureus interaction assay strengthened the host-
pathogen in vitro and ex vivo findings, indicating greater bacterial uptake following 
treatment with physiological and suppraphysiological estrogen. Ashcroft and co-
researchers reported that ovariectomized mice presented with high numbers of 
macrophages in injured tissues compared to wounds of normal healthy mice. 
Interestingly, in this thesis estrogen increased the number of macrophages that 
become active phagocytes following exposure to pathogens, thereby providing a 
justifiable reason for enhanced bacterial clearance described by Gilliver et al. 
(2007). 
The effect of estrogen on the absolute killing of bacteria was investigated in the  
gentamycin protection assay. Gentamicin eradicates extracellular bacteria but it has 
no effect on intracellular bacteria due to poor ability to permeate the macrophage 
membrane (Waldbeser et al., 1994; Hess et al., 2004; Oelschlaeger, 2010; Hamad et 
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al., 2010). Interestingly, there was a significant decrease in the number of viable 
intracellular viable bacteria recovered following treatment of macrophages with 
physiological or supraphysiological estrogen, demonstrating estrogen promotes the 
killing of internalised pathogens, not just the uptake of bacteria by phagocytes. 
Published research demonstrated that extended exposure of ex vivo macrophages 
to estrogen augments the expression of iNOS and the production of numerous 
cytokines, particularly IL-1β, IL-12 and IL-6 following TLR4 activation by LPS  in vitro 
(Deshpande et al., 1997; Ghisletti et al., 2005). The findings of this report combined 
with findings in Crompton et al. (2016) and Li et al. (2000) support the data in this 
Chapter, showing estrogen promotes the microbicidal activities of macrophages 
against bacteria. 
In order to visualise the phagocytosis of S. aureus and P. aeruginosa with/without 
estrogen treatment, host-pathogen assays were conducted using fluorescent GFP S. 
aureus or mCherry P. aeruginosa. Visualisation of host-pathogen interactions was 
conducted via epifluorescent microscopy (Figure 3.14) and confocal microscopy 
(Figure 3.15). The findings demonstrated estrogen increased the internalisation of  
S. aureus and P. aeruginosa by macrophages, in concordance with the bacterial 
recovery data obtained from in vitro host-pathogen assays. 
Images captured by SEM also confirmed increased host-pathogen interaction 
following treatment of macrophages with estrogen. It was noted that estrogen-
treated macrophages had distinct morphological responses to MRSA and PAO1, in 
terms of pseudopodial formation. This finding was in concordance with data in the 
host-pathogen assays showing PAO1 recovery was consistently higher than MRSA 
recovery. The SEM images represent novel results that merit further investigation 
to determine the underlying mechansisms that might lead to pathogen-specific 
differences in pseudopdial formation. In order to better understand the 
biochemical processes occurring at the host-pathogen interface, future work could 
determine the effect of estrogen on physical and chemical changes in phagocytes. 
Fourier Transform Infra-Red (FTIR), spectroscopy and Raman spectroscopy can be 
used to determine changes in the functional groups on the cell surface of active 
phagocytes treated with estrogen. 
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The underlying mechanism by which estrogen affects bacterial phagocytosis has not 
been investigated yet. It is possible that estrogen promotes bacterial clearance by 
inducing genes or pathways involved in the processes of phagocytosis via activation 
of ER proteins. Future investigations will determine the precise ER pathways 
involved in estrogen-enhanced phagocytosis. Determining the mechanisms by 
which estrogen induces phagocytosis my lead to  novel therapeutic strategies that 
combat wound infections in the elderly by modulating the host immune response. 
One potential avenue will be to use selective estrogen receptor modulators 
(SERMs) such as tamoxifen that act as agonists of ER proteins in a tissue-specific 
manner.  
Tissue macrophages exist in different activation states: either pro-inflammatory 
(classically activated) by LPS or IFN-γ, referred to as M1 macrophages, or anti-
inflammatory (alternatively activated) by IL-13 or IL-4, referred to as M2 
macrophages (Aron-Wisnewsky et al., 2009). Preliminary assays in this study were 
performed on PMA-differentiated M0 macrophages. Further work will investigate 
M1 and M2 macrophages to determine whether estrogen influences phagocytosis 
in an activation-dependent manner. 
Images from the SEM (Figure 3.16) illustrated major morphological changes in the 
membrane of phagocytes (macrophages) following estrogen treatment, with the 
establishment of multiple pseudopodial structures suggesting estrogen induces 
significant alterations in the actin cytoskeleton of phagocytes. These findings 
suggested the downstream genes mediated by estrogen may include mediators of 
the actin cytoskeleton. Thus, further investigations could measure differences in 
activated/total levels of proteins involved in the regulation of the actin 
cytoskeleton, such as members of the Rho GTPase family. 
Findings of this study are novel and support the preliminary work performed by 
Crompton et al. (2016). In summary, bacterial phagocytosis by macrophages was 
elevated following stimulation with physiological (typical of youth) and 
supraphysiological estrogen levels compared to estrogen deprivation and an 
absolute absence of estrogen. This suggests that the ageing process (age-related 
decline in estrogen levels) may increase the propensity and progression of wound 
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infections in the elderly, in line with the findings of Ashcroft et al. (1999a). The 
findings of this study suggest local and/or systemic hormone replacement therapy 
(HRT) might resolve or reduce the likelihood of Gram-positive and Gram-negative 
wound infections in the elderly. 
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4.1 Introduction 
4.1.1 Macrophages Polarisation and Plasticity  
The plasticity of macrophages is established by acquisition of distinct functional and 
morphological characteristics directed by particular tissues, and/or immunological 
and environmental stimuli (Mantovani et al., 2005; Gordon and Martinez, 2010; 
Wynn et al., 2013). Macrophages in tissues have several similar characteristics but 
they are an extremely heterogeneous population of cells in relation to their 
function and expression of surface markers (Figure 4.1) (Mackaness, 1964; Nathan 
et al., 1983; Stein et al., 1992; Mantovani et al., 2005; Murray and Wynn, 2011; 
Murray et al., 2014). Macrophages are key effectors of the innate immune system, 
providing an initial defence against foreign invaders such as bacteria (Duque and 
Descoteaux, 2015). They also play key roles in initiating and controlling the adaptive 
immune responses (Duque and Descoteaux, 2015). Macrophages are crucial in 
tissue repair, haemostasis, inflammation and remodelling (Mosser and Edwards, 
2010). As a condition of a favourable resolution of inflammation, macrophages 
remove apoptotic leukocytes, and dysregulation in this particular macrophage role 
leads to chronic inflammatory and autoimmune diseases (Balhara and Gounni, 
2012). Macrophages have multiple functions and characteristics (pro-inflammatory 
or anti-inflammatory) in immunity, depending on the type of stimulation and  
resulting functional phenotype (Martinez et al., 2008). Macrophages were initially 
classified into two major phenotypes based on type 1 helper T-cell (Th1) and type 2 
helper T-cell (Th2) polarisation (Hesse et al., 2001; Puig-Kröger et al., 2004; Yona et 
al., 2013; Martinez and Gordon, 2014). Cytokines mainly released by Th1 cells, such 
as IFN-γ differentiate macrophages to pro-inflammatory M1 macrophages. 
However, cytokines released by Th2 cells such as IL-4 have been reported to 
dampen macrophage activation, resulting in M2 anti-inflammatory macrophages 
(Raes et al., 2002; Kzhyshkowska et al., 2006). 
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  Classically Activated Macrophages 
In response to cytokines such as IFN-γ, and/or bacterial components such as LPS, 
macrophages are polarized to a pro-inflammatory phenotype and are referred to as 
classically activated or M1 macrophages. Classical activation or M1 polarisation are 
terms that were first used during the 1960s when studies on mice reported 
macrophages with enhanced anti-bacterial activities towards infections with 
Mycobacterium bovis bacillus Calmette-Guerin (BCG) or Listeria monocytogenes 
(Mackaness, 1964). The cytokine IFN-γ produced by TH1 cells was described as the 
main activator of antimicrobial and cytotoxic activities of macrophages (Mosmann 
et al., 1986). Genetic deficiencies of IFN-γ and/or its receptors confirmed that 
macrophages polarisation to the M1 phenotype is essential for host defence against 
pathogenic infections in knockout mice models and in humans. Components of 
intracellular pathogens (e.g. LPS), TNF, GM-CSF and TLR4 ligands were also 
described to encourage M1 polarisation (Mantovani et al., 2005). 
M1 macrophages stimulate TH1 immunity by releasing high levels of IL-12 
(Mantovani et al., 2004), producing microbicide enzymes such as inducible NO 
synthase (iNOS) to destroy pathogenic invaders, secreting pro-inflammatory 
cytokines, such as, IL-1β, IL-6, IL-12, IL-23, TNF-α, and releasing chemokines to 
attract immune cells to the infection site and MMPs (Mantovani et al., 2004). 
  Alternatively Activated Macrophages 
In 1990, a study reported for the first time the inhibition of M1 polarisation. This 
study revealed that the production of IFN-γ induced superoxide (O2-) by IL-4 was 
inhibited (Abramson and Gallin, 1990). Later on the 1990s, Gordon and colleagues 
described the term “alternatively activated macrophages (Stein et al., 1992). It is 
commonly believed that M2 macrophages are involved in tissue repair, fibrosis and 
tumour progression (Wynn, 2004). They are identified by expression of surface 
markers, mainly the macrophage mannose receptor CD206 (Stein et al., 1992) and 
CD163 (Zeyda et al., 2007). Arginase (Arg-1) is an enzyme that is involved in the 
production of proline via conversion of arginine to ornithine (Martinez et al., 2008). 
Proline has been linked with ECM formation and collagen deposition (Hesse et al., 
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2001). M2 macrophages release anti-inflammatory cytokines, such as, IL-10, and 
are crucial in resolving chronic inflammation, stimulating angiogenesis and 
fibrogenesis and promoting tissue remodelling (Mosser and Edwards, 2008). 
Depending on the stimuli that induces polarisation of macrophages to the M2 
phenotype, M2 macrophages were divided into three subpopulations: M2a 
encouraged by stimulation with IL-4 and/or IL-13, M2b encouraged by TLR lignans, 
immune complexes (ICs), or IL-1R and M2c induced by IL-10/TGF-β  (Mantovani et 
al., 2004). 
 
Figure 4.1. Plasticity of macrophages in wound healing. Following an injury, monocytes  
infiltrate to the wound site and become macrophages (M0). During the early stage of 
inflammation, macrophages switch to the M1 phenotype. M1 macrophages have a 
microbiocidal activity and induce TH1 responses via release of IL-12. Close to the end of the 
inflammatory stage, the microenvironment of the wound changes and the process of 
clearing apoptotic cells initiates the polarisation of macrophages toward M2 macrophages. 
M2 cells play a key role in the resolution of inflammation and progression to subsequent 
stages of wound healing. Both M1 and M2 macrophages are key players in switching from 
inflammation to proliferation (angiogenesis, re-epithelialisation and matrix production). 
Figure drawn based on information in (Benoit et al., 2008; Krzyszczyk et al., 2018). 
4.1.2 Macrophage Phenotypes and Plasticity in Wound Healing 
The proliferation of primary monocytes is limited in vitro but evidence suggests skin 
macrophages can auto-renew in vivo (Davies et al., 2013). In contrast, it remains 
unclear if macrophages are only recruited to the wound site when required and 
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removed after wound repair, or if macrophages deriving from monocytes can 
proliferate in vivo (Italiani and Boraschi, 2014). 
Macrophages were initially classified into two major phenotypes referred to as M1 
and M2 macrophages. M1 macrophages are commonly linked with pro-
inflammatory events, while M2 macrophages are known to be anti-inflammatory 
and pro-regenerative. It is essential to understand that M1 and M2 macrophages 
are not separate types of cells, but they form a scale in which they take varying 
degrees of M1 or M2 properties. In addition, in vivo studies propose that 
macrophages are a heterogeneous group of cells all displaying a diversity of M1 and 
M2 characteristics (Martinez and Gordon, 2014; Murray et al., 2014; Ogle et al., 
2016). 
Distinct M1 and M2 macrophages classification is not applied when comparing 
wound healing macrophages in vivo. However, this classification is widely used in 
vitro when molecules inducing the polarisation are known and experimentally 
introduced to the system (Novak and Koh, 2013). The types and suggested roles of 
macrophages related with wound healing in vitro and in vivo are illustrated (figure 
4.2). 
 
Figure 4.2. The role of macrophage phenotypes in wound repair. During haemostasis and 
inflammation, pro-inflammatory macrophages invade the wound area and start removing 
dead cells and bacteria. During the proliferative stage, pro-wound healing macrophages are 
present and release factors such VEGF, PDGF, TGF-β to aid angiogenesis, ECM and scar 
formation and re-epithelialization. During remodelling, pro-resolving macrophages are 
involved in strengthening the new skin barrier. 
In line with the wound healing process, pro-inflammatory macrophages are 
dominant at the wound site after an injury, followed by pro-wound healing 
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macrophages that stimulate the growth of cells during  the proliferative phase, and 
finally pro-resolving macrophages that dampen immune responses and stimulate 
the remodelling and maturation of collagen (Vannella and Wynn, 2017). 
During wound healing, pro-inflammatory macrophages are a source of NO, ROS, IL-
1, IL-6, and TNF-α. They release MMPs in order to disrupt the extracellular matrix 
and create a space for inflammatory cells to infiltrate the wound (Murray and 
Wynn, 2011). They also release important levels of growth factors such as PDGF, 
VEGF, insulin-like growth factor 1 (IGF-1) and TGF-β1 which facilitate the 
proliferation of cells involved in angiogenesis and ECM deposition (Murray and 
Wynn, 2011). Pro-resolving macrophages dampen inflammation by upregulating IL-
10 and produce MMPs to remodel and reinforce the ECM (Vannella and Wynn, 
2017). The main roles of pro-resolving macrophages are to reinstate homeostasis 
and minimize fibrosis via apoptosis of myofibroblasts, and suppression T cell 
proliferation (Murray and Wynn, 2011). 
Knowing that wound healing is a sequence of overlapping phases, all types of 
macrophages share many characteristics simultaneously. This is particularly true for 
pro-wound healing macrophages as they fluctuate between the early and late 
stages of wound repair, and therefore display similar features to pro-inflammatory 
and pro-resolving macrophages. 
M1 macrophages are the dominant pro-inflammatory macrophages during the 
early pro-inflammatory stage of wound repair. They are phagocytic, and serve as 
cleaners of the wound site by removing foreign invaders and dead tissue. In vitro, 
M1 macrophages are induced by intracellular cytokines such as IFN-γ, and/or 
bacterial elements, such as LPS and peptidoglycans. M1 macrophages are 
distinguished in vitro by the expression of the chemokine receptor CCR7 (CD197) 
and high levels of the co‐stimulatory molecules CD80 and CD86, resulting in 
efficient antigen presentation capacity (Mantovani et al., 2004). 
M2 macrophages play a regenerative role in wound healing. They are induced by IL-
4 and IL-13 and characterised by a high expression of the mannose receptor 
(CD206) (Stein et al., 1992), the haemoglobin scavenger receptor (CD163) (Zeyda et 
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al., 2007), IL-10, and TGF-β. M2 macrophages release only very low levels of pro-
inflammatory mediators such as TNF-α, IL-12, and IL-8. In wounds M2 macrophages 
have been divided into three subtypes (M2a, M2b and M2c) relating to expression 
of different surface markers. The three subtypes are commonly identified and used 
in vitro to investigate M2 phenotype characteristics. However, distinct M2 
macrophages classification is not widely applied when referring to wound healing in 
vivo. This is due to the heterogeneous populations present, which are generated 
from a variety of stimuli within wounds (Novak and Koh, 2013). Studies have 
reported that the wound healing M2 macrophages align with the well-defined 
subset of M2a (Ogle et al., 2016). M2a macrophages are induced by IL-4/IL-13 and 
distinguished by the expression of CD206. They produce arginase-1, IGF-1, PDGF-BB 
and a variety of chemokines (CCL17, CCL18, CCL22) (Ogle et al., 2016). They are 
crucial in the proliferative stage of wound healing by aiding ECM formation via 
production of collagen precursors and stimulation of fibroblasts.  M2 macrophages 
also release high levels of PDGF, which is involved in angiogenesis (Vannella and 
Wynn, 2017). 
Overall, macrophage classification is complex and not yet fully understood with 
uncertainty whether macrophage phenotypes are distinct, or even appropriate to in 
vivo models of wound healing (Martinez and Gordon, 2014). Although the 
mechanism is not understood, a balance between the M1 and M2 phenotypes is 
essential to preserve a homeostatic environment, and imbalance leads to disturbed 
inflammation. 
Exogenous estrogen supplementation enhances healing in elderly people, indicating 
that the systemic and peripheral age-related decrease in endogenous estrogen 
levels impairs healing in both sexes (Ashcroft et al., 1997b; Hardman and Ashcroft, 
2005). Known for its anti-inflammatory proprieties, estrogen is reported to resolve 
excessive inflammation by directly effecting inflammatory responses of monocytes 
and macrophages (Ashcroft et al., 2003; Guo and DiPietro, 2010). Estrogen has 
been reported to accelerate re-epithelialisation, promote angiogenesis, increase 
matrix deposition and wound contraction, dampen the inflammatory response and 
inhibit the release of pro-inflammatory cytokines (Ashcroft and Ashworth, 2003). 
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These findings suggest estrogen modulated both pro-inflammatory (M1) and anti-
inflammatory / pro-regenerative (M2) macrophages during wound repair. Estrogen 
is also believed to be a key player in regulating immune responses against bacterial 
infections in wounds (Cutolo et al., 2004). Data in the previous chapter showed that 
estrogen significantly enhanced the phagocytosis of MRSA and P. aeruginosa by 
classical M0 macrophages, in a concentration-dependant manner when above 
levels described as estrogen deprivation. Using models of macrophage polarisation 
into M1 and M2 phenotypes, the effect of estrogen on the phagocytosis of MRSA 
and P. aeruginosa by M1-like and M2-like macrophages was investigated. 
4.2 Aim and Objectives 
4.2.1 Aim 
To investigate the effect of estrogen (age-related changes in estrogen 
concentrations) on the phagocytic function of both pro-inflammatory (M1) and 
anti-inflammatory (M2) macrophages using in vitro and ex vivo models of host-
pathogen interactions. 
4.2.2 Objectives 
 
 Generate an in vitro model of HPBM and U937 monocyte differentiation into 
M1-like and M2-like macrophages. 
 
 Compare the phagocytic function of M1 and M2 macrophages under 
conditions of physiological and supraphysiological levels of estrogen with 
conditions of estrogen deprivation or an absolute absence of estrogen. 
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 Compare the effect of age-related changes in estrogen levels on the 
phagocytosis of Gram-positive and Gram-negative bacteria by M1-like and 
M2-like macrophages. 
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4.3 Methods 
4.3.1 Flow Cytometry 
U937 and HPBM were differentiated into M1-like and M2-like macrophages in vitro 
(Figure 4.3) as described in section 2.2.5. The expression of surface markers specific 
for M1 (CD197) and M2 (CD206) macrophages (relative MFI and % fluorescence) on 
M1- and M2-like cells were compared with untreated M0 control macrophages. 
4.3.2 In vitro and Ex Vivo Models of Host-Pathogen Interactions 
U937 and HPBM M1-like/M2-like macrophages were adhered to wells and treated 
with different concentrations (1 x 10-7 M, 1 x 10-8 M, 1 x 10-9 M and zero M) of 
estrogen in antibiotic-free medium for 24 hours to represent the models of age-
related changes in estrogen levels described in Sections 2.2.2 and 2.2.8.2. Cells 
were incubated with MRSA or P. aeruginosa (1 x 104 CFU) for 3 hours at 37 °C and 
5% CO2 prior to counting bacterial colonies (CFU/mL) following the methods 
described in Section 2.2.8.2. 
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Figure 4.3. Experimental Generation of M1 and M2 Macrophages. U937 and CD14+ HPBM were differentiated into adherent M0 macrophages using PMA 
for 24 hours (with medium being changed after 24 hours). Further polarisation into classically activated (M1) or alternatively activated (M2) macrophages 
was performed using LPS + IFN-γ or IL-4 + IL-13 for 24 hours, respectively. The medium was changed every other day to generate resting M1-like and M2-
like macrophages. 
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4.4 Results 
4.4.1 Differentiation of Monocytes into M1 and M2 Macrophages  
The expression of CD197 and CD206, which are surface markers for M1 (Mantovani 
et al., 2004) and M2 (Stein et al., 1992) macrophages respectively, were examined 
by flow cytometry (Figure 4.4). The findings confirmed the successful conversion of 
U937 M0 macrophages into CD197+ M1 and CD206+ M2 macrophages. The U937 
macrophages treated with LPS/IFN‐γ were 94.7% CD197+ and 0.4% CD206+, 
whereas the U937 macrophages treated with IL-4/IL-13 were 6.6% CD197+ and 
79.8% CD206+. The MFI for M1 surface marker CD197 was significantly (P<0.01) 
higher in U937 macrophages treated with LPS/IFN‐γ compared to untreated U937 
macrophages or U937 macrophages treated with IL-4/IL-13. In contrast, the MFI for 
the M2 surface marker CD206 was significantly (P<0.01) higher in U937 
macrophages treated with IL-4/IL-13 compared to untreated U937 macrophages or 
macrophages treated with LPS/IFN‐γ. 
Similarly, the findings confirmed the successful conversion of HPBM-derived 
macrophages into CD197+ M1 and CD206+ M2 macrophages (Figure 4.5). There was  
substantial expression of the M1 surface marker CD197 (67.2%) by HPBM-derived 
macrophages treated with LPS/IFN‐γ, whereas CD197 was almost absent in HPBM-
derived M0 macrophages (1%) and at very low levels (5.7%) in HPBM-derived 
macrophages treated with IL-4/IL-13. The M2 surface marker CD206 was 
substantially expressed (73.4%) by HPBM-derived macrophages treated with IL-
4/IL-13 whereas CD206 was almost absent from HPBM-derived M0 macrophages 
(0.1%) and HPBM-derived macrophages treated with LPS/IFN‐γ (0.2%). The MFI for 
CD197 from HPBM-derived macrophages treated with LPS/IFN‐γ was significantly 
(P<0.01) greater than from HPBM-derived M0 macrophages or HPBM-derived 
macrophages treated with IL-4/IL-13.In contrast, the MFI  for CD206 from HPBM-
derived macrophages treated with IL-4/IL-13 was significantly (P<0.01) higher than 
from HPBM-derived M0 macrophages or HPBM-derived macrophages treated with 
LPS/IFN‐γ.
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Figure 4.4. Differentiation of U937 M0 macrophages onto M1/M2 macrophages. The polarisation of U937 M0 macrophages into M1-like and M2-like 
macrophages was confirmed by through detection of CD197 and CD206 surface markers by flow cytometry respectively. M0 macrophages did not express 
CD197 or CD206 markers (0.2% and 0.4% respectively). U937 macrophages treated with LPS/IFN‐γ expressed high levels of CD197 (94.7%) but almost lacked 
CD206 (0.4%). U937 macrophages treated with IL-4/IL-13 expressed CD206 (79.8%) but very low levels of CD197 (6.6%) (A). Three distinct populations of 
U937 macrophages were identified (D) with significantly higher MFI for CD197 from M1 macrophages compared to M0 and M2 macrophages (B), and a 
significantly higher MFI for CD206 from M2 macrophages compared to M0 and M1 macrophages. Data represent averages of n = 3 experiments. ** 
Indicates significant difference (One-way ANOVA) in MFI (P<0.01) compared to M0 macrophages. Error bars represent the standard error of the mean 
(StEM).  
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Figure 4.5. Polarisation of HPBM M0 macrophages into M1/M2 macrophages. The polarisation of HPBM M0 macrophages into M1 and M2 macrophages 
was confirmed via detection of CD197 and CD206 surface markers by flow cytometry respectively. PMA-differentiated M0 macrophages almost lacked both 
CD197 (1%) and CD206 (0.1%). In contrast, macrophages treated with LPS/IFN‐γ expressed CD197 (67.2%) but almost lacked CD206 (0.2%). Macrophages 
treated with IL-4/IL-13 expressed CD206 (73.4%) but very low levels of CD197 (5.7%) (A). Three distinct populations of HBPM macrophages were detected 
(D) with significantly higher MFI for CD197 from M1 macrophages compared to M0 and M2 macrophages (B), and significantly higher MFI for CD206 from 
M2 macrophages compared to M0 and M1 macrophages. Data represent an average of n = 3 experiments. ** Indicates significant difference (One-way 
ANOVA) in MFI (P<0.01) compared to M0 macrophages. Error bars represent the standard error of the mean (StEM). 
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4.4.2 Effect of Age-Related Changes in Estrogen Levels on In vitro Phagocytosis 
of MRSA and P. aeruginosa by U937-derived M1 and M2 Macrophages 
The effect of age-related changes in estrogen levels on the clearance of MRSA and 
P. aeruginosa by U937-derived M1 and M2 macrophages was investigated (Figure 
4.6). Compared to the negative control, conditions representing an absolute 
absence of estrogen (zero M) and estrogen deprivation (1 x 10-9 M)  had no 
significant effect (P>0.05) on the clearance of MRSA or PAO1 by both U937-derived 
M1 and M2 macrophages. 
In contrast, physiological and supraphysiological levels of estrogen significantly 
(P<0.01) reduced the recovery of MRSA and P. aeruginosa by both U937-derived 
M1 and M2 macrophages in a dose-dependent manner compared to the negative 
control. After a 3-hour incubation with U937-derived M1 macrophages, the MRSA 
recovery was significantly (P<0.05) reduced to 1586 CFU/mL and 1476 CFU/mL 
following treatment with physiological and supraphysiological levels of estrogen 
respectively, compared to the negative control (2117 CFU/mL). Although somewhat 
less effective, after a 3-hour incubation with U937-derived M2 macrophages with 
physiological or supraphysiological levels of estrogen still significantly (P<0.05) 
reduced the recovery of MRSA to 2927 CFU/mL and 2533 CFU/mL respectively 
compared to the negative control (3538 CFU/ml).  
Similarly, treating U937-derived M1 macrophages with physiological or 
supraphysiological levels of estrogen significantly (P<0.05) reduced PAO1 recovery 
to 2405 CFU/mL and 1920 CFU/mL respectively compared to the negative control 
(2660 CFU/mL). Although somewhat less effective, treating U937-derived M2 
macrophages with physiological or supraphysiological levels of estrogen still 
significantly (P<0.05) reduced the recovery of PA01 to 3052 CFU/mL and 2594 
CFU/mL respectively compared to the negative control (3790 CFU/mL). 
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Figure 4.6. Estrogen enhances the phagocytosis of MRSA (A) and PAO1 (B) by U937-
derived M1/M2 macrophages in vitro. The recovery of MRSA (A) and PAO1 (B) after 
incubation with  U937-derived M1/M2 macrophages were significantly (*: P<0.05, **: 
P<0.01) decreased following treatment with physiological (1 x 10-8 M) or supraphysiological 
(1 x 10-7 M) levels of estrogen compared to the negative control. U937-derived M1 
macrophages internalised significantly (P<0.05) more MRSA/PAO1 respectively than U937-
derived M2 macrophages. Data is mean ± StEM, n = 10. 
4.4.3 Effect of Age-Related Changes in Estrogen Levels on the Phagocytosis of 
MRSA and P. aeruginosa by Ex Vivo M1 and M2 Human Macrophages 
The effect of estrogen on the phagocytosis of MRSA and P. aeruginosa by ex vivo 
HPBM-derived M1/M2 macrophages was investigated (Figure 4.7). After a 3-hour 
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incubation of MRSA or P. aeruginosa  with HPBM-derived M1/M2 macrophages, the 
number of recovered MRSA and P. aeruginosa under conditions representing an 
absolute absence of estrogen (zero M) and estrogen deprivation (1 x 10-9 M) were 
not significantly different (P>0.05) to the negative control. 
Physiological and supraphysiological levels of estrogen significantly (P<0.05) 
reduced MRSA and P. aeruginosa recovery by HPBM-derived M1 and M2 
macrophages compared to the negative control. After a 3-hour incubation with 
HPBM-derived M1 macrophages, the MRSA recovery significantly (P<0.05) 
decreased from 2825 CFU/mL in the negative control to 2023 CFU/mL and 1343 
CFU/mL following treatment with physiological and supraphysiological levels of 
estrogen respectively. Although significantly less effective than M1 macrophages, 
treatment of HPBM-derived M2 macrophages with physiological or 
supraphysiological levels of estrogen still significantly (P<0.05) reduced the recovery 
of MRSA to 2745 CFU/mL and 2437 CFU/mL respectively compared to the negative 
control (3635 CFU/mL). 
Similarly, treating HPBM-derived M1 macrophages with physiological or 
supraphysiological levels of estrogen significantly (P<0.05) reduced P. aeruginosa 
recovery to 2430 CFU/mL and 2083 CFU/mL respectively compared to the negative 
control (3352 CFU/mL). Although somewhat less effective, treating HPBM-derived 
M2 macrophages with physiological or supraphysiological levels of estrogen still 
significantly (P<0.05) reduced the recovery of P. aeruginosa to 3062 CFU/mL and 
2339 CFU/mL respectively compared to the negative control (4052 CFU/mL). 
Intriguingly, the MRSA and P. aeruginosa uptake was significantly (P<0.05) greater 
with both U937-derived and HPBM-derived M1 macrophages compared to M2 
macrophages. 
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Figure 4.7. Estrogen improves the phagocytosis of MRSA (A) and PAO1 (B) by ex vivo 
HPBM-derived M1/M2 macrophages. The recovery of MRSA (A) and P. aeruginosa (B) after 
incubation with HPBM-derived M1/M2 macrophages were significantly (*: P<0.05, **: 
P<0.01) decreased following treatment with physiological (1 x 10-8 M) or supraphysiological 
(1 x 10-7 M) levels of estrogen compared to the negative control. HPBM-derived M1 
macrophages internalised significantly (P<0.05) more MRSA/PAO1 respectively than HPBM-
derived M2 macrophages. Data is mean ± StEM, n = 10. 
 
120 
4.5 Discussion 
Plasticity of macrophages is a crucial process for an effective inflammatory phase 
during wound healing. Macrophages ability to continuously switch from a 
phenotype to another was demonstrated in mice (Thomas et al., 1992; Erwig et al., 
1998). Experiments in this study were conducted using pro-inflammatory (M1-like) 
and anti-inflammatory (M2-like) macrophages. In vitro M1 macrophages can be 
induced by differentiation with IFN-γ and/or LPS, and distinguished through the 
expression of the surface markers CD197 and/or CD86 (Mantovani et al., 2004). In 
contrast, M2 macrophages can be induced by differentiation with IL-4 and/or IL-13, 
and distinguished through the expression of the macrophage mannose receptors, 
CD206 (Stein et al., 1992; Daigneault et al., 2010) and/or CD163 (Zeyda et al., 2007). 
Successful polarisation of U937-derived, and HPBM-derived M0 macrophages into 
M1-like and M2-like macrophages was achieved in this study, with high expression 
of CD197 confirming polarisation into M1-like macrophages by IFN-γ/LPS, and high 
CD206 expression confirming polarisation into M2-like macrophages by IL-4/IL-13. 
The effect of estrogen on the phagocytosis of MRSA and P. aeruginosa by U937-
derived M1-like and M2-like macrophages was investigated in vitro. In line with 
findings of chapter 3, the results from this chapter demonstrated that the 
physiological and supraphysiological levels of estrogen enhanced the clearance of 
both MRSA and PAO1 in a dose-dependent manner in both U937-derived M1 and 
M2 macrophages. Interestingly, the bacterial recovery followed a similar pattern 
throughout, regardless of the macrophage phenotype, with estrogen consistently 
increasing (P<0.05) the phagocytosis of bacteria. These results are supported by the 
findings of Crompton et al. (2016), when estrogen was found to significantly 
enhance the rate of wound repair in mice in a K. pneumonia LPS model of infection, 
and by Li et al. (2000) when a 48-hour stimulation with estrogen was found to 
enhance the uptake of amyloid β‐peptide and E. coli by macrophages extracted 
from human brain tissues (microglial cells). Cutolo et al. (2004) also described 
estrogen as a key regulator of immune responses against bacterial infections in 
macrophages as estrogen was found to enhance the expression of growth and 
proliferation markers in macrophages in patients with autoimmune diseases. 
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It is believed that during early stages of wound healing, M1 macrophages are highly 
phagocytic, and serve as cleaners of the wound site by removing foreign invaders 
and dead tissue (Stein et al., 1992) whereas M2 macrophages have anti-
inflammatory properties and play a more regenerative role as the inflammatory 
response phase subsides (Mantovani et al., 2004). In line with this, M1 
macrophages were described to be highly phagocytic in vitro, and produce 
microbicide enzymes such as iNOS, essential for pathogen destruction. They also 
release many pro-inflammatory cytokines, such as, IL-1β, IL-6, IL-12, IL-23 and TNF-
α (Mantovani et al., 2004). Werner and Grose (2003) reported an up-regulation of 
these cytokines during the inflammatory phase of wound repair. In addition, 
research indicated that genetic deficiencies of IFN-γ and/or its receptors confirmed 
that macrophages polarisation to the M1 phenotype is essential for host defence 
against pathogenic infections in knockout mice models and in humans. Components 
of intracellular pathogens (e.g. LPS), TNF, GM-CSF and TLR4 ligands were also 
described to encourage M1 polarisation (Mantovani et al., 2005). Collectively, data 
from the host-pathogen assays support these reports, with significantly enhanced 
clearance of MRSA and P. aeruginosa by M1 macrophages compared to M2 
macrophages or M0 macrophages (results in chapter 3). 
The assays were conducted first using the immortal cell line “U937 monocytes”. In 
vitro results would provide an insufficient evidence to predict effects in vivo. To 
avoid this limitation, primary monocytes derived from human peripheral blood 
were used to conduct an ex vivo model of host-pathogen interactions. 
Unsurprisingly, the findings were consistent with the in vitro assays. The bacterial 
recovery was shown to decrease with increasing estrogen concentrations with both 
HPBM-derived M1 and M2 macrophages, with a significantly greater uptake of 
bacteria with M1 macrophages compared to M2 macrophages. This suggests 
enhanced phagocytosis is a feature of M1 macrophages, regardless of their source. 
In support of these results, Deshpande et al. (1997) reported that estrogen causes 
an increase in the production of iNOS by murine macrophages as well as many 
other cytokines, particularly, IL-1β, IL-12 and IL-6. This is due to TLR4 activation with 
LPS in murine macrophages. In contrast, other studies reported many anti-
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inflammatory effects of estrogens on macrophages in vitro. Indeed, a 2-hour 
estrogen treatment of macrophages (RAW 264.7 cell line) in vitro caused a 
substantial diminution in the expression of inflammatory mediators, mainly NF-κB, 
subsequent to TLR4 activation (Ghisletti et al., 2005). Long-time (chronic) exposure 
to estrogen was found to promote the alternative activation of macrophages and to 
dampen the IFN-γ/LPS actions on human macrophages (Campbell et al., 2014; 
Toniolo et al., 2015). In this study, a 24-hour incubation with estrogen was shown 
to increase the rate of bacterial phagocytosis in all macrophages regardless the 
macrophage subtype. Further investigations are warranted to determine whether 
estrogen have an effect on the polarisation of macrophages in vitro. One 
application will be to measure the expression of the M1-like and M2-like specific 
markers (e.g. CD197 and CD206 respectively) before and after treatment of 
macrophages with estrogen. 
Human trials have confirmed that estrogen supplementation accelerates healing by 
reducing inflammatory response in the elderly (Deshpande et al., 1997; Srivastava 
et al., 1999) but further in vivo investigations are needed to demonstrate the effect 
of estrogen on bacterial clearance in elderly subjects. Investigations could also be 
conducted using existing animal models of age-related impaired healing 
(Deshpande et al., 1997; Ghisletti et al., 2005) to confirm in vivo effects of estrogen 
on the phagocytic function of M1 and M2 macrophages. 
Billiau and Vandekerckhove (1991) reported that bacterial clearance in wounds is 
reliant on good regulation of TNF-α. Interestingly, estradiol was shown to suppress 
the production of TNF-α in murine macrophages (Deshpande et al., 1997; Srivastava 
et al., 1999). The work presented in this chapter suggests that TNF-α could be 
associated with the mechanism of estrogen-enhanced phagocytosis in M1 
macrophages. Further research is warranted to investigate the change in TNF-α 
levels and other pro-inflammatory cytokines (e.g. MIF) involved in the estrogen-
increased phagocytosis in macrophages. 
Compared to results reported in chapter 3, M1-like macrophages were shown to be 
more phagocytic than M0-like macrophages regardless of the source of 
macrophage. Further work investigating mechanisms of estrogen-enhanced 
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phagocytosis in this thesis will therefore be conducted using pro-inflammatory M1-
like macrophages instead of M0-like or M2-like macrophages. Investigations were 
conducted (chapter 5) to determine the ER pathways linked with the estrogen-
mediated enhancement of phagocytosis through the use of: selective estrogen 
receptor modulators (SERMs) (e.g. Tamoxifen), selective estrogen receptor 
degraders (SERDs) (e.g. Fulvestrant), selective ER-α and/or ER-β agonists (e.g. PPT, 
DPN) to determine the exact ER activation profile involved in the estrogen-
enhanced phagocytosis. In order to investigate the mechanism by which estrogen 
enhanced bacterial clearance in M1 macrophages, the changes in the levels of 
proteins that regulate the actin cytoskeleton dynamics including Rho GTPase 
proteins, and focal adhesion proteins on the cell membrane of estrogen-treated M1 
macrophages are presented (detailed in chapter 6). 
In summary, these findings confirm for the first time that estrogen 
deprivation inhibits phagocytosis by both M1-like and M2-like human macrophages 
whereas physiological/supraphysiological levels of estrogen stimulate the 
phagocytic function of M2 but particularly M1 human macrophages against Gram-
positive and Gram-negative wound pathogens. Together, the results suggest topical 
or systemic estrogen supplementation may potentially resolve or reduce the 
likelihood of wound infections in the elderly. 
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5.1 Introduction 
5.1.1 Estrogen Receptors 
Estrogen signals principally through the estrogen receptor (ER) proteins that are 
part of the nuclear receptor (NR) family. ERs display a structure that is typical of the 
NR family, containing six domains (A-F) (Kuiper et al., 1998; Klinge, 2000; Begam et 
al., 2017) (Figure 5.1). 
ER-alpha (ER-α) was first discovered in 1958 and cloned in 1985 (Jensen, 1962; 
Kuiper et al., 1998). However, ER-beta (ER-β) was first characterised in 1996 in rat 
prostate and ovary. Later in 1998, a human ER-β was identified (Mosselman et al., 
1996; Kuiper et al., 1998). Both ERs are located in various tissues (Campbell et al., 
2010). ER-α is highly expressed in ovaries, cancer breast tissues and reproductive 
tissues (Kuiper et al., 1997; Ali and Coombes, 2000; Campbell et al., 2010).  ER-β is 
mainly found in peripheral tissues such as bone, heart and hypothalamus, but it can 
also be found in healthy breast tissue, the prostate and testis (Kuiper et al., 1997; 
Ali and Coombes, 2000; Campbell et al., 2010). ERs are expressed in the skin, 
suggesting that estrogen regulates skin functions and development (Ashworth, 
2005). Both ER-α and ER-β have been identified in the epidermis of young and old 
women, with isoforms observed in epithelial cells of the hair follicles (Ashworth, 
2005). 
 
Figure 5.1. Schematic representation comparing the structure of human ER-α with ER-β. 
Homology between domains (A-F) is represented as percentage (%) similarity. NHD = N- 
terminal homology domain, DBD = DNA-binding domain, LBD = ligand-binding domain. 
Figure adapted from (Webb et al., 1999; Klinge, 2000; Begam et al., 2017). 
Estrogen signals predominantly by binding to inactive ERs in the nucleus of the cell 
(Klinge, 2000). When estrogen binds to ERs, they become activated and dimerize 
(Klinge, 2000). Each ER has a DNA-binding domain (DBD) which binds to the target 
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gene at a site called the estrogen response element (ERE) (Kuiper et al., 1998; 
Klinge, 2000). In cells expressing a single ER subtype, homodimers of ER-α or ER-β 
are formed (Kuiper et al., 1998). In cells that express both ER subtypes, a 
heterodimer containing one ER-α and one ER-β may form (Kuiper et al., 1998). ERs 
heterodimers and ER-α homodimers bind to DNA with a similar affinity. However, 
ER-β homodimers bind to DNA with a lower affinity (Kuiper et al., 1998). DNA-
bound homodimers and heterodimers bind to steroid receptor coactivator-1 and 
trigger gene transcription (Marino et al., 2006). 
Both ER-α and ER-β enhance acute wound repair, however, their functions are 
different; ER-α is described to control and regulate inflammation, however, ER-β is 
linked with the modulation of wound healing (Campbell et al., 2010). While ER-α 
and ER-β express a 97% homology in the DBD region, they only have 55% homology 
in the LBD region (Barkhem et al., 1998; Webb et al., 1999; Klinge, 2000). This made 
possible the design of artificial estrogens such as SERMs with specific binding 
affinity to one isoform over another. 
5.1.2 Estrogen Receptor Agonists 
Estrogen receptor agonists are molecules that induce one or both ER subtypes in 
order to partially or fully induce a pharmacological effect (Sun et al., 1999). 
Selective agonists of ER-α and ER-β are extensively used to investigate the distinct 
functions of the ERs in several human diseases. Propyl pyrazole triol (PPT) and 
Diarylpropionitrile (DPN) are the most frequently used selective ERs agonists. PPT is 
a selective ER-α agonist (Thammacharoen et al., 2009) that has 410-fold more 
selectivity for ER-α than ER-β (Thammacharoen et al., 2009). In 1999, PPT was used 
for the first time to investigate the role of ER-α in several tissues (Sun et al., 1999). 
DPN is a selective ER-β agonist (Minutolo et al., 2011) that has 70-fold more 
selectivity for ER-β than ER-α (Meyers et al., 2001). DPN was first used in 1999 in a 
purpose  to develop new ligands selective for ER-β (Sun et al., 1999; Meyers et al., 
2001) (Figure 5.2). 
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Figure 5.2. Structure of DPN (A) and PPT (B). 
5.1.3 Estrogen Receptor Antagonists 
Estrogen receptor antagonists are compounds characterised to have high affinity to 
bind to one or both of the ER subtypes, without the potential of inducing the 
normal pharmacological effects typically mediated by the receptors (Wakeling et 
al., 1991; Barkhem et al., 1998). ER antagonists compete with estrogen to bind to 
the specific receptor site (Morris and Wakeling, 2002; Osborne et al., 2004). 
Therefore, the physiological effect produced in response to estrogen will be 
dampened in the presence of ER antagonists. ER antagonists have been used 
clinically to control fertility or treat various cancers (Morris and Wakeling, 2002; 
Osborne et al., 2004). 
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Theophylline, 8-[(benzylthio)methyl]-(7CI,8CI) (TPBM) is a potent inhibitor of ER-α 
via blocking the binding of ER-α to the ERE DNA (Mao et al., 2008). TPBM is highly 
selective for ER-α compared to ER-β, with a greater selectivity for blocking gene 
transcription mediated by ER-α  relative to ER-β (Mao et al., 2008). TPBM has been 
used  to investigate the role of ER-α in many biological processes and disorders 
including cancer (Mann, 2008; Plant and Zeleznik, 2014). 
 
Figure 5.3. Structure of TPBM.  
5.1.4 Selective Estrogen Receptor Modulators (SERMs) 
Selective estrogen receptor modulators (SERMs) are ER-interacting molecules that 
have the ability to bind the ERs and act as agonists in specific tissues whilst acting as  
antagonists in different tissues (Cho and Nuttall, 2001). SERMs have been used 
clinically to promote the beneficial effects of estrogen in target tissues whilst 
avoiding/decreasing detrimental effects of estrogen in other non-target tissues 
such as increasing the risk of breast cancer in breast tissues (Mirkin and Pickar, 
2015). SERMs can be differentiated from ER agonists/antagonists due to their 
opposing effects in tissues (Park and Jordan, 2002). SERMs are structurally different 
to estrogens but their chemical structures allow them to bind to the LBD of ERs 
(Brzozowski et al., 1997). 
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Tamoxifen (Figure 5.4) is one of the most documented and frequently used SERMs. 
It is known to have estrogenic effects in numerous peripheral tissues such as bone, 
but is anti-estrogenic in the breast tissue and therefore used extensively in breast 
cancer research (Furr and Jordan, 1984; Morris and Wakeling, 2002; Park and 
Jordan, 2002; Mirkin and Pickar, 2015). Tamoxifen was discovered and reported by 
the Food and Drug Administration (FDA) in 1977 (Park and Jordan, 2002; Jordan, 
2006; Mirkin and Pickar, 2015; Quirke, 2017). Tamoxifen binds to both ERs, and its 
effects depend on the cell and tissue types. It is anti-estrogenic in the breast, and is 
therefore commonly used to prevent and/or treat breast cancer in postmenopausal 
and premenopausal females (Zidan et al., 2004; Quirke, 2017). Tamoxifen has also 
been reported to maintain the density of bone in rats and humans (Jordan et al., 
1987; Zidan et al., 2004). However, it has multiple side effects and is frequently 
linked with endometrial cancer due to its estrogenic effects in the uterus (Kedar et 
al., 1994). 
 
Figure 5.4. Structure of Tamoxifen. 
5.1.5 Selective Estrogen Receptor Degraders (SERDs) 
Selective estrogen receptor degraders (SERDs) are molecules that have high affinity 
to bind ERs but lead to their degradation, leading to reduced levels of functional 
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ERs (Lee et al., 2017). Along with SERMs and aromatase inhibitors, SERDs are mainly 
used to treat breast cancer (Lee et al., 2017).  Fulvestrant, the most commonly used 
SERD, was officially discovered in 2002 (Lee et al., 2017). In November 2016, other 
SERDs such as elacestrant and brilanestrant were developed (Lai and Crews, 2017). 
Fulvestrant is an analogue and competitive inhibitor of 17β-estradiol (Osborne et 
al., 2004), with a high selective binding affinity (89% that of estrogen) to the ER 
(Morris and Wakeling, 2002). The binding of fulvestrant to the ER weakens the 
receptor dimerization and blocks the nuclear localisation of ER (Morris and 
Wakeling, 2002; Osborne et al., 2004). In addition, the fulvestrant-ER complex is 
unstable, which leads to its rapid degradation leading to enhanced cellular ER 
deprivation compared with estrogen or other SERMs (e.g. tamoxifen) (Morris and 
Wakeling, 2002). The reduced levels of functional ER protein does not cause any 
decrease in the levels of ER mRNA. Therefore, after binding to, blocking and 
accelerating the destruction of the ER protein, fulvestrant inhibits estrogen 
signalling (Morris and Wakeling, 2002; Osborne et al., 2004). 
 
Figure 5.5. Structure of Fulvestrant. 
5.1.6 Estrogen Receptors and Wound Infection 
ER-α and ER-β are both expressed by inflammatory cells, including neutrophils and 
macrophages (Ashcroft et al., 2003). More widely, ER-α is expressed in human skin, 
fibroblasts and the adipose tissue (Kuiper et al., 1997; Kuiper et al., 1998; Campbell 
et al., 2010; Campbell et al., 2014). ER-β is expressed in the dermis, epidermis, 
fibroblasts, endothelial cells  and muscle cells (Thornton et al., 2003). 
Estrogen is key molecule that enhances wound healing in both genders and these 
actions appear to be mediated via the ERs (Ashcroft et al., 1999a). Age-related 
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estrogen deprivation is frequently linked with delayed wound healing and might 
contribute to the development of chronic wounds in the elderly (Ashcroft and 
Ashworth., 2003). In particular, polymorphisms of the ER-β gene are associated 
with venous ulceration and a pronounced inflammatory response (Ashworth, 2005). 
ER-α has been implicated in reducing the inflammatory response in wounds by 
dampening levels of pro-inflammatory cytokines such as macrophage migration 
inhibitory factor (MIF) (Campbell et al., 2010). In contrast, ER-α activation by PPT 
has been shown to considerably reduce early wound strength in models of 
ovariectomized mice compared to untreated ovariectomized mice, whereas 
activation of ER-β  with DPN had no effect on early wound strength (Gál et al., 
2010). Although the involvement of ER subtypes in the wound healing process is 
documented, there is a lack in knowledge regarding the precise roles of ER-α and 
ER-β in the clearance of bacteria from infected wounds. 
Ashcroft et al. (1999a) showed that estrogen replacement therapy accelerates 
wound repair in postmenopausal females. Furthermore, this study has showed 
estrogen enhances the clearance of the typical wound pathogens MRSA and P. 
aeruginosa (chapter 3 and 4). However, Anderson et al. (2004) reported that 
estrogen supplementation in postmenopausal females is associated with a higher 
risk of breast cancer and heart diseases. Thus, rather than using systemic estrogen 
supplementation, the use of appropriate ERs agonists/antagonists, SERDs and 
particularly SERMs could be beneficial in treatment of age related impaired healing 
and infected wounds. 
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5.2 Aim and Objectives 
5.2.1 Aim 
To investigate the involvement of ERs in mediating the beneficial effects of 
estrogen on promoting phagocytosis by human M1 macrophages using in vitro and 
ex vivo models of host-pathogen interactions. 
5.2.2 Objectives 
 Determine the effect of ERs agonists and antagonists, SERDs and SERMs on 
the phagocytosis of Gram-positive (MRSA) and Gram-negative (P. 
aeruginosa) bacteria by U937- and HPBM-derived M1 macrophages. 
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5.3 Methods 
5.3.1 Estrogen Receptors Stimulation/Blockade 
In order to test the effect of ERs agonists/antagonists, SERMs and SERDs on the 
MRSA and P. aeruginosa clearance, in vitro and ex vivo host-pathogen assays were 
conducted as described in section 2.2.12. 
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5.4 Results 
Similar to previous results, supraphysiological estrogen levels significantly 
decreased (P<0.01) MRSA and P. aeruginosa recovery compared to the negative 
control and the absence of estrogen (Figure 5.6). Treatment with the ER agonist 
tamoxifen mirrored the effects of estrogen, significantly (P<0.01) decreasing the 
bacterial recovery of both MRSA and P. aeruginosa. In contrast, treatment with the 
ER degrader fulvestrant blocked the effects of supraphysiological levels of estrogen 
on the phagocytosis of MRSA and P. aeruginosa, with no significant difference in 
bacterial recovery (P>0.05) detected compared to the negative control and the 
absence of estrogen. Of interest, ER-α agonism with PPT significantly reduced 
(P<0.01) the recovery of both MRSA and P. aeruginosa in fashion similar to 
supraphysiological estrogen levels when compared to the negative control and the 
absence of estrogen.  In contrast, ER-β stimulation with DPN did not significantly 
(P>0.05) affect the uptake of MRSA and P. aeruginosa by M1 macrophage 
compared to the negative control or the absence of estrogen. Intriguingly, the 
selective ER-α antagonist, TPBM, reversed the effect of estrogen and PPT on the 
phagocytosis of MRSA and P. aeruginosa, with no significant difference (P>0.05) in 
bacterial recovery detected compared to the negative control or the absence of 
estrogen. 
 
135 
 
 
Figure 5.6. Estrogen, tamoxifen and the selective ER-α agonist, PPT, enhances the 
phagocytosis of MRSA (A) and P. aeruginosa (B) by U937 M1 macrophages. Estrogen, 
tamoxifen and PPT significantly decreased the MRSA (A) and P. aeruginosa (B) recovery 
compared to the negative control or the absence of estrogen (E 0M). Fulvestrant and TPBM 
significantly blocked the effects of estrogen on the phagocytosis of both MRSA and P. 
aeruginosa, with no significant difference in bacterial recovery detected compared to the 
negative control or the absence of estrogen. DPN did not significantly affect bacterial 
uptake compared to the negative control or the absence of estrogen. Data represent an 
average of n = 6 experiments. ** Indicates significant difference (P<0.01). Error bars 
represent the standard error of the mean (StEM). 
The in vitro host-pathogen assays were repeated using ex vivo primary HPBM-
derived M1 macrophages in order to confirm these initial findings (Figure 5.7). The 
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results were similar to those obtained with U937-derived M1 macrophages, with 
estrogen, tamoxifen and PPT significantly (P<0.01) reducing MRSA and P. 
aeruginosa recovery compared to the negative control and the absence of 
estrogen. Again, fulvestrant and ER-α antagonism with TPBM blocked the effects of 
estrogen whereas ER-β agonism with DPN had no significant (P>0.05) effect on the 
phagocytosis of MRSA and P. aeruginosa compared to the negative control or the 
absence of estrogen. 
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Figure 5.7. Estrogen, tamoxifen and the selective ER-α agonist, PPT, enhance MRSA (A) 
and P. aeruginosa (B) uptake by HPBM M1 macrophages. Estrogen, tamoxifen and PPT 
significantly decreased the recovery of MRSA (A) and P. aeruginosa (B) compared to the 
negative control and the absence of estrogen (E 0M). Fulvestrant and TPBM significantly 
blocked the effects of estrogen on the phagocytosis of both MRSA and P. aeruginosa, with 
no significant difference in bacterial recovery detected compared to the negative control or 
the absence of estrogen. DPN did not significantly affect bacterial uptake compared to the 
negative control or the absence of estrogen. Data represent an average of n = 6 
experiments. ** Indicates significant difference (P<0.01). Error bars represent the standard 
error of the mean (StEM). 
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5.5 Discussion 
The age-related change in estrogen levels is linked with skin degeneration and 
impaired wound healing (Ashcroft et al., 1999b). Estrogen is frequently linked with 
pathological wounds (Ashcroft and Ashworth., 2003) and a case-cohort study 
reported that elderly (over 65 years old) patients treated with estrogen were 30-
40% less likely to develop a venous leg ulcer than untreated patients (Margolis et 
al., 2002)..  Moreover, estrogen deprivation diminishes the phagocytic capability of 
neutrophils and macrophages, and increases the risk of infection and a 
postponement in healing (Ashcroft and Ashworth., 2003).  
Due to their possession of nuclear ERs, the function of inflammatory cells such as 
macrophages are known to be influenced directly by estrogen (Weusten et al., 
1986; Suenaga et al., 1996; Suenaga et al., 1998) through its binding to ER-α and/or 
ER-β (Kuiper et al., 1998; Klinge, 2000). SERMs and SERDs are ER-interacting 
molecules that are able to bind to the ERs and achieve normal mechanisms of 
estrogen signalling to function as agonists or antagonists of estrogen in a tissue-
specific manner (Cho and Nuttall, 2001). SERMs and SERDs are compounds typically 
used to treat several ER-mediated pathologies (e.g. breast cancer) due to their 
tissue-specific responses (Mirkin and Pickar, 2015; Lee et al., 2017). Estrogen 
stimulated the phagocytic function of human macrophages against MRSA and P. 
aeruginosa (Chapter 3 and 4). This study used SERMs and SERDs to investigate 
which ERs are involved in the estrogen-mediated stimulation of bacterial clearance 
by M1-like macrophages. 
An accumulating body of evidence demonstrates that tamoxifen acts as ER 
antagonist in breast tissue, but is agonist in the uterus and peripheral tissues such 
as bone (Fisher et al., 2005; DeMichele et al., 2008). Tamoxifen enhanced the 
phagocytosis of MRSA and P. aeruginosa by human M1 macrophages suggesting 
tamoxifen was acting in a similar manner to estrogen. In support of this, tamoxifen 
was shown to enhance neutrophils chemotaxis and phagocytosis functions, boost 
human neutrophil bactericidal ability against a range of bacteria in vitro and 
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improve clearance of the leading nosocomial antibiotic-resistant bacteria, MRSA, in 
vivo (Corriden et al., 2015). 
Tamoxifen has been shown to accelerate wound healing in ovariectomized mice, 
suggesting that it can potentially be used to treat impaired wound repair in the 
elderly (Hardman et al., 2007). This study adds weight to this theory by showing 
tamoxifen may be beneficial in the treatment of infected wounds in the elderly. 
Pickar et al. (2010) have detailed the beneficial effects of SERMs on females health 
after menopause, SERMs such as tamoxifen are more beneficial during wound 
healing when they are applied locally on wounds rather than orally. A new group of 
SERMs, such as Ophena, are now developed to mimic the positive biological and 
tissue specific estrogen functions but not the undesirable side effects such as the 
risk of breast and uterine cancers (Pickar et al., 2010). 
Fulvestrant is a compound structurally different to SERMs that due to its high 
binding affinity to the ERs, binds in competition with estrogen to the ERs (Morris 
and Wakeling, 2002). When bound to ERs, fulvestrant deteriorates the receptor 
dimerization and blocks nuclear localisation of the ERs (Morris and Wakeling, 2002; 
Osborne et al., 2004). The findings showed that, unlike treatment with estrogen or 
tamoxifen, pre-treatement of M1 macrophages with fulvestrant blocked 
stimulation of bacterial clearance by estrogen. This provided additional evidence 
that estrogen may be acting through the ERs to promote phagocytosis and that 
disruption of the ERs prevents the beneficial effect of estrogen on bacterial 
clearance. Collectively, data generated from the use of tamoxifen and fulvestrant 
provide evidence that estrogen is enhancing the phagocytosis of bacteria, by pro-
inflammatory M1 macrophages via binding and activation of the ERs. 
It has been reported that the anti-proliferative effects of fulvestrant on cells in 
breast are due to the degradation of the ER-α protein (Long and Nephew, 2006). 
Interestingly, it has been reported that ER-α is the key receptor in regulating the 
thickness of epidermis during wound healing (Stumpf et al., 1974; Bidmon et al., 
1990). Toutain et al. (2009) reported that ER-α is also the main isoform involved in 
promoting the beneficial effects of 17β-estradiol in a model of skin necrosis. On the 
other hand, ER-β was described to be the key receptor in the protection against 
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skin damage resulted from exposure to UV (Chang et al., 2010). Both ER subtypes 
are expressed on fibroblasts and inflammatory cells such as neutrophils and 
macrophages (Campbell et al., 2010). ER-α has been noted to control and regulate 
inflammation, whereas ER-β is mainly linked with modulating the later phases of 
wound healing (Campbell et al., 2010). This study used two major agonists of ER-α 
(PPT) and ER-β (DPN) to investigate the effect of activating ER isoforms on the 
phagocytosis of MRSA and P. aeruginosa. PPT is an ER-α agonist that is 410-fold 
more selective for ER-α than ER-β  whereas DPN is an ER-β agonist with a 70-fold 
higher selectivity for ER-β than ER-α (Campbell et al., 2010). Intriguingly, selective 
activation of ER-α with PPT mirrored the effects of estrogen by significantly (P<0.01) 
increasing the phagocytosis of both MRSA and P. aeruginosa by U937-derived and 
HPBM-derived M1 macrophages. In contrast, stimulation with the ER-β agonist DPN 
failed to improve the phagocytosis of either MRSA or P. aeruginosa by 
macrophages. Of interest, blocking the ER-α with TPBM overturned the effect of 
PPT on the bacterial clearance. The results of this study are in concordance with 
published findings implicating ER-α as the key mediator of the inflammatory 
response, with activation of ER-α in M1 macrophages with PPT increasing bacterial 
clearance whereas activation of ER-β by DPN had no effect on the phagocytosis of 
MRSA and PAO1. Moreover, blockade of ER-α with TPBM reversed the effect of 
PPT. Collectively, these novel findings suggest that estrogen stimulates promotion 
of phagocytosis by human macrophages through ER-α rather than ER-β. 
Tamoxifen is estrogenic in the uterus, therefore, this molecule is frequently linked 
with a high risk of uterine cancer (Jordan and Morrow, 1999; Bergman et al., 2000). 
Another commonly used SERM, called raloxifene, is in contrast estrogenic in bone 
(Heaney and Draper, 1997) and ovaries (Neven et al., 2002), but displays anti-
estrogenic effects in the uterus (Bryant et al., 1996). Hardman and Ashcroft (2008) 
indicated that estrogen, tamoxifen and raloxifen all accelerated wound healing in 
ovariectomised mice. Future research could investigate a range of SERMs including 
raloxifen to determine the most effective mediator(s) of bacterial clearance in 
macrophages. This might potentially help detecting the most promising topical 
SERM to treat wound infections in the elderly. 
141 
In summary, novel findings reported in this chapter provide clear evidence that ER-
α is the ER isoform through which estrogen stimulates phagocytosis by U937- and 
HPBM-derived M1 macrophages. Selective targeting of ER-α with agents such as 
PPT may potentially lead to the development of therapeutic approaches to combat 
wound infections in the elderly. 
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6.1 Introduction 
Macrophages are immune cells characterised by the ability to engulf and digest 
bacteria, damaged cells and any foreign substance that does not express on its 
surface normal host-cell specific proteins via a process known as phagocytosis 
(Duque and Descoteaux, 2015). Phagocytosis is a vital process for protecting the 
host against foreign dangers such as bacterial invasion (Desjardins et al., 2005). This 
process needs to be performed efficiently because unsuccessful or imperfect 
clearance of bacteria can have detrimental circumstances on the host, and is linked 
with the progression of several pathological conditions such as chronic 
inflammation, wound infections and several autoimmune diseases (Engelich et al., 
2001). Attracted to sites of infection via chemotaxis, phagocytes such as 
macrophages recognize and attach to microorganisms. This results in actin 
polymerisation within the phagocyte, re-arrangement of the actin cytoskeleton to 
form pseudopodia followed by engulfment of the microorganism to form a 
phagosome and subsequent phagolysosome formation on fusion with a lysosome 
(Freeman and Grinstein, 2016; Garcia-Gomez et al., 2016). Finally, the destruction 
of bacteria is mediated by lysosomal enzymes and ROS within the phagolysosome 
(Pauwels et al., 2017). Successful engulfment of pathogens requires continuous 
reorganization of the phagocyte cell membrane that involves dynamic 
rearrangement of the actin cytoskeleton. The control of these mechanical changes 
on the cell membrane during cell movement and pathogen engulfment involves 
Rho GTPase proteins that regulate the polymerisation of actin filaments (Etienne-
Manneville and Hall, 2002; Groves et al., 2008). 
In this study it has been shown that estrogen enhances the phagocytosis of both 
MRSA and P. aeruginosa by human macrophages. The interaction between 
macrophages and bacteria were visualised by SEM (Figure 3.16), demonstrating 
estrogen promotes the formation of pseudopodia by macrophages during the 
uptake of both MRSA and P. aeruginosa. These findings suggest estrogen may be 
regulating the levels or activation of one or more proteins involved in the regulation 
of the actin cytoskeleton during phagocytosis. 
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6.1.1 The Actin Cytoskeleton and Phagocytosis: 
The process of engulfing a foreign particles, phagocytosis, is a crucial process for 
the wide diversity of organisms. From simple unicellular organisms that use 
phagocytosis for nutrition, to complex ones in which phagocytic cells play a 
fundamental role in the immune response. Phagocytosis is a step-wise process in 
which particles are first recognized and bind to the cell surface, followed by 
internalisation and formation of membrane‐bound vacuoles known as phagosomes 
(Jilkine, 2009). After a target particle is recognised the phagocytic process requires 
a dynamic assemblage of the actin cytoskeleton to promote the formation of 
pseudopodia (Alberts et al., 2008; Freeman and Grinstein, 2016; Garcia-Gomez et 
al., 2016; Pollard et al., 2016; Pauwels et al., 2017). 
The actin cytoskeleton is constructed by a wide range of proteins (Insall and 
Machesky, 2009). Actin is an abundant protein found in all cells and it exists in two 
different forms; globular monomers named G-actin, and polymeric chains of the 
two G-actin subunits, F-actin and filamentous actin (Holmes et al., 1990). The F-
actin filaments are structurally polarised (Wegner, 1976). The negative (known as 
“pointed”) end holds a subunit with an open ATP binding site, whereas the positive 
(known as “barbed”) end is open to adjacent G-actin monomers (Wegner, 1976). 
The polymerisation/depolymerisation of actin is a continuous constant process 
(Wegner, 1976) during which, the energy generated from ATP conversion to ADP 
stimulates the accumulation of G-actin monomers at the barbed end before 
polymerisation to F-actin filaments (Wegner, 1976; Alberts et al., 2008) (Figure 6.1). 
After the complete establishment of F-actin filaments, actin-binding proteins add an 
extra layer of control over the actin cytoskeleton network. For instance, actin 
severing proteins, such as profilin and cofilin, can bind the actin polymers and alter 
the filaments length and strength (T. D. Pollard and Borisy, 2003), and 
increase/decrease the amount of barbed ends by cleaving actin filaments 
(Devreotes and Horwitz, 2015). 
Capping proteins can also bind to the termination of the filaments regulating their 
attachment and detachment (Isenberg et al., 1980). Additionally, F-actin filaments 
145 
bind to integrin and myosin II filaments producing focal adhesive complexes, which 
allow cells to slide past each other and connect with the extracellular matrix and 
other adjacent cells via the cytoskeleton network, therefore allowing cell-cell and 
cell-matrix exchange (Burridge et al., 1988; Peskin et al., 1993; Pollard and Borisy., 
2003; Alberts et al., 2008). 
 
Figure 6.1. Actin cycle. F-actin filaments are separated due to Cofilin binding at the pointed 
end. Profilin binds to F-actin filaments at the barbed end before capping proteins are 
attached, allowing the attachment and detachment of filaments. Figure drawn based on 
details of the actin cycle described by Brown (2016). 
6.1.2 Regulation of the Cytoskeleton Organisation by Rho GTPases 
Estrogen was shown to promote the phagocytosis of the two major wound 
pathogens MRSA and P. aeruginosa (Chapters 3, 4 and 5). However, the link 
between estrogen and regulators of the actin cytoskeleton such as Rho GTPases 
during phagocytosis has not been investigated to date. 
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The organised movement of membranes and actin cytoskeleton are coordinated in 
phagocytosis by a family of proteins known as Rho GTPase (Etienne-Manneville and 
Hall, 2002). The small GTPases of the Rho-family (Rho-GTPases) are members of the 
Ras superfamily of small GTPases. The Rho-GTPase family includes 20 members 
distributed into 8 subfamilies (Figure 6.2) (Etienne-Manneville and Hall, 2002). 
While RhoA, Cdc42 and Rac1 are the most highly conserved and well-studied 
members in eukaryotic species, the 17 other members of the Rho GTPase family are 
less studied and their functions and effects have not been fully investigated and 
understood yet (Etienne-Manneville and Hall, 2002). Rac1, Cdc42 and RhoA are best 
known for their functions in regulating the actin cytoskeleton (Nobes and Hall, 
1995; Machesky and Hall, 1996; A. Hall, 1998; Machesky and Insall, 1999; Etienne-
Manneville and Hall, 2002). Working on 2D tissue-culture fibroblast models, (Ridley 
and Hall, 1992; Nobes and Hall, 1995) it has been reported that RhoA was mainly 
involved in rearranging actin and myosin filaments to form new stress fibres, 
however, Cdc42 and Rac1 induced actin polymerisation causing the formation of 
lamellipodia and filopodia. RhoA, Cdc42 and Rac1 have all emerged as master 
regulators of cell polarity and contractility, progression of the G1 cell cycle, gene 
transcription and microtubule dynamics (Etienne-Manneville and Hall, 2002). In 
addition to regulating the actin cytoskeleton dynamics, Rho GTPases have been 
linked with many biological functions such as cytoskeletal regulation, phagocytosis, 
cell polarity establishment, cell proliferation and motility, reactive oxygen species 
(ROS) production, and tumorigenesis (Etienne-Manneville and Hall, 2002; Jaffe and 
Hall, 2005). 
Proteins of the Rho GTPase family are key regulators of the polymerisation of actin 
filaments resulting in cytoskeleton reorganisation (Etienne-Manneville and Hall, 
2002). These proteins are parts of the GTP-binding proteins (G-proteins) family, 
which are conserved in eukaryotic organisms from yeast and amoeba to mammals 
(Etienne-Manneville and Hall, 2002). G-proteins contain a GTP-binding domain and 
function as molecular switches (Raftopoulou and Hall, 2004). In order to become 
active, the protein must bind to GTP causing its hydrolysation (Raftopoulou and 
Hall, 2004). The process of GTP hydrolysation is the origin of the name GTPase. As a 
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consequence of GTP hydrolysation to GDP, the protein changes structurally and 
converts into an inactive form (Raftopoulou and Hall, 2004). The Rho GTPase 
proteins receive signals from cell surface receptors, and interact indirectly with 
actin, via binding to effector molecules, which causes rearrangement of the 
cytoskeleton and enable phagocytosis (Raftopoulou and Hall, 2004). 
 
Figure 6.2. Phylogenetic tree representation of the Rho GTPases family. Rho GTPases 
family comprises 20 proteins divided into eight major groups according to sequence and 
phylogenetic similarities:  Rho, Rac, Cdc42, RhoD/F, Rnd, RhoU/V, RhoH and RhoBTB. Figure 
based on published details of Rho GTPases (Aspenström et al., 2007; Heasman and Ridley, 
2008). 
  Cdc42 
Cdc42 is an important Rho GTPase protein that controls signalling pathways 
regulating many cell functions essentially phagocytosis, cell cycle development and 
cell migration (Ridley et al., 1992; Kozma et al., 1995; Qadir et al., 2015). Cdc42 is a 
key regulator of the cytoskeleton dynamics, which is essential for the phagocytosis 
process (Ridley et al., 1992; Kozma et al., 1995). In order to elucidate the functions 
of Cdc42 in humans, researchers studied the dominant negative (DN) and the 
constitutively active (CA) forms of Cdc42 (Van Aelst and D’Souza-Schorey, 1997), 
and demonstrated that cdc42 is potentially required in the initiation of cell signals 
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crucial for the regulation of actin cytoskeleton (Van Aelst and D’Souza-Schorey, 
1997; Johnson, 1999). The Cdc42-related proteins stimulate the formation of 
filopodia, through binding to and activation of an effector protein known as 
“Wiskott Aldrish Syndrome Protein (WASP)” via Cdc42- and Rac-interacting and 
binding domain (CRID) (Johnson, 1999; Rohatgi et al., 1999; Carlier et al., 2003). 
This leads to the recruitment of G-actin and a specific actin protein called the 
“Arp2/3 complex”, which bind to the existing actin filaments resulting in a new 
filament (Rohatgi et al., 1999; Carlier et al., 2003). 
Similar to WASP, other proteins such as the tyrosine p21-activated kinases (PAK1 
and PAK2) and focal adhesive kinase (FAK), attach to Cdc42 via the CRIB domain and 
initiate the cytoskeleton reorganisation leading to membrane deformation, 
essential for phagocytosis (Hofmann et al., 2004). 
Cdc42 treadmills continuously and reversibly from an active GTP-bound form to an 
inactive GDP-bound form. This balance is initiated and controlled by guanine 
nucleotide exchange factors (GEFs) which encourage the conversion of GDP-bound 
molecules to unbound GTP (Van Aelst and D’Souza-Schorey, 1997). GTPase 
activating proteins (GAPs) promote GTP hydrolysis to GDP (Lamarche and Hall, 
1994), whereas guanine nucleotide dissociation inhibitors (GDIs) block the 
detachment of the nucleotide from Cdc42 and result in deactivation of the protein 
(Olofsson, 1999; Valdés-Mora et al., 2009). 
  Rac1 
The GTPase Rac1 is one of the most documented and well-studied members of the 
Rho family (Bishop and HALL, 2000; Etienne-Manneville and Hall, 2002). Rac1 is a 
member of the Rac subfamily that comprises RhoG, Rac1b, Rac2, and Rac3 
(Aspenström et al., 2007; Heasman and Ridley, 2008). The Rac proteins all share 
more than 80% sequence homology and differ principally in the C-terminal region 
(Wennerberg, 2004). Rac1 is known for being a master regulator of the actin 
cytoskeleton organisation. Rac1 participates in the initial step of pseudopodia 
formation (Etienne-Manneville and Hall, 2002) during phagocytsosis, but is also 
involved in many other cell functions including cell killing mediation via ROS, cell 
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differentiation, cell adhesion, apoptosis, signalling transcription factors and gene 
expression (Jaffe and Hall, 2005). The activity of Rac1 has been extensively studied 
in recent years, with findings showing active Rac1 induces the formation of 
membrane extensions called lamellipodium (Ridley et al., 1992). In addition, RAC1 is 
essential in moderating several signalling pathways linked with cell growth and cell 
division (Bid et al., 2013). Similar to Cdc42, the activities of Rac1 are mediated via 
interaction with specific effectors such as the protein kinase PAK that changes from 
an inactive to active state after interacting directly with GTP-Rac1 (Bid et al., 2013). 
 RhoG 
RhoG is a member of the Rac subgroup of the Rho GTPase family that was reported 
for the first time in 1992 (Vincent et al., 1992). It shares 72% sequence identity with 
Rac1 but is characterised by its incapability to bind to proteins such as PAKs (Leung 
et al., 1996; Gauthier-Rouviere et al., 1998). Similar to most Rho GTPase proteins, 
RhoG is involved in a various cell signalling mechanisms including the regulation of 
actin cytoskeleton (Katoh et al., 2006), phagocytosis (Prieto-Sánchez et al., 2006), 
gene transcription (Vigorito et al., 2003) and the regulation of NADPH oxidase in 
neutrophils (Condliffe et al., 2006). 
Both Rac1 and RhoG are able to signal downstream effectors after binding to GTP 
and become inactive when bound to GDP. Three protein families interact with Rac1 
or RhoG to control the GTP/GDP balance: 1) GEFs are involved in facilitating the 
conversation of GDP for GTP, leading to the promotion of RhoA/RhoG-mediated 
signalling (Van Aelst and D’Souza-Schorey, 1997); 2) GAPs promote hydrolysis of 
GTP to GDP, thereby ending RhoA/RhoG-mediated signalling (Lamarche and Hall, 
1994); 3) GDIs inhibit the GDP dissociation and lock the G protein in its inactive 
state (Olofsson, 1999). 
It has been reported that the activation of RhoG  provokes Rac1- and Cdc42-like 
activities such as lamellipodia and filopodia formation (Gauthier-Rouviere et al., 
1998). Activated Rac1 and/or RhoG are believed to be coupled with numerous 
downstream effectors, leading to the control of several signalling pathways. The 
mechanism by which RhoG signals is not fully understood. However, a detailed 
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signalling pathway of RhoG leading to activation of Rac proteins, via GEFs, has been 
described. This mechanism of RhoG-dependent Rac signalling was reported to 
encourage the phagocytosis of apoptotic cells in C. elegans (Katoh and Negishi, 
2003; Nakaya et al., 2006). 
  RhoA 
RhoA is a small protein member of the Rho GTPase family. Like the other GTPases, 
RhoA acts as a molecular switch to regulate signalling pathways that mediate the 
actin cytoskeleton dynamics and organisation (Hall, 1998). RhoA was initially 
reported to be a key player in the regulation of the cytoskeletal dynamics, and the 
formation of actin stress fibres in fibroblasts stimulated with growth factors (Ridley 
and Hall, 1992). It was later shown by Hackam and Grinstein in 1997 that RhoA is an 
essential requirement in phagocytosis. Olson et al. (1995) also demonstrated that 
RhoA regulates the growth of cells and triggers cell cycle progression via the phase 
G1. 
The majority of downstream targets of RhoA are serine-threonine kinases, including 
ROCK1 which binds to RhoA in a GTP-dependant manner (Leung et al., 1995). RhoA 
was also demonstrated to form actin stress fibres and focal adhesion complexes via 
binding to the ROCK kinase, an isoform of Rho kinase. Another Rho kinase known as 
Rho kinase-alpha or ROK was also shown to bind to RhoA in a GTP-dependent 
manner, leading to the assembly of actin filaments and the cytoskeleton 
organisation (Leung et al., 1996). 
The interaction between estrogen and Rac1 in cardiovascular disease has been 
documented, with estrogen downregulating the expression and activity of Rac1 in 
monocytes and vascular smooth muscle cells and resulting in a decrease in the 
production of ROS in the cardiovascular system (Laufs et al., 2003). Estrogen 
enhances the phagocytic activity of rat peritoneal macrophages (Csaba, 2017) but 
inhibits monocyte recruitment and adhesion in the cardiovascular system (Friedrich 
et al., 2006) 
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6.1.3 Focal Adhesion Kinase (FAK) 
The focal adhesion kinase (FAK) was first discovered in the early 1990s (Kanner et 
al., 1990; Schaller et al., 1992) as a new tyrosine kinase that does not possess a 
receptor but is expressed in several tissues (Hanks et al., 1992). FAK  is highly 
conserved among different species with human FAK sharing high percentage 
homology with mice (97%) and zebrafish (90%) (Schaller, 2010). It has been 
reported that FAK plays a key role in integrin signalling which regulates 
phagocytosis, cell adhesion and cell survival (Schlaepfer et al., 2004). The gene 
protein tyrosine kinase 2 (PTK2) encodes for FAK (André and Beckerandre, 1993). It 
has been demonstrated that blockage of FAK in breast cancer cells reduce their 
metastatic ability by decreasing cell mobility (Chan et al., 2009). 
FAK is expressed in all cell types except some blood cells, and is naturally localised 
in structures called focal adhesions. Focal adhesions are sites where the 
cytoplasmic cytoskeleton interact with the ECM (Chrzanowska-Wodnicka and 
Burridge, 1996). When FAK tyrosine kinase is activated, intracellular signalling 
pathways involved in cell migration are initiated (Hanks et al., 1992; Schaller et al., 
1992). Estrogen is a known regulator of cytoskeletal constituents (Sapino et al., 
1986), mainly actin fibres via the control of actin dynamism and organisation 
(Giretti et al., 2008; Flamini et al., 2009). Estrogen also regulates cell morphology 
and cell interaction with the ECM, a key process in phagocytosis (Giretti et al., 2008; 
Flamini et al., 2009; Flamini et al., 2011). Flamini et al. (2011) investigated the effect 
of estrogen on the remodelling of actin cytoskeleton in the Ishikawa endometrial 
adenocarcinoma cell line and endometrial stromal cells (ESC). This study showed 
remodelling estrogen promotes FAK phosphorylation in Ishikawa and ESC cells in a 
dose-dependent manner, resulting in an enhancement of actin and membrane 
remodelling, and phagocytosis. 
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6.2 Aim and Objectives 
6.2.1 Aim 
To investigate the effect of estrogen on regulating protein levels of Rac1, RhoA, 
Cdc42, RhoG and FAK in U937-derived M1 macrophages. 
6.2.2 Objectives 
To compare protein levels of Rac1, RhoA, Cdc42, RhoG and FAK in U937-derived M1 
macrophages treated with/without supraphysiological levels of estrogen for 24 
hours against BSA-treated negative control. 
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6.3 Methods 
6.3.1 Generation of U937-derived M1 Macrophages 
U937 monocytes were differentiated into M0 macrophages and polarised into M1-
like macrophages using methods described in Section 2.2.5. 
6.3.2 Immunoblotting  
U937-derived M1 macrophages were treated with 1 x 10-7 M BSA, zero M estrogen 
(17β-estradiol) or 1 x 10-7 M estrogen for 24 hours. Macrophages were retrieved 
and lysed prior to extracting and quantifying proteins following methods described 
in Section 2.2.13.1. Immunoblotting assays were conducted as described in Section 
2.2.13.2 to quantify levels of Rac1, RhoA, Cdc42, RhoG and FAK with protein 
normalisation conducted against the housekeeping gene β-tubulin. 
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6.4 Results 
6.4.1 Estrogen Enhances Rac1 by U937-Derived M1 Macrophages 
The effect of estrogen on levels of the GTPase Rac1 by U937-derived M1 
macrophages was investigated (Figure 6.3). Estrogen had no significant effect 
(P>0.05) on levels of β-tubulin in U937-derived M1 macrophages compared to 
untreated macrophages (zero M estrogen) and the negative control (Figure 6.3.A 
and C). However, estrogen supplementation (Figure 6.3. B and C) significantly 
(P<0.01) increased relative Rac1 levels (1.9-fold change) compared to the negative 
control (NC). There was no significant difference (P>0.05) between Rac1 levels in 
the NC and untreated macrophages that lacked estrogen supplementation.  
 
Figure 6.3. Rac1 levels in U937-derived M1 macrophages increase following exposure to 
supraphysiological estrogen. Rac1 levels were assessed by immunoblotting with β-tubulin 
used as loading control. Estrogen (E) had no effect on the β-tubulin levels in macrophages 
(P>0.05) (A and C), but significantly (P<0.01) increased Rac1 levels compared to the 
negative control (NC) and untreated (E 0M) macrophages (B and C). Results represent an 
average of n = 12 experimental repeats. ** Indicates significant difference in protein levels 
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(fold-change) compared to the NC (P<0.01). Error bars represent the standard error of the 
mean (StEM). 
6.4.2 Estrogen Decreases RhoA in U937-Derived M1 Macrophages 
Estrogen had no significant (P>0.05) effect on the housekeeping protein β-tubulin 
(Figure 6.4.A and C) but significantly (P<0.01) reduced relative levels of RhoA (0.7-
fold change) in U937-derived M1 macrophages compared to the negative control 
(NC). There was no significant (P>0.05) difference in RhoA levels between the NC 
and untreated macrophages lacking estrogen supplementation (Figure 6.4.B and C).   
 
Figure 6.4. RhoA levels in U937-derived M1 macrophages reduce following treatment 
with supraphysiological estrogen. RhoA levels were measured by immunoblotting using β-
tubulin as the housekeeping protein. Estrogen (E) had no significant (P>0.05) effect on 
levels of β-tubulin (A and C) but significantly (P<0.01) decreased RhoA levels compared to 
the negative control (NC) and untreated (E 0M) macrophages (B and C). Results represent 
an average of n = 12 experimental repeats. ** Indicates significant difference (P<0.01) in 
protein levels (fold-change) compared to the NC. Error bars represent the standard error of 
the mean (StEM). 
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6.4.3 Estrogen Increases Levels of Cdc42 in U937-Derived M1 Macrophages 
Estrogen had no significant (P>0.05) effect on levels of the housekeeping protein β-
tubulin (Figure 6.5.A and B). In comparison to the negative control (NC), the 
absence of estrogen in untreated macrophages had no significant (P>0.05) effect on 
Cdc42 levels (1.0-fold change). However, estrogen induced a significant (P< 0.01) 
increase in levels of Cdc42 (2.3-fold change) compared to the NC (Figure 6.5.B and 
C). 
 
Figure 6.5. Cdc42 levels in U937-derived M1 macrophages increase following  exposure to 
supraphysiological estrogen. Cdc42 levels were assessed by immunoblotting with β-tubulin 
used as loading control. Estrogen (E) had no effect on the β-tubulin levels in macrophages 
(P>0.05) (A and C), but significantly (P<0.01) increased Cdc42 levels compared to the 
negative control (NC) and untreated (E 0M) macrophages (B and C).  Results represent an 
average of n = 12 experimental repeats. ** Indicates significant difference in protein levels 
(fold-change) compared to the NC (P<0.01). Error bars represent the standard error of the 
mean (StEM). 
6.4.4 Estrogen Increases Levels of RhoG in U937-Derived M1 Macrophages 
The effect of estrogen on levels of RhoG in U937-derived M1 macrophages was 
investigated (Figure 6.6). Estrogen had no significant effect on levels of β-tubulin in 
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U937-derived M1 macrophages, compared to negative control (NC) and untreated 
macrophages (E 0M) (Figure 6.6.A and C). Compared to the NC, the level of RhoG 
was not significantly (P>0.05) altered in untreated (E 0M) macrophages (1.1-fold 
change). However, estrogen significantly (P< 0.01) increased relative levels of RhoG 
(2.3-fold change) in comparison to the NC (Figure 6.6.B and C). 
 
Figure 6.6. RhoG levels in U937-derived M1 macrophages increase following treatment 
with supraphysiological estrogen. RhoG levels were assessed by immunoblotting with β-
tubulin used as loading control. Estrogen (E) had no effect on the β-tubulin levels in 
macrophages (P>0.05) (A and C), but significantly (P<0.01) increased RhoG levels compared 
to the negative control (NC) and untreated (E 0M) macrophages (B and C).  Results 
represent an average of n = 12 experimental repeats. ** Indicates significant difference in 
protein levels (fold-change) compared to the NC (P<0.01). Error bars represent the 
standard error of the mean (StEM). 
6.4.5 Estrogen Increases Levels of Focal Adhesion Kinase (FAK) in U937-Derived 
M1 Macrophages 
Levels of the housekeeping protein β-tubulin did not significantly change (P>0.05) 
following treatment of U937-derived M1 macrophages with supraphysiological 
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estrogen (Figure 6.7.A and C). Levels of FAK in untreated macrophages (1.0-fold 
change) were not significantly (P>0.05) different to levels found in the negative 
control (NC). Intriguingly, relative levels of FAK significantly increased (P<0.01) 
following treatment with estrogen (2.3-fold change) compared to the NC (Figure 
6.6.B and C). 
 
Figure 6.7. FAK levels in U937-derived M1 macrophages increase following treatment 
with supraphysiological estrogen. FAK levels were assessed by immunoblotting with β-
tubulin used as loading control. Estrogen (E) had no effect on the β-tubulin levels in 
macrophages (P>0.05) (A and C), but significantly (P<0.01) increased FAK levels compared 
to the negative control (NC) and untreated (E 0M) macrophages (B and C).  Results 
represent an average of n = 12 experimental repeats. ** Indicates significant difference in 
protein levels (fold-change) compared to the NC (P<0.01). Error bars represent the 
standard error of the mean (StEM). 
 
 
 
159 
6.5 Discussion 
Estrogen promotes the phagocytosis of both MRSA and P. aeruginosa by human 
macrophages through specific binding to ER-α. (Chapter 5). Moreover, data from 
the SEM (Chapter 3) demonstrated major changes in the morphology of phagocytic 
macrophages following estrogen supplementation, with the formation of 
pseudopodia suggesting estrogen induces substantial changes in the actin 
cytoskeleton. In order to determine whether Estrogen stimulates the phagocytic 
activity of macrophages through changes in the actin cytoskeleton, this study 
measured the protein levels of four major Rho GTPase proteins (Cdc42, Rac1, RhoG 
and RhoA) and the focal adhesion kinase (FAK) in U937-derived M1 macrophages in 
the presence/absence of estrogen for 24 hours. 
Estrogen significantly increased  the level of FAK in M1 macrophages. FAK has been  
shown to be an important regulator of phagocytosis (Tzircotis et al., 2011). Tzircotis 
et al. (2011) transfected macrophages with RNAi against FAK and found that 
macrophages lacking FAK presented a 65% decrease in the number of phagocytes 
produced with FcγR- and CR3-mediated phagocytosis. Activation of FAK was also 
associated with provoking Rac1- and Cdc42-like activities, such as lamellipodia and 
filopodia formation (Gauthier-Rouviere et al., 1998), but not RhoA activities 
(Tzircotis et al., 2011). It has been reported that fibroblasts lacking FAK have 
impaired cell motility. Importantly, FAK is an important regulator of the pathogen-
killing functions of neutrophils (Kasorn et al., 2009). FAK signalling is linked with the 
organisation of integrin-based adhesion sites and the formation of lamellipodia in 
migrating cells, such as neutrophils and macrophages (Kasorn et al., 2009). 
Moreover, FAK deficiency in macrophages reduces cell adhesion, and is associated 
with failure to form lamellipodia and cell migration to sites of infection and 
inflammation in vivo (Owen et al., 2007). 
Estrogen is a known regulator of cytoskeletal constituents, mainly actin fibres 
(Giretti et al., 2008; Flamini et al., 2009) via the control of actin dynamism and 
organisation. Estrogen also regulates cell morphology and interaction with the ECM, 
a key process in phagocytosis (Giretti et al., 2008; Flamini et al., 2009). Flamini et al. 
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(2011) investigated the effect of estrogen on the remodelling of actin cytoskeleton 
and on regulating cell mobility in an Ishikawa cell line and ESC. They showed 
estrogen encourages FAK phosphorylation in Ishikawa and ESC cells in a dose-
dependent manner, resulting in an enhancement of cell mobility, actin and 
membrane remodelling (Flamini et al., 2011). 
Importantly, estrogen has been shown to stimulate the production of membrane 
ruffles and pseudopodia in breast cancer cells via activation of ER-α in concordance 
with the findings (Chapter 3) of this study (Song et al., 2002). Simoncini et al. (2006) 
confirmed that estrogen encourages the migration of endothelial cells via 
phosphorylation and activation of FAK. Song and Santen (2006) indicated that 
estrogen enhances the formation of filopodia and lamellipodia with localisation of 
ER-α in the plasma membrane. Stimulation of cancer cells with estrogen induces 
cell migration and motility via interaction of FAK with ER-α and other factors 
including phosphatidylinositol 3 kinase and p60 Src tyrosine kinase (c-Src) (Li et al., 
2010). Given estrogen stimulated phagocytosis via ER- (Chapter 3) and increased 
levels of FAK further investigations in this area are now warranted to confirm a 
causal link between elevated FAK levels and enhanced phagocytosis in estrogen 
supplemented M1 macrophages. 
In this study, macrophage levels of Rac1 significantly increased following treatment 
with estrogen for 24 hours compared to the negative control or macrophages 
lacking estrogen supplementation. Rac1 is crucial for dynamic rearrangement of the 
actin cytoskeleton that is essential for membrane ruffling and the development of 
focal complexes that are needed for filopodia and lamellipodia formation (Ridley et 
al., 1992; Allen et al., 1997). Rac1 regulates the organisation of actin cytoskeleton 
and cell adhesion in murine macrophages in vitro (Allen et al., 1997). Upregulation 
of active Rac1 have been detected in phagocytic cups (Hoppe and Swanson, 2004) 
while its inhibition was found to reduce the phagocytosis of both C3bi- and IgG-
opsonised molecules (Cox et al., 1997). It is noteworthy that estrogen-like 
molecules such as daidzein have been shown to have an effect on the regulation of 
Rac1 during the phagocytic process. Daidzein, a soy isoflavone extract, was found to 
stimulate the production of estrogen in trophoblast cells (Richter et al., 2009). 
161 
Moreover, diadzein enhances the macrophage phagocytic capability via 
upregulation of the Rac1 activity (Yen et al., 2014). 
In another report, it has been shown that the estrogen metabolite (2-ME) blocks 
the RhoA/ROCK1 pathway in human smooth muscle cells through downregulation 
of RhoA (Rigassi et al., 2015). It has also been reported that the upregulation of 
RhoA inhibits the process of phagocytosis in macrophages (Tosello-Trampont et al., 
2003; Colucci-Guyon et al., 2005; Nakaya et al., 2006). Results in this study have 
demonstrated that treatment of macrophages with estrogen for 24 hours 
significantly decreased protein levels of RhoA compared to the negative (BSA) 
negative control and macrophages cultured in the absence of estrogen. Whether 
estrogen stimulates phagocytosis by dampening the RhoA/ROCK1 pathway 
warrants further investigation but accumulating evidence has indicated that 
upregulation of RhoA inhibits the process of phagocytosis in macrophages (Tosello-
Trampont et al., 2003; Colucci-Guyon et al., 2005; Nakaya et al., 2006). 
It is worth pointing out that many other reports support the findings of this study 
and show a harmonised balance of Rac1 and RhoA is essential for a successful 
phagocytosis. Research investigations on Candida elegans in mammals have 
reported that Rac1 and RhoA, are antagonistically implicated in the modulation of 
cytoskeleton reorganisation during the process of phagocytosis, as their signalling 
oppose each other (Ohta et al., 2006; Freeman and Grinstein, 2014). To date, their 
exact functions are not fully clear, but recent studies using mutants of Rac1 and 
RhoA specified that upregulation of Rac1 stimulates phagocytes to engulf apoptotic 
cells (Akakura et al., 2004; Nakaya et al., 2008) whereas  RhoA had an opposite 
effect (Kim et al., 2017). Kim et al. (2017) investigated the role of Rac1 and RhoA in 
the clearance of apoptotic cells and showed a dynamic balance between the two 
proteins was needed to regulate efferocytosis, with Rac1 upregulated and RhoA 
downregulated during pseudopodial formation. 
RhoG is associated with the regulation of actin cytoskeleton dynamics (Katoh et al., 
2006), phagocytosis (Prieto-Sánchez et al., 2006), gene transcription (Vigorito et al., 
2003) and the regulation of NADPH oxidase in neutrophils (Condliffe et al., 2006). 
Data in this chapter demonstrates for the first time that treatment of macrophages 
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with estrogen causes an increase in RhoG levels leading to enhanced phagocytosis 
of bacteria. This result supports the findings of Tzircotis et al. (2011) that 
demonstrated that RhoG stimulates phagocytosis of IgG-opsonised (for FcγR) or 
C3bi-opsonised (for CR3) sheep red blood cells (RBCs) in mouse macrophages. 
However, the findings in this chapter are the first to show that estrogen stimulates 
RhoG in human M1 macrophages. Therefore, elevation of RhoG levels could 
potentially be a novel and effective therapeutic approach for the treatment of 
wound. However, further investigations are needed to provide a confirmation of 
this hypothesis. 
In this study, levels of Cdc42 in M1 macrophages following treatment with estrogen 
significantly increased. Resveratrol, a plant-derived polyphenol found in grapes and 
associated products such as wine, has both anti-estrogenic effects in breast cancer 
and but is believed to be estrogenic in peripheral tissues such as bone (Bhat et al., 
2001; Tou, 2015). Azios et al. (2007) investigated the effect of resveratrol in 
estrogen-responsive breast cancer, and found that resveratrol decreased the 
activity of Cdc42 and Rac1 whereas a combination of resveratrol with estrogen 
resulted in a significant upregulation of both Cdc42 and Rac1 in breast cancer cells. 
Cdc42 is linked with the organisation of the actin cytoskeleton, membrane ruffling 
and formation of filopodia in fibroblasts and macrophages (Kozma et al., 1995; Cox 
et al., 1997). Research indicates Cdc42 is crucial for successful phagocytosis of 
Salmonella in COS-1 cells (L.-M. Chen et al., 1996; Cox et al., 1997). In addition, the 
injection of macrophages with activated Cdc42 results in the formation of long and 
indistinct filopodia in vitro (Allen et al., 1997). Cdc42 is an essential requirement for 
Fc receptor-mediated phagocytosis and for the formation of membrane ruffling 
mediated by diverse receptors in macrophages (Allen et al., 1997). 
In summary, estrogen increased levels of Rac1, Cdc42, RhoG and FAK, but reduced 
levels of RhoA in U937-derived M1 macrophages. Further interrogation of pathways 
involved in the actin cytoskeleton could potentially reveal other mediators of 
estrogen-induced phagocytosis. Whilst results presented in this chapter provided 
exciting and novel links between estrogen and proteins of the cytoskeleton during 
the process of phagocytosis, further investigations are warranted to determine the 
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effect of estrogen on relative amounts of proteins in their activated 
(phosphorylated) state during the process of phagocytosis. Western blotting, kinase 
activity assays (to measure FAK activation), and intracellular flow cytometry would 
be very robust methods of measuring activated protein levels. Inhibitors of 
phagocytosis pathways could also be exploited to further understand the 
mechanisms by which estrogen induces phagocytosis. In addition, further work is 
required to determine whether the changes in protein levels are mirrored by 
concomitant alterations in gene expression. In order to determine the effect of ER-α 
activation on downstream gene expression in macrophages, RNA sequencing 
(RNAseq) and real time polymerase chain reaction (qPCR) analysis could be 
adopted. Understanding the precise mechanisms by which estrogen promotes 
phagocytosis might reveal key downstream targets to interrogate further and may 
ultimately lead to the development of novel therapies to treat wound infections in 
the elderly with high efficacy and minimal side effects. 
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7.1 Discussion 
Chronic wounds are difficult to treat and often become colonised with bacteria 
leading to substantial mortality and morbidity in the elderly. Impaired wounds can 
become colonised with a varied range of pathogens including S. aureus and P. 
aeruginosa (Gjødsbøl et al., 2006; Kirketerp-Møller et al., 2008; Rybtke et al., 2015). 
Treatment of bacterial infections in wounds requires aggressive medication, and 
the use of last-generation antibiotics (Beasley and Hirst, 2004). Thus, the treatment 
of wound infections in the elderly represents a big challenge for the healthcare 
services (Beasley and Hirst, 2004). The propensity for wound infections increases in 
the elderly, in part due to the delay in wound repair (Cooper et al., 2015). Estrogen 
is a key regulator of the wound healing process and estrogen deprivation in the 
elderly is linked with pathological wound healing (Ashcroft et al., 1999a; Margolis et 
al., 2002). Indeed, impaired healing in the elderly is mediated by changes in steroid 
hormones, particularly declining levels of estrogen with increasing age (Ashcroft et 
al., 1999a; Ashcroft et al., 2003; M. J. Hardman and G. S. Ashcroft, 2008). Estrogen 
deficiency causes a significant delay in wound repair, with topical and systemic 
estrogen replacement reversing this delay (Ashcroft et al., 1997a; Ashcroft et al., 
1999a). Furthermore, estrogen supplementation promotes age-related wound 
healing in both elderly males and females (Ashcroft et al., 1999a; Guo and DiPietro, 
2010). Delayed wound healing in the elderly is associated with a delayed, but 
prolonged and excessive inflammatory response, with dysregulated expression of 
pro-inflammatory cytokines and proteolytic mediators. The key role of estrogen in 
regulating inflammation has been extensively reviewed (Gilliver et al., 2007; Guo 
and DiPietro, 2010), with estrogen supplementation decreasing the inflammatory 
response in elderly subjects of both genders (Ashcroft et al., 1999a). However, 
despite the pronounced inflammatory response, evidence suggests declining levels 
of estrogen with increasing age can result in an impaired ability of inflammatory 
cells to eliminate bacteria from infected wounds (Emori et al., 1991; Thomas, 2001). 
The possible role estrogen plays in macrophage-mediated bacterial clearance has 
not been fully characterised to date. In order to elucidate the effect of age-related 
changes in estrogen levels on the clearance of bacteria by human macrophages, 
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this study conducted host-pathogen interaction assays to investigate the 
phagocytosis  of two major wound pathogens, MRSA and P. aeruginosa by in vitro 
U937-derived macrophages and ex vivo human peripheral blood monocyte (HPBM)-
derived macrophages. Investigations were performed under conditions that model 
estrogen levels found in the elderly (estrogen deprivation), young adults (referred 
to as physiological estrogen in this thesis) and following exogenous estrogen 
supplementation. 
The conversion of monocytes into macrophage-like cells in vitro was an essential 
requirement to conduct all the host-pathogen assays in this study. PMA is reported 
to induce the differentiation of monocytes into macrophages in vitro (Martinez et 
al., 2006; Rios de la Rosa et al., 2017) via upregulation of cell adhesion molecules 
such as beta‐2integrins (CD11a, CD11c, CD18 and CD11b) (Luscinskas et al., 1994), 
enabling cells to adhere to cell culture flasks in vitro. The differentiation of 
monocytes into macrophages was assessed in this study via the detection of the 
CD11c surface marker by flow cytometry. The high expression of CD11c in PMA-
differentiated macrophages, compared with monocytes incubated in the absence of 
PMA, confirmed the successful transformation of U937 monocytes and HPBMs into 
macrophage-like cells in vitro. 
Macrophage stimulation with supraphysiological levels of estrogen increases the 
phagocytic function of human brain macrophages (microglial cells) to take up 
amyloid β‐peptide and E. coli (Li et al., 2000). Evidence has indicated that estrogen 
increases bacterial clearance in an in vitro LPS model of K. pneumoniae infection in 
acute wounds Crompton et al. (2016). In concordance with these reports, novel 
findings presented in this thesis (Chapter 3) have demonstrated that physiological 
(typical of youth) and supraphysiological levels of estrogen promote the engulfment 
of both Gram-positive and Gram-negative live bacteria by both human U937-
derived macrophages and HPBM-derived macrophages. Further, in vitro host-
pathogen assays involving the uptake of fluorescent bacteria (GFP-S. aureus) by 
U937-derived macrophages validated these findings, with significantly increased 
intracellular fluorescence following treatment of phagocytes with estrogen.  Due to 
the poor ability of the antibiotic gentamicin to permeate the macrophage 
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membrane, a gentamicin protection assay was performed to determine the number 
of viable bacteria inside the phagocytes following the killing of extracellular bacteria 
using gentamicin (Hamad et al., 2010; Rios de la Rosa et al., 2017). Novel findings 
from this assay indicated that physiological (typical of youth) and supraphysiological 
levels of estrogen promote not just the internalisation, but also the killing, of both 
MRSA and P. aeruginosa in a dose-dependent manner. Further evidence captured 
by fluorescent microscopy (epifluorescent and confocal microscopes) indicated a 
higher uptake of both GFP-S. aureus and mCherry-P. aeruginosa by estrogen-
treated macrophages in comparison to estrogen-deprived macrophages, with Z-
stack analysis confirming co-localisation of the bacteria within macrophages. 
Images captured by SEM provided additional evidence of enhanced host-pathogen 
interactions following treatment of macrophages with estrogen, with macrophages 
showing pathogen-specific morphological changes in response to MRSA and P. 
aeruginosa. Macrophages generated longer membrane extensions (pseudopodia) in 
response to P. aeruginosa compared to MRSA. This pathogen-specific difference is 
intriguing since the clearance of MRSA was consistently higher than the uptake of P. 
aeruginosa (P<0.05) regardless of the experimentals conditions. The lower bacterial 
uptake and longer pseudopodia produced by macrophages following interaction 
with  P. aeruginosa, may be due to P. aeruginosa’s being a motile bacterium 
(O'Toole and Kolter, 1998) and therefore phagocytes may have reduced success 
when stretching out further to capture a moving target due to increased demands 
on cytoskeleton reorganisation. 
Known for its anti-inflammatory proprieties, estrogen reduces excessive and 
prolonged inflammation by directly affecting the inflammatory response of 
monocytes, macrophages and neutrophils (Ashcroft et al., 2003; Guo and DiPietro, 
2010). Estrogen dampens the inflammatory response via inhibition of pro-
inflammatory cytokines production by tissue macrophages (Ashcroft and 
Ashworth., 2003). However, estrogen also stimulates tissue regeneration and 
remodelling following the resolution of inflammation (Ashcroft et al., 1999b; 
Ashcroft and Ashworth, 2003; Ashcroft et al., 2003). Collectively, these reports 
suggest that estrogen modulates both pro-inflammatory (M1) and pro-regenerative 
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(M2) macrophages during wound repair. The effect of estrogen on the phagocytosis 
of MRSA and P. aeruginosa by U937-derived and HPBM-derived M1/M2 
macrophages was investigated in Chapter 4. High expression of CD197 confirmed 
the polarisation of U937-derived and HPBM-derived M0 macrophages into M1-like 
macrophages by IFN-γ/LPS, whilst high CD206 expression confirmed polarisation 
into M2-like macrophages by IL-4/IL-13 (Stossi et al., 2012; Rios de la Rosa et al., 
2017). Consistent with the data in Chapter 3, physiological (typical of youth) and 
supraphysiological levels of estrogen were found to promote the phagocytosis of 
MRSA and P. aeruginosa in a dose-dependent manner by both M1 and M2 
macrophages compared to estrogen deprivation and the absolute absence of 
estrogen. However, the phagocytosis of bacteria by M1 macrophages was 
significantly (P<0.05) higher than that with M2 or M0 macrophages, regardless of 
whether the macrophages were derived from U937s or HPBMs. This data 
demonstrated the enhanced phagocytosis of bacteria by M1 macrophages which is 
in agreement with published findings  (Mantovani et al., 2004; Benoit et al., 2008; 
Murray and Wynn, 2011; Krzyszczyk et al., 2018).  
Further work assessing potential mechanisms of estrogen-enhanced phagocytosis 
was subsequently conducted using pro-inflammatory M1-like macrophages instead 
of M0-like or M2-like macrophages. In order to elucidate the importance of the ERs 
in mediating the estrogen-enhanced phagocytosis of bacteria by human M1 
macrophages, host-pathogen interaction assays were conducted using the SERM 
tamoxifen and the SERD fulvestrant. Tamoxifen and fulvestrant are mainly used to 
treat breast cancer (Cole et al., 1971; Cummings et al., 1999) owing to their 
antiestrogenic effects in breast tissue (Love et al., 1992; Black et al., 1994). 
Tamoxifen acts as an ER antagonist in the breast, but is agonist in peripheral tissues 
such as the bone and the uterus (Love et al., 1992; Black et al., 1994). Interestingly, 
stimulation of macrophages with tamoxifen mirrored the effects of estrogen by 
significantly (P<0.01) increasing the phagocytosis of both MRSA and P. aeruginosa 
by U937-derived and HPBM-derived M1 macrophages. These results are supported 
by the findings of Corriden et al. (2015) which showed tamoxifen improves the 
phagocytic function of human neutrophils against a range of bacteria, including 
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MRSA. Hardman et al. (2007) also reported that tamoxifen accelerates wound 
healing in ovariectomised mice by exhibiting estrogenic effects, principally by 
reducing the inflammatory response. Collectively, these findings suggest that 
tamoxifen could potentially be a beneficial therapeutic strategy to treat infected 
wounds in the elderly. 
Degradation of the ER by fulvestrant blocked the beneficial effects of estrogen on 
the phagocytosis of MRSA and P. aeruginosa by U937-derived and HPBM-derived 
M1 macrophages. Compared with estrogen, fulvestrant has a higher binding affinity 
to the ER (Morris and Wakeling, 2002), and when fulvestrant is coupled with the ER,  
the nuclear localisation of the ER is blocked leading to its degradation (Morris and 
Wakeling, 2002; Osborne et al., 2004). 
Together, these data from the use of tamoxifen and fulvestrant provide evidence 
that estrogen is promoting phagocytosis via the binding and activation of the ER.  
Consequently, the role of the two estrogen receptor subtypes, ER-α and ER-β, in 
this process was investigated using ER isoform-specific agonists and antagonists. In 
a similar manner to estrogen and tamoxifen, selective activation of ER-α with PPT 
increased the phagocytosis of both MRSA and P. aeruginosa by M1 macrophages. 
However, treatment with the ER-β agonist DPN failed to promote the phagocytosis 
of either MRSA or P. aeruginosa. Intriguingly, blockade of ER-α with TPBM reversed 
the effect of PPT on the bacterial clearance. These novel findings collectively 
indicate that estrogen induces the phagocytosis of bacteria through activation of 
ER-α.  This supports published findings showing that ER-α regulates inflammation, 
with ER-β modulating the later phases of wound healing (Campbell et al., 2010). 
Toutain et al. (2009) identified ER-α as the main isoform involved in promoting the 
beneficial effects of 17β-estradiol in a model of skin necrosis.  ER-α has also been 
shown to be the predominant ER involved in regulating the thickness of epidermis 
during wound healing (Stumpf et al., 1974; Bidmon et al., 1990). In summary, the 
findings described in Chapter 5 provide an indication that ER-α is the ER isoform 
through which estrogen promotes phagocytosis by macrophages. Selective 
targeting of ER-α with agents such as PPT may potentially lead to the development 
of therapeutic strategies to combat wound infections in the elderly. 
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Images from the SEM (Figure 3.16) illustrated major morphological changes in the 
membrane of phagocytes (macrophages) following estrogen treatment, with the 
establishment of multiple pseudopodial structures suggesting estrogen induces 
significant alterations in the actin cytoskeleton of the phagocytes. These findings 
suggested that the downstream genes mediated by estrogen may include 
mediators of the actin cytoskeleton. 
In chapter 6, protein levels of four major Rho GTPase proteins (Cdc42, Rac1, RhoG 
and RhoA) and the focal adhesion kinase (FAK) were measured in M1 macrophages 
following treatment with/without estrogen. 
FAK is a key molecule involved in regulating the actin cytoskeleton during 
phagocytosis (Cote-Vélez et al., 2001; Tzircotis et al., 2011). Immunoblotting 
analysis of FAK levels in this thesis indicated that estrogen supplementation 
significantly induced the levels of FAK in M1 macrophages. The importance of FAK 
in phagocytosis was highlighted by a study showing that in vitro transfection of 
macrophages with RNAi against FAK caused a 65% fall in the number of phagocytes 
during FcγR- and CR3-mediated phagocytosis (Tzircotis et al., 2011). The pathogen-
killing activities of neutrophils and macrophages were mediated by FAK through the 
formation of lamellipodial structures (Kasorn et al., 2009). In contrast, FAK 
deficiency in macrophages is associated with a reduction in cell adhesion, and a 
failure in the formation of lamellipodia (Owen et al., 2007). These findings suggest 
that FAK is a potential therapeutic target that may (at least in part) mirror the 
beneficial effects of estrogen on bacterial clearance by macrophages. 
Whilst estrogen increased the levels of Rac1 in M1 macrophages, an opposite effect 
on RhoA was observed. This was interesting in light of studies showing that Rac1 
enhanced the phagocytosis of apoptotic cells (Akakura et al., 2004; Nakaya et al., 
2008) whereas RhoA was shown to dampen the process (Kim et al., 2017). These 
reports also highlighted the need of a dynamic balance between the two proteins 
to regulate the apoptosis process, with concurrent upregulation of Rac1 and 
downregulation of RhoA required for engulfment of apoptotic cells. Similarly, other 
studies have also shown the opposing  nature of Rac1 and RhoA during 
cytoskeleton reorganisation in Candida elegans (Ohta et al., 2006; Freeman and 
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Grinstein, 2014). The concomitant increase of Rac1 and FAK as inducers of 
phagocytosis is consistent with the fact that Rac1 is downstream from FAK in the 
regulation of actin dynamics (Kallergi et al., 2003; Papakonstanti et al., 2003; 
Siesser and Hanks, 2006; Kallergi et al., 2007). These findings suggest that 
manipulating the balance of Rac1 and RhoA in phagocytes of the elderly may be an 
additional therapeutic strategy to increase the appetite of macrophages to engulf 
bacteria, particularly in individuals where hormone replacement therapy (HRT) is 
contraindicated. 
Similar to Rac1, RhoG is linked with the regulation of the actin cytoskeleton (Katoh 
et al., 2006), phagocytosis (Prieto-Sánchez et al., 2006), gene transcription (Vigorito 
et al., 2003) and the regulation of NADPH oxidase in neutrophils (Condliffe et al., 
2006). Novel data in this study demonstrate that stimulation of macrophages with 
estrogen results in an increase in RhoG levels and enhanced phagocytosis. This 
result is in concordance with the findings of Tzircotis et al. (2011) that showed 
RhoG stimulates phagocytosis of IgG-opsonised (for FcγR) or C3bi-opsonised (for 
CR3) sheep red blood cells (RBCs) in mouse macrophages. However, the findings in 
this thesis are the first to show that estrogen stimulates RhoG in human M1 
macrophages.  Thus, promotion of RhoG may be an effective and extremely novel 
therapeutic strategy for infected wounds since it may recapitulate (at least in part) 
the beneficial effect of estrogen on bacterial clearance. However, further 
investigations are required to confirm this hypothesis.  
Activation of Cdc42 is required for the regulation of the actin cytoskeleton 
dynamics, the formation of membrane ruffling and the formation of filopodia, a 
crucial requirement for effective phagocytosis in macrophages (Kozma et al., 1995; 
Cox et al., 1997). Immunoblotting analysis in this study showed an increase in the 
levels of Cdc42 in M1 macrophages following supplementation with estrogen. The 
concurrent increased levels of both Cdc42 and FAK in M1 macrophages are 
consistent with Cdc42 being downstream of FAK in the signalling cascade that 
promotes pseudopodia formation by phagocytes (Schaller, 2010). The increased 
levels of Cdc42  agrees with the findings of Allen et al. (1997) who showed that 
injection of macrophages with active Cdc42 resulted in the formation of long and 
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indistinct filopodia in vitro. Thus, further investigations are warranted to determine 
whether the longer pseudopodia produced by macrophages in this study, following 
interaction with P. aeruginosa compared with MRSA could be associated with 
higher levels of Cdc42. Such work may lead to novel therapeutics designed to be 
more effective against problematic Gram-negative/motile bacteria such as P. 
aeruginosa. 
7.2 Future Work 
 In order to reinforce the findings of this study, in vitro and ex vivo 
investigations using other phagocytes such as neutrophils (e.g. HL-60 cell 
line or ex vivo neutrophils) are warranted. One development of this would 
be to determine the effect of estrogen on the formation of neutrophil 
extracellular trap (NET) formation during host-pathogen interaction assays. 
This would help build a wider picture of the effects of estrogen on the 
clearance of wound pathogens. 
 
 Bacterial growth in chronic wounds has been reported to take the form of 
irregularly shaped micro-colonies that can comprise hundreds of bacteria 
known as biofilms (Bjarnsholt et al., 2008; Rybtke et al., 2015). Host 
pathogen assays in this study investigated the effect of estrogen on bacterial 
clearance by macrophages. However, only single (planktonic) bacterial 
pathogens were utilised throughout the study. Replicating the in vitro and 
ex vivo experiments using biofilms of MRSA and P. aeruginosa would 
improve our in vitro model of chronic wound infections. 
 
 Unpublished research in the Ashworth laboratory has shown that 
androgens, such as testosterone and dihydrotestosterone (DHT) inhibit the 
phagocytosis of MRSA in U937-derived macrophages. Indeed, the literature 
suggests that testosterone has opposing effects to estrogen (Gilliver et al., 
2007). This creates many opportunities and directions for extending the 
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scope of this research, linking various sex steroid hormones with 
phagocytosis in wounds. Future work could investigate the effect of other 
steroid hormones and steroid hormone precursors such as 
dehydroepiandrosterone (DHEA) and dehydroepiandosterone-sulfate 
(DHEA-S) on the phagocytosis of bacteria by various human phagocytes. 
Moreover, local conversion of testosterone to estrogen could be 
investigated using aromatase inhibitors and conversion of testosterone to 
DHT could be investigated using 5α-reductase inhibitors. 
 
 The findings of this study were obtained from host-pathogen assays 
conducted using in vitro and ex vivo macrophages. Repeating these 
experiments in vivo would provide robust evidence to confirm the beneficial 
effects of estrogen on promoting bacterial clearance during wound 
infections. One application would be to use mouse models that have been 
used previously to study age-related impaired healing (Ashcroft et al., 
1997b; Hardman et al., 2007). In vivo investigations in animal models will be 
needed to develop potential therapeutic approaches for the treatment of 
wound infections before conducting human clinical trials involving chronic 
wounds in the elderly. 
 
 The SEM data in Chapter 3 (Figure 3.16) illustrated distinct morphological 
changes occurring in macrophages when incubated with MRSA and P. 
aeruginosa. Future research is needed to determine the physical and 
biochemical effects induced by estrogen on pathogen-specific interactions 
with host cells. Fourier Transform Infra-Red (FTIR) Spectroscopy and Raman 
Spectroscopy could be used to determine changes in the functional groups 
on the membrane of host cells and cell wall of bacteria during host-
pathogen interactions. 
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 Tamoxifen enhanced the phagocytic activity of macrophages against Gram-
positive and Gram-negative bacteria (Chapter 5). Hardman and Ashcroft 
(2008) indicated that estrogen, tamoxifen and raloxifen all improve wound 
repair in ovariectomised mice. Future work could investigate a range of 
SERMs, including raloxifen, to determine the most effective mediator(s) of 
bacterial clearance. This could help identify the most promising topical 
SERM(s) to treat wound infections in the elderly. 
 
 Several proteins involved in regulating the actin cytoskeleton were found to 
be mediated by estrogen (Chapter 6). Protein levels were measured by 
simple immunoblotting due to time restrictions, but these initial findings 
should now be confirmed by an additional technique, such as Western 
blotting. Moreover, Western blot analysis of phosphorylation (activation) 
patterns of these proteins at different time-points before and after 
stimulation with estrogen would add depth to current findings and 
potentially reveal further details on the mechanisms of estrogen-mediated 
phagocytosis. Intracellular flow cytometry could be used to explore these 
proteins in phagocyte populations, and kinase activity assays could be 
adopted to measure FAK activity. In addition, further investigations are 
required to determine whether the changes in protein levels are mirrored 
by concomitant alterations in gene expression. In order to determine the 
effect of ER-α activation on downstream gene expression in macrophages, 
RNAseq and qPCR analysis could be adopted. Future work would also be to 
replicate the findings using agonist/antagonist treatments to 
stimulate/block the activity of the proteins investigated in chapter 6. 
Inhibitors of phagocytosis could also be exploited to further understand the 
mechanisms by which estrogen induces phagocytosis. 
7.3 Conclusion 
In conclusion, this thesis delivers a body of experimental evidence demonstrating 
that estrogen directly enhances the phagocytosis of the two major wound 
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pathogens, MRSA and P. aeruginosa, by human macrophages via activation of ER-α 
and possible transcription of genes involved in regulating the actin cytoskeleton of 
phagocytes. When translating the findings to the context of wound infections, the 
data suggest that estrogen may promote the clearance of wound infections during 
youth but this protection is lost as estrogen levels decline with increasing age, 
resulting in increased propensity and progression of wound infections in the 
elderly. Understanding the precise mechanisms by which estrogen promotes 
phagocytosis would assist in identifying downstream targets to develop effective 
novel therapies for the treatment of wound infections with minimal side effects. 
Based on the findings in this thesis, novel dressings that provide estrogen 
supplementation or selective activation of ER-α and/or specific targeting of proteins 
that regulate the actin cytoskeleton of phagocytes may provide effective 
therapeutic options for infected wounds in the elderly and warrant further 
investigation. 
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